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RESUME))La! carcinose! péritonéale! (CP)! correspond! le! plus! souvent! à! l’envahissement!métastatique!de!la!cavité!péritonéale!survenant!dans!85!à!90%!des!cas!de!l’ovaire!et!5!à!20%! des! cancers! colorectaux.! La! pauvreté! de! des! signes! cliniques! explique! que! le!diagnostic!se!fasse!à!un!stade!souvent!avancé.!!Jusque!récemment,! le! traitement!d’une!CP!était!exclusivement!palliatif!avec!une!chirurgie! de! nécessité! incomplète! et! une! chimiothérapie! systémique,! et! une! survie!médiocre.! La! cause! du! décès! est! dans! la!majorité! des! cas! la! carcinose! elleGmême.! Les!avancées! en! matière! de! chirurgie! péritonéale! extensive! et! de! chimiothérapie!intrapéritonéale! combinée! ou! non! à! une! hyperthermie! ont! fait! naître! de! nombreux!espoirs!de!curabilité.!La!chirurgie!de!cytoreduction!complète!représente!le!facteur!pronostic!essentiel,!quelque! soit! l’origine! tumorale! primitive.! L’association! d’une! chirurgie! et! d’une!chimiothérapie! intraperitonéale! a! été! développée! dans! le! cancer! de! l’ovaire! avec! des!taux! de! survie! impressionnants.! L’hyperthermie! induit! une! destruction! sélective! des!cellules!en!hypoxie,!dans!des!zones!tumorales!en!acidose,!tout!en!préservant!le!tissu!sain!environnant.! Pour! les! patients! atteints! de! CP,! une! technique! nommée! CHIP! a! été!developpée! permettant! de! délivrer! une! chimiothérapie! intrapéritonéale! en! condition!d’hyperthermie.! Une! augmentation! importante! de! la! survie! de! patients! atteints! de! CP!colorectal!ou!de!maladie!rare!du!péritoine!a!été!mise!en!évidence.!Des!essais!cliniques!sont!en!cours!afin!de!vérifier!le!bénéfice!attendu!de!l’HIPEC!dans!différentes!pathologies.!
Premièrement,! compte! tenu! de! large! développement! de! la! laparoscopie,!l’adressage!de!patients!avec!une!carcinose!localisée!est!fréquent.!Nous!avons!développé,!sur! modèle! animal,! une! technique! de! péritonectomie! laparoscopique! avec! CHIP! à!l’oxaliplatine.! Les! paramètres! pharmacocinétiques! (PK)! en! terme! d’absorption! de! la!drogue!et!de!pénétration!intraGtissulaire!ont!été!analysés!avec!mise!en!évidence!du!rôle!favorable! de! l’hyperpression! intraabdominale.! Ces! travaux! ont! été! publié! dans!
Gynecologic*Oncology,!dans!Annals*of*Surgical*Oncology!(2!articles)!et!inclus!dans!un!
chapitre*de*livre*international*(Humana*Press)*concernant!la!pharmacologie!et!la!PK!des!sels!de!platine.!
Ensuite,! nous! avons! établi! un! nouveau! modèle! de! pharmacocinétique! des!populations!que!nous!avons!appliqué!à!la!comparaison!de!deux!modes!d’administration!de!la!chimiothérapie!lors!des!CHIP!à!l’oxaliplatine,!sur!24!patients.!Ce!travail!a!été!publié!dans!Cancer*Chemotherapy*and*Pharmacology.!!
Enfin,!différentes!études!cliniques!et!pharmacodynamiques!(PD)!ont!été!réalisée!afin!d’évaluer! et!de!prédire! la! toxicité! spécifique!des!CHIP! réalisées! au!Cisplatine!et! à!l’Oxaliplatine.!Trois! travaux! successifs! ont! été! réalisés! pour! évaluer! la! toxicité! rénale! liée! au!Cisplatine.!Dans!une!étude!pilote!de!PK,!non!publiée,!de!désescalade!de!dose,!nous!avons!montré!que!le!risque!d’insuffisance!rénale!n’est!pas!expliqué!par!la!PK!(présentation!au!Congrès!de!PharmacoGOncologistes).!Cela!a!été! confirmé!dans!une!étude! rétrospective!bicentrique! avec! mise! en! évidence! de! facteurs! de! risque.! Ce! travail! est! soumis! à!publication!dans!European* Journal*of*Surgical*Oncology.!Enfin!une!étude!de!phase! I!
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d’escalade! de! dose! a! été! réalisée! permettant! de! déterminer! la! dose! optimale! de!Cisplatine!en!CHIP!et!est!soumise!à!publication!dans!Journal*of*Clinical*Oncology.!!Compte!tenu!de!la!toxicité!rénale!du!cisplatine,!une!étude!prospective!de!phase!II!a!évalué!la!morbidité!de!l’oxaliplatine!en!CHIP!dans!le!cancer!de!l’ovaire.!Cet!essai!a!été!clos!de!façon!anticipée!compte!tenu!du!taux!d’hémopéritoine!et!publié!dans!European*
Journal*of*Surgical*Oncology.!Afin!d’analyser!et!prédire!ce!risque,!une!étude!PKGPD!a!été! conduite! sur! 75! patients! traités! par! CHIP! à! l’oxaliplatine! avec! une! corrélation! PK!entre! ! l’absorption! et! la! survenue! de! thrombopénie! et! d’hémoperitoine.! Ce! travail! est!publié!dans!Cancer*Chemotherapy*and*Pharmacology.!!
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SUMMARY)
)Peritoneal!carcinomatosis!(PC)!is!usually!caused!by!widespread!cancer!metastatic!cells!within!the!peritoneal!cavity!and!occurred!in!85%!of!ovarian!cancer!patients!and!5–20%!of! colorectal! carcinoma! patients.! Because! of! the! poverty! of! symptoms,! patients! are!diagnosed!with!an!advanced!stage.!PC!will!be!the!leading!death!cause!of!these!patients.!Recently,! the! treatment! was! limited! to! standard! palliative! surgery! and! intravenous!chemotherapy! with! very! poor! results! in! term! of! survival.! The! development! of! new!surgical!techniques!combined!with!intraperitoneal!chemotherapy!associated!or!not!with!hyperthermia!provided!new!hope!of!a!potential!cure!for!patients!with!PC.!!Indeed,! complete! cytoreductive! surgery! represents! the! most! important! prognostic!factor!for!patients!with!PC!whatever!the!primary!cancer!locations.!Combined!treatment!using! complete! cytoreductive! surgery! and! intraperitoneal! chemotherapy! has! been!developed! leading! to! unprecedented! survival.! Hyperthermia! induces! a! selective!destruction! of! tumor! cells! in! hypoxic! and! acidic! parts! of! tumors,! but! leaves! normal!tissues! intact.! In! addition! heat! is! acting! for! synergy! with! the! cytotoxic! agent.! A! new!technique! to! deliver! intraoperative! intraperitoneal! chemotherapy! associated! with!hyperthermia,!called!HIPEC,!was!developed!for!patient!with!PC.!It!significantly!increases!survival! in!patients!with!colic!cancer!PC,!peritoneal!mesothelioma!and!pseudomyxoma!peritonei.!Several!ongoing!trails!have!been!designed!to!establish!the!real!role!of!HIPEC!for!different!pathology.!!
First,! because! of! the!major! development! and! the!widespread!use! of!minimal! invasive!surgery,! recruitment! of! patients! has! been! profoundly! changed! with! localized! PC.! We!have! demonstrated! in! an! experimental! study! the! feasibility! and! reliability! of!laparoscopic!peritonectomy!followed!by!oxaliplatin!based!intraperitoneal!chemotherapy!and! its! pharmacokinetics! consequences! regarding! the! peritoneal! drug! absorption,! the!increased!tissue!diffusion,!and!the!role!of!intraperitoneal!pressure.!Several!articles!were!published! in! Gynecologic* Oncology! and! in! Annals* of* Surgical* Oncology) and! in! an!international! book* chapter* (Humana* Press)! concerning! pharmacology! and!pharmacokinetics!of!platinum!salts.!
Then,) to! establish! a! new! population! pharmacokinetic! model! and! to! compare! two!procedures! of! drug’s! delivery! during! HIPEC,! data! from! 24! patients! treated! with!oxaliplatin! based! HIPEC! were! collected! and! analyzed.! This! work! was! published! in)
Cancer*Chemotherapy*and*Pharmacology.!
Finally,!different!clinical!and!pharmacodynamic!studies!were!performed!to!evaluate!the!toxicity! for! patients! who! underwent! complete! cytoreductive! surgery! associated! to!Cisplatin!or!Oxaliplatin!based!HIPEC.!)Three!different!works!were!performed!to!evaluate!the!renal! toxicity!of!cisplatin!based!HIPEC.! An! unpublished! PK! study! regarding! acute! renal! failure! in! a! doseGdeescalation!study!was!presented!at!a!PharmacoGoncologists!Meeting.!The!results!were!confirmed!in!a! bicentric! retrospective! study! highlighting! some! risk! factors! (Submitted! to! the!
European* Journal* of* Surgical* Oncology).! Finally,! a! phase! I! study! dose! escalation! of!hyperthermic! intraperitoneal! cisplatin! was! conducted! with! the! establishment! of! the!
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recommended! dose! of! cisplatin! for! HIPEC! (Submitted! to! the! Journal* of* Clinical*
Oncology).!Because!of!renal!toxicity!related!to!cisplatin!based!HIPEC,!a!phase!II!prospective!study!was!conducted!to!evaluate!the!morbidity!of!oxaliplatin!based!HIPEC.!As!a!result!of!this!high!morbidity!rate!(hemoperitoneum),!this!trial!was!prematurely!closed!and!published!in! the* European* Journal* of* Surgical* Oncology.! Finally,! to! evaluate! the! relationship!between!oxaliplatin!exposure!and!observed!toxicity,!a!population!pharmacokinetics!was!conducted! in! 75! patients! treated! with! CRS! and! oxaliplatin! based! HIPEC.! A! PK!contribution,! relative! to! the! absorption! phenomenon,! on! the! severity! of! the!thrombocytopenia! and! hemoperitoneum! was! shown.! This! work! was! published! in!
Cancer*Chemotherapy*and*Pharmacology.!
)
)
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GLOSSARY)
)
)
AUC)) ) ) ! Area!Under!the!Curve!
AUCIP) ) ) ) Intraperitoneal!Area!Under!the!Curve)
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!Peritoneal!carcinomatosis!(PC)!is!usually!caused!by!widespread!cancer!metastatic!cells!within!the!peritoneal!cavity.!PC!is!a!terrific!issue,!especially!in!ovarian!cancer!as!85G90%!of! ovarian! cancer! patients! have! peritoneal!metastasis! at! diagnosis.! 5–10%!of! patients!with! colorectal! carcinoma!present!with! synchronous!metastases! of! the! peritoneum! at!the!time!of!initial!colon!resection!and!20–!50%!will!face!with!metachronous!peritenoal!cancer! progression! [1].! Primary! cancers! of! the! peritoneum! including! mesothelioma!represent!a!rare!disease!with!a!wide!extension!into!the!peritoneal!cavity.!Because!of!the!poverty!of!symptoms,!patients!are!diagnosed!with!advanced!stage![2]!and!the!PC!will!be!the!leading!cause!of!death!of!these!patients.!The! physiological! mechanisms! associated! with! peritoneal! spreading! are! multiple:!peritoneal!dissemination!of! free!cancer!cells!may!be!a!result!of!serosal! involvement!of!the!primary!tumour,!adhesion!of!free!cancer!cells!and!presence!of!cancer!cells!in!lymph!fluid!or!peritoneal!venous!blood.!In! a! recent! past,! the! treatment! of! this! metastatic! disease! was! limited! to! standard!palliative! surgery! and! intravenous! chemotherapy! with! very! poor! results! in! term! of!survival.! Patients’! death! is! due! to! progression! of! PC,! and! distant! metastasis! are!uncommon.! Finding! efficient! treatments! of! PC! is! the! major! concern! and! certainly! a!crucial!part!of!clinical! research! in!PC.!The!rate!of! failure!and! the!dramatic!situation!of!patients! encouraged! pushing! forward! direct! intraperitoneal! treatment! and! a! surgical!effort.!In!the!past!oncologists!have!assumed!that!PC!is!equal!to!distant!metastases!and!as!such!regarded! it! as! an! incurable! component! of! intraabdominal! malignancy.! PC! has! been!regarded! as! beyond! current! treatment! modalities.! Over! the! two! last! decades,! the!development!of!new!surgical! techniques!combined!with! intraperitoneal!chemotherapy!provided! new! hope! of! a! potential! cure! for! patients! with! PC.! Many! different!methods!have! been! developed! to! deliver! intraperitoneal! chemotherapy! during! surgical! time!period,! usually! associated! with! hyperthermia! (HIPEC:! hyperthermic! intraperitoneal!chemotherapy)! or! with! high! pressure! (PIPAC:! pressurized! intraperitoneal! aerosol!chemotherapy),! during! early! postoperative! period,! or! sequentially! with! a!intraperitoneal!catheter.!Curing! selected! patients! with! PC! is! a! realistic! goal.! PC! should! be! not! systematically!considered! a! terminal! event.! The! term! “metastases”! may! be! replace! by! “implant”! to!avoid! the!connotation!of!a! terminal!condition!and!death.!PC!has! to!be!considered!as!a!localGregional! disease!warranting! localGregional! chemotherapy! to! treatment.! Indeed,! a!10! years! median! overall! survival! is! achieved! with! complete! cytoreduction! and! IP!chemotherapy!in!advanced!ovarian!cancer![3].!LongGterm!outcome!data!of!patients!with!pseudomyxoma!peritonei!treated!by!complete!cytoreductive!surgery!and!HIPEC!shown!a! 16! years!median! survival! rate! [4].! In! colorectal! PC,! 15%! of! patients! are! considered!definitively!cured!after!a!combined!treatment:!IV!chemotherapy,!complete!cytoreductive!surgery!with!or!without!HIPEC![5].!!!!
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1.1):)ROLE)OF)COMPLETE)CYTOREDUCTIVE)SURGERY)!Surgery! remains! the! mainstay! of! therapy! in! solid! cancer,! and! complete! resection!represents!by! itself! the!most! important!determinant! to! cure.!Complete! surgery!allows!removal! of! chemoresistant! clones! and!of!poorly! vascularized! tumors,! a!higher! growth!fraction! in! better! perfused! small! residual! tumors! increasing! chemosensitivity,! and!improval! of! host! immunocompetence! [6].! The! limitations! to! achieve! complete!cytoreduction! are! surgical! experience,! the!performance!of! extensive!bowel! resections,!and!poor!performance!status.!Considering!the!whole!peritoneum!as!an!organ!for!which!metastatic! dissemination,! it! can! be!mainly! addressed! by! chemotherapy! and! complete!surgery.!Peritonectomy!and!cytoreductive!surgery!were!described!and!tailored!20!years!ago!as!the!treatment!of!choice!for!selected!patients!with!evidence!of!peritoneal!carcinomatosis![7,!8].!The!clockwise!procedure!can!be!categorized!into:!!G!right!subdiaphragmatic!and!parietal!peritonectomy,!!!G!left!subdiaphragmatic!and!parietal!peritonectomy,!!G!greater!omentectomy!with!splenectomy,!!G!lesser!omentectomy!and!stripping!of!the!omental!bursa,!!G!pelvic!peritonectomy!with!resection!of!involved!organs.!Visceral! resections! such! as! uterus! and! ovaries,! gallbladder,! stomach,! distal! pancreas,!colon!and!limited!small!bowel!should!be!performed!if!a!complete!cytoreduction!can!be!achieved! as! a! result.! Completeness! of! Cytoreduction! Scoring! of! CC0,! G1! and! G2! is!commonly!used!to!describe!residual!disease!of!<2.5!mm,!2.5!to!25mm!and!>25!mm![9].!The! use! of! validated! scales,! such! as! the! PCI! (Peritoneal! Cancer! Index),! Gilly! score,!laparoscopic!Fagotti! score,! and!CC! score! is! recommended! for!ovarian! cancer! [10]! and!nonGgynaecological!PC![11,!12].!The!quality!of!surgery!represents!the!most!important!prognostic!factor!for!patients!with!PC!whatever!the!primary!cancer!locations,!confirmed!in!several!publications![13].!As!a!consequence,!the!remaining!macroscopic!lesions!size!appears!every!time!as!the!weighty!parameter!of!survival.!For!colorectal!or!gastric!PC,!longGterm!survival!was!obtained!only!in!patients!who!underwent!complete!macroscopic!resection!(CC0)![5,!14G16].!According!to! a! transversal! oncologic! point! of! view,! these! results! were! confirmed,! whatever! the!primary! cancer! locations,! in!a! large!multicenter! cohort! study!of!1290!patients! treated!for! nonGgynecological! PC! [13].! For! advanced!ovarian! cancer,! the! largest!metaGanalysis!performed!by!Bristow!et!al.![17]!which!included!81!studies!accounting!for!6885!patients,!demonstrated!a!statistically!significant!positive!correlation!between!percent!of!maximal!cytoreduction!and!median!survival!time.!!The! use! of! these! scores! as! general! cutGoffs! represents! an! important! tool! to! exclude!patients! from! this!morbid! procedure! [18].! Survival! analyses! studies! have! shown! that!patients!with! PCI! scores! less! than! 19! (colorectal)! and! 10! (gastric)! benefit!most! from!CRS!+!HIPEC![19].!
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Standardization! and! trained! teams! are! required! to! achieve! improved! completeness! of!cytoreduction! [20].! In! high! volume! ovarian! cancer! centres,! complete! cytoreductive!surgery!(CC0)!was!reported!in!70%!of!patients!in!advanced!ovarian!cancers!in!a!french!multicentre! study! [21].! To! achieve! absence! of! remaining! disease,! specific! surgical!training! is! mandatory,! including! colorectal! resection! and! diaphragm! stripping! and!visceral!resection![10,!22].!Quality!of!surgical!care!as!a!component!of!a!comprehensive!regimen!of!multidisciplinary!management!has!been!shown!to!benefit!the!patient!in!many!types!of!malignancies![23,!24].!!
1.2:)ROLE)OF)INTRAPERITONEAL)CHEMOTHERAPY)!Over!the!last!decades,!combined!treatment!using!complete!cytoreductive!surgery!(CRS)!and! intraperitoneal! chemotherapy!has!been!developed!especially! in! advanced!ovarian!cancer.!The!advantage!of!intraperitoneal!chemotherapy!includes!the!ability!to!achieve!a!significantly! higher! concentration! of! chemotherapy! in! the! locoregional! environment.!Depending!on!their!molecular!weight,!their!affinity!to!lipids!and!clearance!by!the!liver,!the!median!peak!peritoneal!concentration,!evaluated!by!the!area!under!the!curve!(AUC),!is!20!to!1000!times!that!of!the!plasmatic!AUC![25]!(Fig.!1).!In!fact,!the!peritoneal!plasma!barrier!provides!doseGintensive!therapy.!High!concentrations!of!anticancer!drugs!can!be!in!direct!contact!with!tumor!cells,!with! lower!systemic!toxicity.! !Clinical!or!preGclinical!results! support! the! favorable! impact! of! increasing! the! dose! or! durationGofGexposure!(AUC)!on!the!cytotoxic!potential!of!drugs.!This!advantage!is!present!in!commonly!used!agents! in! gynecological! and! GI! cancers! such! as! platinum! salts,! 5GFU,! taxanes,!anthracyclin!or!mitomycin!C.!To!be!used! in!peritoneal!cavity,! the!agent!must!be!active!against!the!tumor!being!treated,!should!not!have!vesicant!properties,!and!should!not!be!a!prodrug!requiring!liver!activation.!Its!peritoneal!clearance!must!be!slow,!with!a!rapid!clearance!from!the!systemic!circulation.!!
!
!
!
!
Fig.!1!Molecular!weight!and!AUC!ratio!of!
intraperitoneal!exposure!and!systemic!exposure!of!
drugs!used!to!treat!peritoneal!carcinomatosis!
(Van!der!Speeten!K!et!al.!Current!Drugs!Discovery!
Technologies!2009)![26]!
!
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An! additional! advantage! to! intraperitoneal! chemotherapy! administration! is! that! the!blood! drainage! of! the! peritoneal! surface! provides! an! additional! intravenous!chemotherapy! recently! designed!by! “bidirectional”! chemotherapy! regimens! consisting!in! the! concurrent! intraperitoneal! and! intravenous! administration! of! the! drugs.! The!pharmacokinetic!model!that!governs!this!phenomenon!goes!beyond!a!biGcompartmental!model:!plasma!and!peritoneum.!This!“Dedrick!model”!suggested!it!should!be!possible!to!expose! tumor! present! within! the! peritoneal! cavity! to! higher! drug! concentration!compared!to!intravenous!delivery![27]!(Fig.!2).!But!this!biGcompartment!model!does!not!provide! a! good! theoretical!model! of! the! penetration! of! intraoperative! intraperitoneal!chemotherapy!in!the!space!between!the!peritoneal!membrane!and!the!tumor!nodules.!A!triGcompartmental!model!is!more!frequently!used!associating!plasma,!peritoneal!cavity!and! tumor! [26,! 28].! The! peritoneal! membrane! is! designed! as! an! independent!compartment!with!its!own!ability!to!accumulate!the!drug!(Fig.!3).!!
!!!! !
Fig.!2!Dedrick’s!biLcompartmental!model! ! ! Fig.!3!ThreeLcompartmental!model!Experimental! studies! have! shown! that! drugs! penetration! is! limited! to! a! few! layers!beneath! the! tumor! surface! [29,!30].!Nevertheless,! the!penetration!depth!of!drugs! that!are!intraperitoneally!delivered!was!probably!overGestimated!to!be!a!maximum!of!3!to!5!mm.! This! is! the! reason! why! an! adequate! and! complete! cytoreductive! surgery! must!precede!the!intraperitoneal!chemotherapy.!Encouraging! results! of! randomized! trials! of! IP! adjuvant! chemotherapy! in! the!management! of! advanced! ovarian! cancer! have! been! published,! with! superiority! to!intravenous! adjuvant! chemotherapy! [25].! Three! phase! 3! intergroup! trials! have!compared! intraperitoneal!with! intravenous! chemotherapy! in! advanced,! post! resection!lowGvolume!remaining!disease!ovarian!cancer!patients.!!The! first! trial! (GOG! 104! –! SWOG! 8501)! was! published! in! 1996! [31].! A! statistically!significant! survival! advantage! among! patients! treated! with! intraperitoneal!chemotherapy!was! demonstrated,! but! the! regimen!did! not! include! paclitaxel!which! is!the!major!advanced!for!ovarian!cancer!during!the!90th.!!The!second! trial! (GOG!114),!published! in!2001! [32]! showed!a! significant!difference! in!progressionG! free! survival,! nevertheless! associated! with! increase! treatment! related!toxicities.!Both!effects!were!related!to!the!addition!of!two!cycles!of!intensive!intravenous!carboplatin!in!patients!treated!with!IP!regimen.!!
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The!third!trial!(GOG!172),!published!in!2006![33]!has!compared!intravenous!paclitaxel!plus!cisplatin!with!intravenous!paclitaxel!plus!intraperitoneal!cisplatin!and!paclitaxel!in!patients! with! stage! III! ovarian! cancer.! IP! regimen! improves! survival! in! optimally!debulked! patients.! Results! were! updated! in! 2013! [3].! 110! months! of! median! overall!survival! was! shown! for! patients! without! gross! residual! disease! treated! with! IP!chemotherapy.! This! unprecedented! survival! improved! with! increasing! number! of! IP!cycles! [34].! Risk! of! death! decreased! by! 12%! for! each! cycle! of! IP! chemotherapy!completed.!Younger!patients!were!more! likely! to! complete! the! IP! regimen,!with! a!5%!decrease! in! probability! of! completion! with! each! year! of! age! [34].! It! should! promote!further!investigation!of!novel!strategies!for!implementing!IP!chemotherapy!for!patients!with!no!residual!disease.!Using!IP!chemotherapy!at!the!same!time!to!a!cytoreductive!surgery!is!clearly!a!different!situation! compared! to! adjuvant! sequential! treatment.! It! looks! crucial! then! to!describe!the! impact! of! the! extent! of! peritoneal! resection! on! pharmacokinetics.! Several!publications!have! shown! that! the!extent!of!parietal!peritoneal! resection!did!not! affect!the! pharmacokinetics! of! intraoperative! intraperitoneal! Cisplatin! based! chemotherapy.!The!pharmacological! barrier! between! the! abdominopelvic! cavity! and!plasma! could!be!unrelated!to!the!surface!of!intact!peritoneum![35].!On!the!other!hand,!some!have!shown!the!opposite.!The!extent!of!peritonectomy!increased!the!clearance!of!mitomycin!C!from!the!peritoneal!space![36].!!
1.3:)ROLE)OF)HYPERTHERMIA)!Cancer!cells!are!sensitive! to!heat.!Therapeutic!effects!of!hyperthermia!are!well!known!since! the! beginning! of! the! 20th! century! [37].! The! direct! cytotoxicity! of! hyperthermic!treatment! seems! to! be! based! on! the! denaturation! and! aggregation! of! cytoplasmic,!nuclear! or!membrane! proteins.! The! chaotic! vasculature! inside! the! tumor! tissue! often!leads! to! areas! of! acidosis,! hypoxia! and! energy! deprivation.! Because! of! low! perfusate!area,!temperatures!between!40!and!44!°C!hyperthermia!induces!a!selective!destruction!of!tumor!cells!in!hypoxic!and!acidic!parts!of!tumors,!but!leaves!normal!tissues!intact![38,!39].!In!a!metaGanalysis!published!in!1940,!Johnson!et!al.!has!shown!the!effect!of!exposure!to!heat!in!several!cancer!line!cells:!breast!cancer,!sarcoma,!epithelioma.!Regarding!thermal!death! time,! there! is! a! straightGline! correlation! between! exposure! time! and! level! of!temperature.!In!fact,!a!similar!inGvivo!thermal!destruction!is!observed!after!exposure!of!cancer!cells!during!50!hours!at!40°C!and!respectively!30!hours/41.5°C;!20!hours/42°C;!8! hours/44°C;! and! 1! hour/45°C.! This! strict! timeGtemperature! relationship! was!confirmed!in!several!studies!during!the!1970s!and!1980s.!The!thermal!energy!dose!for!induction!of! cell!death! is! closely! related! to! the!amount!of! energy! required! for! cellular!protein!denaturation.!But,!after!thermal!exposure,!a!mechanism!of!thermoGtolerance!is!developed!with!an!upGregulation!of!specific!proteins!to!prevent!cell!lethal!damage.!In!the!case!of!hyperthermia,!the!proteins!partly!involved!are!heatGshock!proteins!(HSP).![40].!However,! following!more!prolonged!or! intense! thermal!exposure,! these!compensatory!mechanisms!often!fail.!Above!this!“breakpoint!temperature”,!vascular!and!architectural!
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changes! increased! blood! flow,! enhanced! drug! delivery,! drug! extravasation!(chemosensitisation)!and!higher!oxygenation!of!the!tissue!(radiosensitisation)[41].!!
!
Fig.!4!The!antitumoral!effect!of!heat!(Issels!RD,!Eur!J!Cancer!2008)![40].!To!be!effective!in!cancer!therapy,!as!demonstrated!in!animal!tumors,!hyperthermia!has!to!be!uniform!within! the! tumor.! [42].!For!PC!patients,!hyperthermia! is!delivered!after!complete! cytoreductive! surgery! without! persisting! macroscopic! disease.! In! open!abdomen! HIPEC! technique,! because! of! the! surgical! approach! by! laparotomy! and! the!manipulation!by!the!hand!of!the!surgeon,!a!uniform!distribution!of!heated!perfusate!is!easily!achieved.!!!
)1.4:) SYNERGY) BETWEEN) HYPERTHERMIA) AND) INTRAPERITONEAL)
CHEMOTHERAPY)!Heat!has! an!own!direct! cytotoxic! effect,! and! in! addition! is! acting! for! synergy!with! the!cytotoxic! agent.! In! vivo! studies! have! demonstrated! that! the! thermal! enhancement! of!cytotoxicity! is! maximized! at! temperatures! between! 40.5! and! 43! °C! for! many!chemotherapeutic! agents.! In! that! model,! cytofluorometry! analysis! shows! that!hyperthermia! increases! the! intracellular! adriamycin! accumulation! in! different! human!epithelial! cancer! cell! lines! in! mucinous! as! well! as! serous! tumor! [43].! Many! in! vitro!studies!demonstrated!that!heating!strongly!potentiate!the!cytotoxic!effects!of!cisplatin,!by! increasing! the! intracellular! drug! penetration! and! drug! reaction! with! DNA,! and!!inhibits! repair! of! drugGinduced! lethal! or! subGlethal! damage.! In! a!mouse! breast! tumor!model,! cisplatin!and!heat!have! shown! to!be!active!alone,!but! the! combination! is!more!active!than!each!one!alone![44].!In!a!model!of!rat’s!carcinomatosis,!the!pharmacokinetics!data!are!favoring!the!combination!of!cisplatin!and!regional!hyperthermia![45].!!The!AUC!in! the! peritoneal! cavity! for! both! total! and! ultrafiltered! platinum! is! larger! with!hyperthermia,! but,! more! important,! the! AUC! in! the! plasma! is! 4! times! larger! for! rats!receiving!regional!hyperthermia.!Enhanced!platinum!concentrations!are!observed!in!all!
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selected!tissues!after!regional!hyperthermia,!4!times!higher!in!the!tumor!and,!regarding!its!specific!toxicity,!only!of!a!factor!2!in!the!kidney![45].!!The!thermal!enhancement!ratio!varies!with!the!antineoplasic!agent![46].!Chemotherapy!and! heat! ! interact! in! different! ways! (Fig.! 5).! A! linear! enhanced! cytotoxicity! when!temperatures! are! raised! from! 37! to! 40.5! °C! is! demonstrated!with! platinum! salts! and!alkylating!drugs.!Conversely,!antimetabolites!like!5’Fluorouracil!have!not!been!found!to!interact!with!heat.!The!impact!of!hyperthermia!is!different!when!using!carboplatin.!The!cellular!uptake!of!carboplatin!clearly!increases!at!43°C,!when!this!uptake!is!not!modified!between!37!and!41.5°C![47].!However,!the!cytotoxic!effect!is!already!increased!at!40°C,!suggesting!an! increased!activity!of! carboplatin!at!higher! temperatures.!And! the! fact! is!that! the! CarboplatinGDNA! adduct! formation! increases! linearly! with! temperature,!probably!because!more!carboplatin!is!transformed!into!adequate!metabolites!at!higher!temperatures.! Using! the! same! model! of! rat’s! carcinomatosis,! Los! studied! the!pharmacokinetics! of! Carboplatin! administered! alone! or! in! combination! with!hyperthermia.!The!peritoneal!AUC! is!smaller! in!rats!receiving!hyperthermia,!while! the!plasmatic! AUC! is! 3! times! larger! [48].! This! could! be! explained! by! the! fact! that!hyperthermia!fasts!the!peritoneal!clearance!of!carboplatin,!and!slows!its!excretion!from!plasma.!These!results!suggest!an!increase!in!tumor!exposure!via!the!systemic!circulation!according!to!the!Dedrick’s!bicompartmental!model.!The!chemical!structure!of!the!cytotoxic!agent!must!not!be!modified!by!hyperthermia.!!Increasing!and!maintaining! temperature!above!43°C! in! clinical! situation!during!a! long!period!(60!minutes)!is!difficult!because!of!adverse!effects.!Between!41!and!43°C,!blood!flow!and!vascular!permeability!represent!both!the!critical!factors!for!drug!uptake.!
!
Fig.!5!Overview!of!the!interactions!between!some!chemotherapeutic!agents!and!heat!(Issels!RD,!Eur!J!Cancer!
2008)![40].!Clinical! effectiveness! of! the! association! of! locoregional! hyperthermia! with!chemotherapy!was!demonstrated!in!patients!with!advanced!soft!tissue!sarcoma.!Phase!2!studies! have! shown! that! chemotherapy! with! regional! hyperthermia! improves! local!control!compared!with!chemotherapy!alone.!A!phase!3!randomized!study!was!published!in!2010! to!assess! the!safety!and!efficacy!of! regional!hyperthermia!with!chemotherapy!for! localized!high! risk! sarcoma! [49].!341!patients!were!enrolled.!They!were! randomly!
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assigned!to!receive!either!neoGadjuvant!chemotherapy!alone!or!combined!with!regional!hyperthermia.! The! treatment! response! rate! in! the! group! that! received! regional!hyperthermia! was! 28·8%,! compared! with! 12·7%! in! the! group! who! received!chemotherapy! alone! with! a! moderate! toxicity.! An! impact! on! overall! survival! was!reported.!For!the!authors,!this!randomized!trial!provides!the!first!evidence!that!regional!hyperthermia!added!to!preoperative!and!postoperative!chemotherapy!is!clinically!more!effective!than!chemotherapy!alone!in!a!specific!population!of!patients!with!highGrisk!soft!tissue!sarcoma.!!
)1.5:)HYPERTHERMIC)INTRAPERITONEAL)CHEMOTHERAPY)(HIPEC)))!For!patients!with!peritoneal!carcinomatosis,!delivering!of!intraoperative!intraperitoneal!chemotherapy! associated!with! hyperthermia!was! developed! 30! years! ago.! Commonly!called! HIPEC,! this!multimodal! therapeutic! approach! has! been! developed! especially! in!rare!peritoneal!disease!expert!centers.!HIPEC!was!first!tested!in!canine!models!by!Spratt!from!Louisville![50,!51].!There!has!been!a!growing!level!of!support!for!the!use!of!HIPEC!in!peritoneal!surface!malignancies.!Sugarbaker!has!developed!and!refined!the!approach!for!a!variety!of!malignancies!including!mesothelioma,!pseudomyxoma!peritonei,!ovarian!cancer,! and! advanced! colorectal! cancer! [52].! HIPEC! is! delivered! in! only! one! session,!under! direct! surgical! supervision,! after! complete! removal! of! PC! before! tumor! cell!entrapment.! Indeed,! a! high! incidence! and! rapid! progression! of! peritoneal! surface!implantation! to! fibrin! entrapment! of! remaining! free! tumor! cells! on! traumatized!peritoneal!surfaces!occurred!during!the!early!postoperative!period,!promoted!by!growth!factors!involved!in!the!wound!healing!process.!As!collagen!is!laid!down,!the!tumor!cells!are!entrapped!within!scar!tissue,!which!is!dense!and!not!penetrated!by!intraperitoneal!chemotherapy.! It! may! cause! a! high! incidence! of! locoGregional! treatment! failure.! To!eradicate!the!reimplantation!of!malignant!cells!into!peritonectomized!surfaces,!it!seems!logical!to!use!intracavitary!chemotherapy!in!a!large!volume!of!fluid!during!the!operation!as!HIPEC!procedure.!An!other!way!is!to!prevent!adhesion!formation.!It!is!clear!therefore!that!the!reduction!of!adhesive!disease!has!many!immediate!and!delayed!functional!and!therapeutic!consequences!in!PC!management![53].!!Several!phase!2!studies!and!case!series!have!been!published.!If!a!complete!cytoreductive!surgery!is!achieved,!all!phases!2!studies!reported!a!median!survival!longer!than!2!years.!!A! randomized! Dutch! trial! was! conducted! comparing! HIPEC! with! mitomycin! C! and!cytoreductive! surgery! to! intravenous! chemotherapy! alone! (5Gfluorouracil,! leucovorin)!for!treatment!of!carcinomatosis!from!colorectal!origin!showed!that!2Gyear!survival!was!43%!in!the!HIPEC!group!versus!16%!in!the!control!(p=0·014)![54].!Those!results!were!confirmed!after!8!years!of!followGup,!with!45%!of!5!yearGsurvival![55].!In!a!multiGinstitutional!study!of!1290!patients!who!underwent!CRS!and!HIPEC!for!nonGovarian!PC,!Glehen!has!reported!longGterm!survival!in!a!selected!group!of!patients!with!an!acceptable!morbidity![13].!A!case!control!study!was!conducted!by!Elias!to!compare!the!longGterm!survival!of!patients!with!isolated!and!resectable!PC!in!comparable!groups!of! patients! treated!with! CRS! plus! HIPEC! and! systemic! chemotherapy! versus! systemic!chemotherapy!alone![56].!FiveGyear!overall!survival!was!51%!(95%!CI,!36%!to!65%)!for!the!HIPEC!group!and!13%!for!the!palliative!chemotherapy!alone.!
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A! recent!metaGanalysis! has! shown! that! CRS! followed! by!HIPEC! significantly! increases!survival!in!patients!with!advanced!peritoneal!colic!cancer![57].!HIPEC!is!also!proposed!as!a!standard!treatment!for!peritoneal!mesothelioma!and!pseudomyxoma!peritonei.!!Several! ongoing! trails! have! been! designed! to! establish! the! real! role! of! HIPEC! in!recurrent!ovarian!cancer!(CHIPOR!trial),!colorectal!cancer!(Prodige!7)!as!well!as!several!phase!I/II!trials!in!gastric!cancer.!!!
1.6:)PERSONNAL)RESEARCH)OVERVIEW)!Over! the! two! last! decades,! recruitment! of! patients! has! been! profoundly! changed.!Patients! are! currently! referred! at! the! time! of! primary! treatment,! with! localized!peritoneal! carcinomatosis! and! a! low!peritoneal! cancer! index.! A!major! development! is!the!widespread!use!of!minimal! invasive!surgery,!which! is!a! result!of! the! technological!advancement!made!in!laparoscopic!surgery.!Patients!are!usually!treated!by!laparoscopy.!The!first!part!of!this!present!project!was!developed!in!this!context.!!!In! an! experimental! study,! we! first! demonstrated! the! feasibility! and! reliability! of!laparoscopic!peritonectomy!followed!by!oxaliplatin!based!intraperitoneal!chemotherapy!and! its! pharmacokinetics! consequences! regarding! the! peritoneal! drug! absorption,! the!increased!tissue!diffusion,!and!the!role!of!intraperitoneal!pressure.!Several! articles! were! published! in! Gynecologic! Oncology! and! in! Annals! of! Surgical!Oncology! and! in! a! book! chapter! concerning! pharmacology! and! pharmacokinetics! of!platinum!salts:!
Feasibility) of) laparoscopic) peritonectomy) followed) by) intraNperitoneal)
chemohyperthermia:)an)experimental)study.!Ferron!G,!GessonGPaute!A,!Classe!JM,!Querleu!D.!Gynecol!Oncol.!2005!Nov;99(2):358G61.!!
Pharmacokinetics) of) oxaliplatin) during) open) versus) laparoscopically)
assisted) heated) intraoperative) intraperitoneal) chemotherapy) (HIPEC):) an)
experimental)study.!GessonGPaute!A,!Ferron!G,!Thomas!F,!de!Lara!EC,!Chatelut!E,!Querleu!D.!Ann!Surg!Oncol.!2008!Jan;15(1):339G44.!!
Increased) tissue) diffusion) of) oxaliplatin) during) laparoscopically) assisted)
versus)open)heated) intraoperative) intraperitoneal)chemotherapy)(HIPEC).!Thomas!F,!Ferron!G,!GessonGPaute!A,!Hristova!M,!Lochon!I,!Chatelut!E.!!Ann!Surg!Oncol.!2008!Dec;15(12):3623G4.!
Laparoscopically) assisted) Heated) IntraNoperative) Intraperitoneal)
Chemotherapy) (HIPEC):) Technical) aspect) and) pharmacokinetics) data.!Ferron! G,! GessonGPaute! A,! Gladieff! L,! Thomas! F,! Chatelut! E,! Querleu! D.! In!Platinum!and!Other!Heavy!Metal!Compounds!in!Cancer!Chemotherapy.!Bonetti!A!et!al.!Humana!Press!2008.!!
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Then,!we!established!a!new!population!pharmacokinetic!model!and!we!compared!two!procedures!of!drug’s!delivery!during!HIPEC.!!In!fact,!there!is!no!standardized!method!for!HIPEC!delivery.!Technical!parameters,!such!as! open! or! closed! abdomen,! differ! from! institution! to! institution,! still! based! on! the!surgeon’s! personal! preference! and! linked! to! the! “school”! of! HIPEC.! The!marketing! in!France! of! new! European! Community! approved! reheaters! the! method! has! modified!deliver! drug! during! HIPEC! procedure.! Therefore,! there! is! a! need! to! evaluated! new!procedure! using! new!PK!model.! Data! from!24! patients! treated!with! oxaliplatin! based!HIPEC!were!collected!and!analyzed!This!work!was!published!in!Cancer!Chemotherapy!and!Pharmacology.!
Pharmacokinetics) of) heated) intraperitoneal) oxaliplatin.! Ferron!G,! Dattez! S,!Gladieff!L,!Delord!JP,!Pierre!S,!Lafont!T,!Lochon!I,!Chatelut!E.! !Cancer!Chemother!Pharmacol.!2008!Sep;62(4):679G83.!!
Finally,!different!clinical!and!pharmacodynamic!studies!were!performed!to!evaluate!the!toxicity! for! patients! who! underwent! complete! cytoreductive! surgery! associated! to!Cisplatin! or! Oxaliplatin! based! HIPEC.! Indeed,! different! drugs! are! used! for! HIPEC!depending!on!the!origin!of!the!tumor.!Two!drugs!are!predominantly!used!in!France:!!! G!Cisplatin,!for!ovarian!cancer!and!rare!peritoneal!disease!! G!Oxaliplatin,!for!colorectal!cancer,!rare!peritoneal!disease.!!Regarding!Cisplatin!HIPEC!related!toxicity;!a!three!steps!study!was!performed:!1G! PK! data! from! 12! patients!who! underwent! a! CRS! and! Cisplatin! based!HIPEC!were! recorded! according! to! the! renal! function! in! a! retrospective! dose! deGescalation!study! using! a! three! compartmental!model.! Acute! renal! failure!was! reported! in! a! high!rate!of!patient.!Occurrence!of!renal!failure!is!not!dose!dependant,!and!due!to!a!different!mechanism!as!known!with!using!intravenous!cisplatin.!!This! unpublished! work! was! presented! at! the! “13ème! journées! du! Groupe! de!Pharmacologie!Clinique!Oncologique”!–!Nîmes!2010.!
Chimiohyperthermie) Intraperitoneale) à) base) de) Cisplatine:)
Pharmacocinétique)et)tolerance)rénale.!Civade!E,!Ferron!G,!Pierre!S,!Lochon!I,!Rouge!P,!Gladieff!L,!Chatelut!E.!–!Poster!presentation!at!the!“13ème!journées!du!Groupe!de!Pharmacologie!Clinique!Oncologique”!–!Nîmes!2010.!! !2G! As! we! reported! an! high! frequency! of! renal! toxicity,! a! large! bicentric!retrospective! study! was! performed.! Data! from! 66! patients! treated! with! CRS! and!Cisplatin! based! HIPEC! have! been! recorded! in! two! cancer! centers:! Institut! Claudius!Regaud!GToulouse!and!Institut!du!Cancer!–!Montpellier.!This!work!was!presented!at!the!
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French!Society!Of!Gynecologic!Oncology!(SFOG)!Annual!Meeting!!and!is!currently!under!review!at!the!European!Journal!of!Surgical!Oncology.!
Predictive) factors) of) acute) kidney) injury) after) cytoreduction) surgery) and)
cisplatin) based) hyperthermic) intraperitoneal) chemotherapy) for) ovarian)
peritoneal)carcinomatosis:)a)retrospective)bicentric)study.!Vieille!P,!Quenet!F,! Gladieff! L,! Rougé! P,! Chaltiel! L,! Querleu! D,! MD,! Saint! Aubert! B,! Martinez! A,!Carrere!S,!Ferron!G.!!(Under!review!at!the!European!Journal!of!Surgical!Oncology)!–! Poster! presentation! at! the! French! Society! of! Gynecologic! Oncology! Annual!Meeting!–!Toulouse!–!Nov!2014!! !3G! to! identify! the! recommended!dose! of! cisplatin! for!HIPEC! after! cytoreductive!surgery!after!neoadjuvant!chemotherapy,!a!multicentric!phase!I!study!dose!escalation!of!hyperthermic! intraperitoneal! cisplatin! was! then! conducted.! This! work! is! currently!under!reviewat!the!Journal!of!Clinical!Oncology!
Results) of) a) multicenter) phase) I) doseNfinding) trial) of) hyperthermic)
intraperitoneal) cisplatin) after) neoadjuvant) chemotherapy) and) complete)
cytoreductive) surgery) and) followed) by) maintenance) bevacizumab) in)
initially)unresectable)ovarian)cancer.!Gouy!S,!Ferron!G,!Glehen!O,!Le!Deley!MC,!Marchal!F,!Pomel!C,!Quenet!F,!Bereder!JM,!Bayar!A,!Kockler!L,!Morice!P.!(Under!review!at!the!Journal!of!Clinical!Oncology)!!Regarding!Oxaliplatin!HIPEC!related!toxicity;!a!two!steps!study!was!performed:!1G! to! evaluate! the!morbidity! of! oxaliplatin! based!HIPEC,! a! phase! II! prospective!study! was! conducted.! This! work! was! published! in! the! European! Journal! of! Surgical!Oncology!
Hyperthermic) intraNperitoneal) chemotherapy) using) Oxaliplatin) as)
consolidation)therapy)for)advanced)epithelial)ovarian)carcinoma.)Results)of)
a)phase)II)prospective)multicentre)trial.)CHIPOVAC)study.)Pomel!C,!Ferron!G,!Lorimier!G,!Rey!A,!Lhomme!C,!Classe!JM,!Bereder!JM,!Quenet!F,!Meeus!P,!Marchal!F,!Morice!P,!Elias!D.!Eur!J!Surg!Oncol.!2010;36(6):589G93!!! 2G! to! evaluate! the! relationship! between! oxaliplatin! exposure! and! observed!toxicity,! a! population! pharmacokinetics! concerning! oxaliplatin! based! HIPEC! was!conducted!and!published!in!Cancer!Chemotherapy!and!Phamacology!
Population) pharmacokinetics) of) peritoneal,) plasma) ultrafiltrated) and)
proteinNbound) oxaliplatin) concentrations) in) patients) with) disseminated)
peritoneal) cancer) after) intraperitoneal) hyperthermic) chemoperfusion) of)
oxaliplatin) following) cytoreductive) surgery:) correlation) between)
oxaliplatin)exposure)and)thrombocytopenia.!Chalret!du!Rieu!Q,!WhiteGKoning!M,! Picaud! L,! Lochon! I,! Marsili! S,! Gladieff! L,! Chatelut! E,! Ferron! G.! Cancer!Chemother!Pharmacol.!2014;74(3):571G82.!
! 25!
!
In) addition,! we! participated! to! several! publications! regarding! different! aspects! of!HIPEC:!!G! two! articles! were! published! regarding! prevention! of! occupational! exposure! for!operating!room!personnel.!!
[Hyperthermic) intraoperative) intraperitoneal) chemotherapy) (HIPEC):)
evaluation,) prevention) and) policies) to) avoid) occupational) exposure) for)
operating)room)personnel].!Simon!L,!Halilou!MC,!Gladieff!L,!Gadiou!M,!Herin!F,!Hennebelle!I,!Chatelut!E,!Ferron!G.!Bull!Cancer.!2009!Oct;96(10):971G7.!!
Professional) risks) when) carrying) out) peritoneal) carcinomatosis) surgery)
with) Hyperthermic) Intraperitoneal) Chemotherapy) (HIPEC):) a) French)
multicentric) survey.! Ferron! G,! Simon! L,! Guyon! F,! et! al.! (Under! review! at! the!Annals!of!Surgical!Oncology)!!!G! two! review! articles! were! published! in! the! French! peerGreview! “Bulletin! du! cancer”!concerning!HIPEC!and!intraperitoneal!chemotherapy!:!
[Importance) of) hyperthermic) intraperitoneal) chemotherapy) (HIPEC)) in)
ovarian)cancer]!Ferron!G,!Martinez!A,!Mery!E,!Querleu!D,!Thomas!F,!Chatelut!E,!Gladieff!L.!Bull!Cancer.!2009;96(12):1243G52.!!
[Pharmacological) bases) of) intraperitoneal) chemotherapy]) Gladieff! L,!Chatelut!E,!Dalenc!F,!Ferron!G.!Bull!Cancer.!2009;96(12):1235G42.!!!G!and!we!have!also!participated!to!several!case!series!about!HIPEC!and!to!guidelines!for!PC!treatment;!that!are!mentioned!above:!
Survival) Benefit) of) Hyperthermic) Intraperitoneal) Chemotherapy) for)
Recurrent)Ovarian)Cancer:)A)MultiNinstitutional)Case)Control)Study.))Le!Brun!JF,!Campion!L,!BertonGRigaud!D,!Lorimier!G,!Marchal!F,!Ferron!G,!Oger!AS,!Dravet!F,!Jaffre!I,!Classe!JM.!Ann!Surg!Oncol.!2014;21(11):3621G7!
Peritoneal) carcinomatosis) treated) with) cytoreductive) surgery) and)
Hyperthermic)Intraperitoneal)Chemotherapy)(HIPEC))for)advanced)ovarian)
carcinoma:)a)French)multicentre)retrospective)cohort)study)of)566)patients.!Bakrin! N,! Bereder! JM,! Decullier! E,! Classe! JM,! Msika! S,! Lorimier! G,! Abboud! K,!Meeus! P,! Ferron!G,!Quenet! F,!Marchal! F,! Gouy! S,!Morice! P,! Pomel! C,! Pocard!M,!Guyon! F,! Porcheron! J,! Glehen! O;! FROGHI! (FRench! Oncologic! and! Gynecologic!HIPEC)!Group.!Eur!J!Surg!Oncol.!2013!Dec;39(12):1435G43.!
Complete)Cytoreductive)Surgery)Plus) Intraperitoneal)Chemohyperthermia)
With)Oxaliplatin)for)Peritoneal)Carcinomatosis)of)Colorectal)Origin.)Elias!D,!Lefevre! JH,! Chevalier! J,! Brouquet!A,!Marchal! F,! Classe! JM,! Ferron!G,!Guilloit! JM,!Meeus!P,!Goéré!D,!Bonastre!J.!J!Clin!Oncol.!2009!Feb!10;27(5):681G5.!!
! 26!
OxaliplatinNbased) hyperthermic) intraperitoneal) chemotherapy) in) primary)
or)recurrent)epithelial)ovarian)cancer:)A)pilot)study)of)31)patients.!Frenel!JS,!Leux!C,!Pouplin!L,!Ferron!G,!Berton!Rigaud!D,!Bourbouloux!E,!Dravet!F,! Jaffre! I,!Classe!JM.!J!Surg!Oncol.!2011!Jan!1;103(1):10G6.!
Coeliac) lymph) node) resection) and) porta) hepatis) disease) resection) in)
advanced) or) recurrent) epithélial) ovarian,) fallopian) tube,) and) primary)
peritoneal)cancer.!Martinez!A,!Pomel!C,!Mery!E,!Querleu!D,!Gladieff!L,!Ferron!G.!Gynecol!Oncol!2011!May!1;121(2):258G63.!
Adherence)to)guidelines)in)gynecologic)cancer)surgery.)Ferron!G,!Martinez!A,!Gladieff! L,! Mery! E,! David! I,! Delannes! M,! Montastruc! M,! Balagué! G,! Picaud! L,!Querleu!D.)Int!J!Gynecol!Cancer.!2014!Nov;24(9):1675G8.!!!!!!!
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2.1:)DEMONSTRATION)OF)THE)FEASIBILITY)OF)LAPAROSCOPIC)PERITONECTOMY)
FOLLOWED) BY) OXALIPLATIN) BASED) INTRAPERITONEAL) CHEMOTHERAPY) AND)
ITS)PHARMACOKINETICS)CONSEQUENCES!!!Since! 30! years,! after! its! introduction! especially! in! France,! laparoscopic! approach! for!cancer!gained!wide!acceptance.!This!approach!represents!the!first!choice!for!both!early!colic!and!suspected!ovarian!mass!at!the!time!to!diagnostic!but!also!for!resection![58,!59].!It!has!been!shown!to!be!effective!in!selected!cases!in!excluding!unnecessary!laparotomy!associated! with! specific! morbidity.! Laparoscopy! is! considered! as! a! good! diagnostic!modality! in! patients! with! ascites! seen! on! radiologic! studies! who! need! a! definitive!diagnosis! to!determine! the!primary! sites.! It! allows!evaluation!of! tumor!dissemination,!and! histological! diagnosis.! Diagnostic! laparoscopy! provides! a!wide! view! of! the!whole!abdominal! cavity! without! a! large! incision.! 30°! or! flexible! endoscope! improve! the!abdominal!exploration![60].!Endoscopy!is!a!key!tool! in!the!diagnosis!and!management!planning!of!peritoneal!carcinomatosis.!Several!studies!have!shown!the!accuracy!and!the!reproducibility!for!the!PCI!score!in!laparoscopy![61].!Specific!endoscopic!score!has!been!published!and!routinely!used!like!the!Fagotti!score![62].!Because!of!long!term!survival!obtained!in!patients!with!low!PCI,!and!the!development!of!specific! phase! II! trials! in! highGrisk! patients! for! PC! (ProphyloGCHIP),! recruitment! of!patients!has!been!profoundly! changed.!Furthermore,!most!of! the!medical! and! surgical!oncologists! are! convinced! that! complete! cytoreduction! associated! to!HIPEC! represent!the! optimal! treatment! for! patients! with! PC.! Patients! are! currently! referred! to! HIPEC!centers!at!the!time!to!primary!treatment,!with!localized!peritoneal!carcinomatosis.!It! seems! logical! to! evaluate! the! possibility! to! perform! the! cytoreductive! surgery! and!HIPEC!by!laparoscopy.!This!work!was!performed!in!two!successive!steps:!2.1.1:! First! step:! To! demonstrate! the! feasibility! of! laparoscopic! peritonectomy! and!HIPEC.!!An! experimental! study! was! performed! in! five! adults! pigs.! Four! trocars! in! each!abdominal!quadrants!were!placed!in!order!to!perform!a!complete!peritonectomy!and!to!place! the! inGflow! and! outGflow! drains.! When! the! reached! temperature! was! obtained!(43°C),!HIPEC!was!delivered!during!30!minutes.!Manipulation!of!the!bowel!to!obtain!a!adequate!distribution!of!heat!was!performed!by!the!replacement!of!the!umbilical!trocar!by!the!surgeon!hand.!All!the!procedures!were!successfully!completed!with!an!adequate!intraabdominal!temperature!and!distribution.!!It!was!published!in!Gynecologic!Oncology:!Ferron!G,!GessonGPaute!A,!Classe!JM,!Querleu!D.!!
Feasibility) of) laparoscopic) peritonectomy) followed) by) intraNperitoneal)
chemohyperthermia:)an)experimental)study.)Gynecol!Oncol.!2005!Nov;99(2):358G61.!!
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Abstract
Objective. Hyperthermic intraperitoneal chemotherapy (HIPEC) is being evaluated for patients with minimal residual or no residual
disease after primary surgery and chemotherapy for stage III ovarian carcinoma. The use of operative laparoscopy to perform peritonectomy
and HIPEC is reported.
Methods. Five adult pigs were used. The placement of trocars in the four quadrants was planned in order to complete a total
peritonectomy and then to place the HIPEC drains. The umbilical trocar was then replaced manually by the surgeon through a LapdiscR to
manipulate the bowel loops. The abdominal cavity was filled with heated saline (43-C), and the pumps were activated for 30 min.
Results. The procedure was successfully completed with an adequate intraabdominal temperature and distribution.
Conclusion. These preliminary data suggest the technical feasibility of the laparoscopic approach for HIPEC, in an animal model without
carcinomatosis. Our ongoing research is designed to gather pharmacokinetic data in an experimental controlled randomized fashion to
compare a laparoscopic to a laparotomy approach on the same model.
D 2005 Elsevier Inc. All rights reserved.
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Introduction
Ovarian carcinoma is the leading cause of mortality
among gynecologic cancer patients. Most present with
advanced disease and are treated with a combination of
primary, interval, or secondary cytoreductive surgery and
chemotherapy. In a significant number of patients, com-
plete clinical response is achieved. However, approxi-
mately 50% of patients who achieve a complete remission
eventually recur, justifying further attempts to define
additional therapy regimens, including intraperitoneal
chemotherapy [1]. Hyperthermic intraperitoneal chemo-
therapy (HIPEC) has been proposed as a therapeutic tool
in the management of digestive tract cancer patients with
peritoneal carcinomatosis [2,3] and more recently in
ovarian cancer patients [4–7]. HIPEC is currently being
evaluated in a French multi-centre phase I–II trial where
only patients with minimal residual or no residual disease
are included. We believe that HIPEC could be applied
without performing a laparotomy, particularly considering
that laparoscopic surgery is adapted for adhesiolysis and
comprehensive examination of the peritoneal cavity with
acceptable accuracy and morbidity [8].
From the experience of others [9], the prerequisites for a
satisfactory exposition of the diseased peritoneum are
known. Two closed circuits, one in the lower the other
one in the upper abdomen, are needed. A temperature of 42
to 43-C must be maintained for 30 min. Continuous
mobilization of the bowel and high flow of the dialysate
are required. The goal of this study was to verify that all
these criteria could be met using a laparoscopic approach. In
addition, we wanted to assess the feasibility of peritonec-
tomy procedure that usually precedes HIPEC in clinical
practice.
0090-8258/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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This study was supported by the research program of the
Institut Claudius Regaud Cancer Center and by Karl Storz
Inc., who provided the laparoscopic equipment. All the
experiments were carried out in the surgery laboratory of the
Rangueil university hospital in Toulouse, France.
Material and methods
Five adult (20 kg) pigs were used in the experimental
laboratory. The Helsinki rules for the use of animals in
experimentation were met. All procedures were performed
under general anesthesia. The animals were placed in supine
position. A 12 mm trocar was placed in the umbilical area
to accommodate the endoscope. Four additional 12 mm
VersastepR (Tyco Healthcare Group LP, Norwalk, Connect-
icut USA) trocars were placed in each quadrant of the
abdomen (Fig. 1). The design of the reducer of the VerstasepR
was chosen to accommodate large diameter (22 Fr) drains
without leakage of CO2 and perfusate. The positioning of
trocars in the four quadrants was planned in order to perform a
complete peritonectomy and then to place the HIPEC drains.
During HIPEC, the trocars were maintained vertically in order
to prevent fluid leakage. Filters were adapted to the tip of the
drains in order to avoid sticking to the visceral surface and
obstructing the lumen.
Extended peritonectomy of the parietal and pelvic
peritoneum was performed using laparoscopic techniques.
Gas pressure was helpful to find the point of dissection of
the peritoneum and its underlying tissues. Peritoneum of the
anterior abdominal wall, paracolic gutters, undersurface of
both hemidiaphragms, and lateral pelvis was completely
removed. To perform the peritonectomies, the peritoneum
was progressively stripped off the posterior rectus sheath
and the diaphragm. Broad traction must be exerted on the
specimen with electrosurgical dissection allowing separation
of peritoneum and the abdominal wall. Stripping the visceral
peritoneum from the surface of the bladder was impossible
because of the anatomy of the pig’s bladder. The umbilical
trocar was then replaced by a device allowing the placement
of the hand and forearm in the abdomen without any gas or
liquid leak (LapdiscR, Ethicon Endo Surgery Inc, Cincin-
nati, USA). Silicon drains, 22 French, were used to create
the abdominal irrigation circuit. Temperature probes were
placed at the tip of each drain.
The four drains corresponding to the two circuits (one
inflow and one outflow drain for each of them) were
positioned under laparoscopic guidance. One retrohepatic
drain was used as an inflow drain in the upper abdomen.
The outflow drain from the upper abdomen was placed in
the left upper quadrant. The outflow drain from the lower
abdomen was placed in the pelvis. The inflow drain of the
lower abdomen, which was manipulated by the hand of the
surgeon, was used to distribute the flow in all areas of the
abdomen.
The abdominal cavity was then filled with heated (43-C)
saline. In this pilot experiment, no anticancer drug was used.
The pumps were then activated, the bowel loops were hand
mobilized by the surgeon through the LapdiscR for 30 min
(Fig. 2). Temperature of the irrigation fluid was constantly
monitored. At the end of the procedure, methylene blue was
injected in order to check the completeness of peritoneal
exposure to the heated fluid. The animal was then sacrificed,
and a laparotomy was performed. Correct placement of the
drains, diffusion of the dye into the subperitoneum, and
remaining peritoneal surfaces were checked.
Results
The peritonectomy procedure was successfully com-
pleted in all five animals. Average duration of the operation
was 20 min. Parameters of intraperitoneal heated flowFig. 1. Positioning of trocars to complete peritonectomy.
Fig. 2. Positioning of HIPEC drains with the right surgeon’s hand through
the LapdiscR.
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infusion were then assessed. Knowing that the therapeutic
index is optimal at 41–43-C [2 3], the goal of achieving the
adequate intraabdominal temperature was fulfilled using a
perfusate heated at 46-C with a 1500 ml/min flow that
resulted in inflow temperatures at 43–45-C and outflow
temperatures at 41–42-C. Target temperature was reached
after 8 to 12 min. Active permanent manipulation of the
bowel and viscera, and the manual adaptation of the
direction of the inflow from drain number 4 as well,
allowed us to obtain a homogeneous intraabdominal
temperature. The distribution of blue dye was even in the
abdominal cavity in all animals. Exposure of all peritoneal
surfaces to heated perfusate, including the root of the
mesentery and the omental bursa, was achieved.
Discussion
There is currently no evidence that additional therapy is
able to improve the outcome of ovarian cancer patients in
apparent complete remission. Second-look surgeries are no
longer standard in the management of advanced ovarian
cancers, which results in a lack of information about the
actual status of the peritoneal surface at the time of
completion of chemotherapy. The development of intra-
peritoneal drug therapy is one of the main topics of
investigation in an effort to improve the long-term results
in the case of peritoneal spread of ovarian carcinomas.
Randomized controlled studies have demonstrated a sig-
nificant improvement in progression-free survival after
intraperitoneal versus systemic chemotherapy [10]. How-
ever, many drawbacks and morbidity related to sequential
punctures or the use of indwelling catheters have impeded
the spread of intraperitoneal chemotherapy use. Repeated
cycles of intraperitoneal chemotherapy are necessary,
thereby with the risk of possible complications of repeat
abdominal punctures or obstruction of permanent catheters
[11]. The frequent occurrence of intraperitoneal adhesions
may impair the actual exposition of potentially diseased
sites to local drug therapy.
On the other hand, encouraging results have been
obtained by HIPEC in the management of otherwise
inevitable lethal conditions, including peritoneal carcino-
matosis from colorectal cancer, mesothelioma, and pseu-
domyxoma peritonei [2,9]. The complication rate of
extensive peritonectomy procedures followed by HIPEC
is a major limitation to the use of this combined manage-
ment in ovarian cancers. It is assumed that the morbidity
of HIPEC after relatively minor peritonectomy procedures
in patients with minimal residual disease only is more
acceptable. This point is being explored in a French
collaborative phase I–II study. Inherent morbidity related
to completing cytoreduction and chemohyperthermia du-
ring the same session might be reduced in the context of
minimal residual disease, which is the major potential
indication in ovarian carcinomas. Comprehensive assess-
ment of the peritoneal cavity, although long and tedious in
patients with a history of major cytoreductive surgery, may
be successfully achieved using laparoscopic techniques
with acceptable morbidity [12]. Complete adhesiolysis
immediately before exposure to chemotherapy ensures an
adequate repartition of the drug throughout the abdominal
cavity. HIPEC is administered in only one session, under
direct surgical monitoring, which overcomes the problems
encountered with permanent catheters and repeat intra-
peritoneal chemotherapy administration.
The ‘‘closed’’ and the ‘‘coliseum’’ laparotomy techniques
currently used for HIPEC have complementary advantages
and disadvantages [13]. The main disadvantage of the
closed technique is the lack of uniform distribution of the
heated perfusate. On the other hand, the closed technique
allows one to rapidly obtain and maintain hyperthermia,
avoiding exposure of the operating room staff to toxic
drugs. Laparoscopic techniques may prove to be an optimal
route to administer intraperitoneal chemotherapy [14]. The
possibility of using a closed technique, while manipulating
the viscera using the hand-assisted technique and/or laparo-
scopic instruments, combines the advantages of both
laparotomy techniques. In addition, experimental studies
demonstrated that raised intraabdominal pressure might
facilitate drug penetration into tumoral tissue [15].
Conclusion
It is clear that debulking of gross disease is not feasible
laparoscopically and that secondary HIPEC should not be in
the future a substitute for inadequate primary surgery. In
addition, chemoresistant patients are likely not to be good
candidates for HIPEC. It is assumed that hyperthermic
intraperitoneal chemotherapy will be proposed, in the
setting of phase I–II trials, as a consolidation therapy to
patients showing a complete or optimal response to primary
surgery and systemic chemotherapy. Clinical investigation is
needed in this subgroup of patients [10]. The complication
rate of extensive peritonectomy procedures followed by
HIPEC is a major limitation to the use of this combined
management in ovarian cancers. It is assumed that the
morbidity of HIPEC after relatively minor peritonectomy
procedures in patients with minimal residual disease only is
more acceptable. This point is being explored in a French
collaborative phase I–II study. As a consequence, HIPEC
should be first evaluated in a selected group of patients
presenting with (1) a high risk of recurrence, (2) a
demonstrated chemosensitive disease, (3) an acceptable
potential complication rate. All criteria must at this moment
be met, which means that phase I–II studies and further
phase III studies assessing HIPEC are acceptable only in the
setting of consolidation therapy. In this context, the bulk of
the disease has been removed or medically reduced,
supporting the rationale for a laparoscopic approach,
knowing that the requirement for extensive peritonectomy
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may be a limitation to the use of the laparoscopic approach.
However, these preliminary data suggest the technical
feasibility of the laparoscopic approach for HIPEC applied
to ovarian cancer patients with no or minimal residual
disease. Physical parameters including pressure, flow, and
temperature can be controlled, and prerequisites are met.
However, we have not administered chemotherapy in this
preliminary experiment. Our ongoing research is designed
to gather pharmacokinetic data and study drug metabolism
in an experimental controlled randomized study comparing
laparoscopic and laparotomy approaches.
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!2.1.2:! Second! step:! to! compare,! in! an! experimental! study,! the! pharmacokinetics! of!oxaliplatin!during!Open!versus!Laparoscopic!HIPEC.!The!HIPEC!procedure!was!based!on!460!mg/m2!of!oxaliplatin!over!30!minutes!at!41°C!to!43°C,!identical!to!the!drug!schema!used!for!patient.!Two!groups!of!10!pigs!were!studied.!All!the!procedures!were!successfully!completed.!This! study! has! confirmed! the! technical! feasibility! and! reliability! of! the! laparoscopic!approach! for! HIPEC,! and! it! has! extended! knowledge! concerning! peritoneal! drug!absorption.! The! results! have! reported! that! the! mean! half! time! of! IP! oxaliplatin! was!significantly!shorter!in!the!laparoscopic!group!than!in!the!laparotomy!group.!Absorption!and! diffusion! of! oxaliplatin! in! tissue! were! also! better! in! the! laparoscopic! group!suggesting!the!role!of!intraGabdominal!pressure.!This!increased!penetration!of!drug!into!the!tumor!should!enhance!the!antitumor!effect.!!This!second!step!was!published!in!Annals!of!Surgical!Oncology!(2!articles)!and!in!a!book!chapter!concerning!pharmacology!and!pharmacokinetics!of!platinum!salts:!GessonGPaute!A,!Ferron!G,!Thomas!F,!de!Lara!EC,!Chatelut!E,!Querleu!D.!
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Pharmacokinetics of Oxaliplatin During Open
Versus Laparoscopically Assisted Heated
Intraoperative Intraperitoneal Chemotherapy (HIPEC):
An Experimental Study
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Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is being evaluated for
patients with minimal residual or no residual disease after primary surgery and chemotherapy
for stage III ovarian carcinoma. The technical feasibility of the laparoscopic approach for
HIPEC has been demonstrated in a previous study. An experimental study on the porcine
model was carried out to compare oxaliplatin pharmacokinetics during a laparoscopic-assisted
procedure versus the coliseum technique for HIPEC.
Methods: Adult pigs received an HIPEC procedure that was based on 460 mg/m2 of oxa-
liplatin over 30 minutes with a perfusate heated at 41!C to 43!C. The HIPEC drains were
placed in the upper and lower quadrants of the abdomen. Peritoneal fluid and blood samples
were collected every 10 minutes during the procedure, and the pharmacokinetics of oxaliplatin
was studied.
Results: Two groups of 10 adult pigs were studied. All the procedures were successfully
completed with an adequate intra-abdominal temperature and distribution. No major tech-
nical problems were encountered. At the end of the HIPEC, 41.5% of the molecule was
absorbed in the laparoscopic group compared with 33.4% in the laparotomy group
(P = .0543). Peritoneal oxaliplatin half-life (T½) was significantly faster in the laparoscopic
procedure (median, 37.5 vs. 59.3 minutes, P = .02). The area under the curve ratio of peri-
toneal to plasma reflects a more important oxaliplatin crossing through the peritoneal barrier
in the laparoscopic procedure (ratio, 16.4 in the closed procedure vs. 28.1 in the open one;
P = .03).
Conclusions: This study confirms the technical feasibility and reliability of the laparoscopic
approach for HIPEC, and it extends knowledge concerning peritoneal drug absorption. Ox-
aliplatin absorption is far higher with laparoscopy in terms of time course in peritoneal
perfusion. Clinical application in selected patients may be expected after further experimental
investigation designed to define the adequate drug dosage.
Key Words: Hyperthermia—Intraperitoneal chemotherapy—laparoscopy—oxaliplatin—phar-
macokinetics.
Ovarian cancer is the leading cause of mortality
among gynecological cancers. However, an
increasing number of patients experience complete
response after a combination of surgery and
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chemotherapy. Despite complete remission at the
end of managing the primary tumor, recurring
disease is observed in approximately 50% of stage
III patients.1 This justifies the investigation on
additional therapies, including intraperitoneal che-
motherapy applied to digestive tract cancers with
peritoneal dissemination.2,3
Previous experimental data from our laboratory
demonstrated the feasibility of laparoscopic periton-
ectomy and heated intraperitoneal chemohyperther-
mia (HIPEC).4 HIPEC is an accepted option in the
management of digestive tract cancers with peritoneal
carcinomatosis. More recently, HIPEC has been
proposed in selected ovarian cancer patients with
encouraging results5 in an effort to improve the
outcome of stage III ovarian cancer. A French mul-
ticenter phase I–II trial actually includes patients with
minimal residual disease or no residual disease with
ovarian cancer.
We assume that HIPEC could be applied without
performing a laparotomy, particularly when no bulky
disease is present. In addition, laparoscopic surgery is
adapted for adhesiolysis and comprehensive exami-
nation of the peritoneal cavity with acceptable accu-
racy and morbidity.6,7 Here, we report the results of
an experimental study
MATERIALS AND METHODS
This experimental study was performed on adult
pigs. This study was conducted in accordance with
the Declaration of Helsinki rules for the use of ani-
mals in experimentation.
Surgical Procedure
Twenty adult pigs were needed. The study was
conducted in an experimental laboratory. All proce-
dures were performed while the animals were under
general anesthesia and in a supine position.
Half of the group of pigs underwent an HIPEC
performed by laparotomy, and the procedures were
conducted as previously described by Elias et al. 8
with the coliseum technique. Oxaliplatin was
delivered at the dose of 460 or 360 mg/m2 and
heated in the abdominal cavity with a fixed volume
(dextrose 5%—2 L/m2).9 Four drains were placed in
four regions of the abdomen: in the right and left
upper quadrants with, respectively, an inflow and
an outflow circuit. For the lower abdomen, the
outflow drain was placed in the pelvis. The sur-
geon!s hand manipulated the inflow drain to evenly
distribute the flow in the abdominal cavity.
The other group of pigs underwent a laparoscopi-
cally assisted HIPEC that used the same dosage and
physical parameters. A 12-mm trocar was placed in the
umbilical area to accommodate the endoscope. Four
additional 12-mm Versastep trocars (Tyco Healthcare
Group, Norwalk, CT) were placed in each quadrant of
the abdomen (Fig. 1).4,8 The umbilical one was re-
placed by a Lapdisc (Ethicon Endo Surgery, Cincin-
nati, OH), which allowed the placement of the hand
and forearm in the abdomen without any gas or liquid
leak. During HIPEC, the trocars were maintaining
vertically to prevent leakage. Temperature probeswere
placed at the tip of each exit drains. Knowing that the
therapeutic index is optimal at 41!C to 43!C,2,10 the
goal for achieving adequate intra-abdominal temper-
ature was fulfilled by using a perfusate heated between
46!C to 52!C, with a 1360mL/min flow that resulted in
outflow temperature at 41!C to 43!C. Active perma-
nent manipulation of viscera and manual adaptation
of the inflow drain (no. 3) allowed us to obtain a
homogeneous intra-abdominal temperature.
Peritonectomy was not performed in this study.
Peritoneal fluid temperature was constantly moni-
tored in all experiments. Intra-abdominal pressure
was not measured.
Animals were kept under general anesthesia until
their last blood sample was drawn, and then they
were killed. The fluid containing chemotherapy was
destroyed according to regulations after complete
suction of the fluid in the abdomen.
Blood Sampling
Nine blood samples were collected for each animal
at different times: before HIPEC, at time 0 (T0) when
the peritoneal fluid reached 43!C, and every 10 min-
utes during the procedure. Blood samples were then
collected after the HIPEC at 45 minutes and at 1, 1.5,
and 2 hours after T0. Samples were immediately
centrifuged at +4!C, for 10 minutes at 1500 · g. For
samples collected at the end of the procedure (i.e., 30
minutes after T0), at 1 and 2 hours after initiation of
HIPEC, an aliquot of plasma was ultrafiltered by
centrifugation at +4!C for 20 minutes at 2000 · g
through a Amicon MPS1 micropartition system with
YMT membranes (cutoff 30,000 Da).
In the laparotomy group, one of three animals had
additional blood samples drawn at 6 and 7 hours. In
the second group, six animals were kept under gen-
eral anesthesia for the same protocol.
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Peritoneal Fluid Sample Preparation
Five 5-mL samples of peritoneal fluid were col-
lected for each animal at different time points: before
the temperature reached 43!C, at the beginning of the
HIPEC procedure, and then every 10 minutes during
the procedure.
All samples were frozen at )20!C until assay.
Platinum Determination
Platinum levels in the plasma and in the plasma
ultrafiltrate were measured by means of flameless
atomic absorption spectrophotometric analysis
according to a previously described method.11
Nominal values of platinum controls were 21, 105,
and 210 ng/mL for plasma ultrafiltrate and 20.9,
104.7, and 209.3 ng/mL for plasma samples. Platinum
determination in samples was validated when mea-
sured control values were within 10% of the medium-
and high-level controls and 20% for the low-level
control. Results were expressed in nanograms per
milliliter of oxaliplatin.
Pharmacokinetic Study
Pharmacokinetics data were analyzed by 4.1 Ki-
netica software (Innaphase, Philadelphia, PA) with a
noncompartmental method. The area under the ox-
aliplatin concentration-time curve was determined
from T0 to 2 hours (AUC2h) with a mixed log-linear
rule. Pharmacokinetic parameters calculated included
Tmax, Cmax, and elimination half-life T½. The peri-
toneal T½ was calculated by using 4 time points (T0
and 10, 20, and 30 minutes) in each peritoneal fluid
profile.
Statistical Analysis
Pharmacokinetic results were carried out with
Statview software, version 4.55. The AUC and con-
centration data were compared by a t-test. Tmax (the
time to reach the target temperature) and T½ data
were analyzed with the Mann-Whitney test. Differ-
ences were considered significant at P < .05.
RESULTS
A total of 20 adult pigs were used in this experi-
mental study. The procedure was successfully com-
pleted in all 20 HIPEC procedures: 10 pigs underwent
an HIPEC performed by laparotomy, and 10 other
pigs underwent an HIPEC that was laparoscopically
hand-assisted.
Intraoperative Parameters
No noticeable technical problems were encoun-
tered in the laparotomy group as a result of our
experience in human clinical practice.
The most frequently encountered complication
during laparoscopic procedures was circuit obstruc-
tion by the contact of small bowel and omentum with
the tips of the drains. The first procedure was per-
formed with Gamida drains, which were not well
adapted to the level of suction negative pressure
(Fig. 2). The following procedures were thus per-
formedwith the hair curlers routinely used duringopen
procedures, which allowed easiermanual separation of
the bowel from the drains, thanks to the surgeon!s hand
in the abdominal cavity. Overall, technical problems,
which were eventually solved, occurred in three pro-
cedures of the laparoscopic group. As a result, target
temperature was reached after 8 minutes (median va-
lue) in the laparotomy group versus 12.5 minutes for
the laparoscopic group (P = .03). If we excluded
experiments for which technical problems occurred,
the time to reach optimal temperature decreased (7 vs.
12 minutes, P = .03). Fig. 3 shows the temperature
curve of optimal procedure in each group.
Pharmacokinetic Study
Pharmacokinetics of Heated Intraoperative
Intraperitoneal Oxaliplatin
A decrease in platinum concentration was observed
in the peritoneal perfusion during HIPEC in both
groups (Fig. 4). Analysis of T½ of the drug revealed a
significant difference that reflected faster tissular
FIG. 1. Positioning of hyperthermic intraperitoneal chemotherapy
drains with the surgeon!s hand through the Lapdisc.
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absorption of oxaliplatin in the laparoscopic group
(median value, 37.5 minutes vs. 59.3 minutes;
P = .02), giving evidence that the closed technique
seems to influence and raise the platinum absorption
through the peritoneal barrier. At the time of com-
pletion of HIPEC, 41.5% of the molecule was ab-
sorbed in the laparoscopic group, compared with
33.4% in the laparotomy group (P = .05).
Time Course of Oxaliplatin in the Peripheral Blood
Peak plasma concentration of platinum was ob-
served on average 30 minutes after starting HIPEC in
the laparotomy group, whereas the peak plasma con-
centration was obtained after 46.4 minutes (P = .87)
in the laparoscopic group (Fig. 5). Then platinum
concentration dropped rapidly in both groups, result-
ing in a limited systemicAUC.TheAUC2h is higher for
the laparoscopic procedure, as is plasma concentra-
tions at time 2 hours (C2h) in ultrafiltrate (Table 1).
The AUC ratio of peritoneal to plasma (at 30 minutes)
was larger in the laparotomy group (28.1 vs. 16.4,
P = .03), reflecting the fact that themolecule is kept in
the abdominal cavity with less penetration through the
peritoneal barrier in the blood compartment compared
with the laparoscopic group. During HIPEC, oxalipl-
atin was more rapidly absorbed in the laparoscopic
group: 41.5% of oxaliplatin was absorbed in the lapa-
roscopic group, compared with 33.4% in the laparot-
omy group at the end of the HIPEC (P = .0543).
DISCUSSION
This experimental study is part of current clinical
investigation aimed at improving the outcome of
ovarian cancer patients whose disease is in apparent
complete remission. The standard primary initial
management of such cancers combines maximal cy-
toreductive surgery with systemic chemotherapy.
Second-look surgeries are no longer standard in the
management of advanced ovarian cancers, which re-
sults in a lack of information concerning the actual
status of the peritoneal surface at the time of com-
pletion chemotherapy. Encouraging results of a ran-
domized, controlled study of HIPEC in the
management of peritoneal carcinomatosis in colo-
rectal cancer patients have been published.2 HIPEC
has also been proposed in ovarian cancers, meso-
thelioma, and pseudomyxoma peritonei.3,12
HIPEC administered in only one session, under
direct surgical monitoring, might be more applicable
in clinical practice than sequential intraperitoneal
chemotherapy that uses permanent catheters.5 Evi-
dence of a high complication rate of extensive peri-
tonectomy procedures followed by HIPEC is a major
potential limitation. However, it is assumed that the
morbidity of HIPEC alone or after minor periton-
ectomy procedures in patients with minimal residual
disease only or with a negative second-look surgery is
more acceptable. This point is being explored in an
ongoing French collaborative phase I/II study. In
addition, complete adhesiolysis and comprehensive
assessment of the peritoneal cavity can be completed
laparoscopically with acceptable morbidity.6
In this experiment, we developed tips to overcome
the limitations of a closed HIPEC technique in
terms of intra-abdominal temperature homogeneity
and complete exposure of all peritoneal surfaces,
including the root of the mesentery and the omental
bursa, to heated perfusate. Considering that manual
mobilization of the bowel by the surgeon!s hand is
an essential component of even distribution of the
drug and complete exposure of the bowel,8 the use
of a hand-assisted technique has proved to be useful.
Xiphopubic laparotomy is no longer required. In
this regard, the laparoscopic hand-assisted HIPEC is
superior to the standard closed HIPEC procedure
that has been proposed for palliation of debilitating
malignant ascites in a series of 14 patients.13 Hand-
assisted surgery mimics the Sugarbaker modification
of the coliseum technique in that it uses an imper-
meable disposable drape covering the entire opera-
tive field with a cruciate cut in its central portion to
permit access for the surgeon!s arm.14 In addition,
the laparoscopic technique avoids exposure of the
operative room staff from droplets of chemotherapy
and aerosols that may escape into the environ-
ment.15
FIG. 2. First laparoscopic procedure performed with special Ga-
mida drains; the circuit!s obstruction results from strong aspiration.
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This experiment provides evidence that laparoscopic
HIPEC is feasible andwas successfully completed in all
animals after resolution of minor technical problems.
The minimal additional time to reach the target tem-
perature is likely to disappear with experience.
From the pharmacokinetic point of view, we
demonstrated that laparoscopic HIPEC provides
equivalent exposure of the peritoneum compared
with an open one. Evidence is given that intra-
abdominal hyperpressure facilitates drug penetration
FIG. 3. Temperature curve for optimal procedure in the (a) laparotomy and (b) laparoscopy groups.
FIG. 4. Decrease in oxaliplatin concentrations in heated peritoneal instillation (460 mg/m2). The first point (t = 0 minutes) corresponds to
the concentration in the peritoneal fluid before the hyperthermic intraperitoneal chemotherapy (i.e., before the temperature of 43!C was
reached). (a) Laparotomy group. (b) Laparoscopy group.
FIG. 5. Oxaliplatin pharmacokinetics in plas-
ma after heated intraperitoneal chemotherapy
(460 mg/m2).
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into the blood compartment. A massive crossing of
the molecule through the peritoneal barrier has been
observed, but these results must be interpreted with
caution because they are important only for ultrafil-
trate values. Tissue platinum concentration (ongoing
experiment) would confirm other experimental stud-
ies.16,17 Indeed, it has been proved that intraperito-
neal chemotherapy with increased intra-abdominal
pressure improved the tumor accumulation and the
antitumor effect of cisplatin in rats. The tolerance of
sustained intra-abdominal pressure was manageable
in ventilated pigs.
Further experimental studies are required to
investigate the tissue concentration of platinum in
peritoneum, liver, and omentum; to assess the role of
peritoneal pressure; and to define the appropriate
dosage of drug, taking into account the higher blood
concentrations of drug during laparoscopic proce-
dures.
Our group is planning an additional experimental
program in small animals with induced peritoneal
carcinomatosis.
In conclusion, this experimental study on adult
pigs provides further evidence of the feasibility and
reliability of a HIPEC laparoscopic approach. We
obtained optimal conditions in terms of temperature
and agent diffusion. The revolutionary hand-assisted
concept matches the requirements of the open ap-
proach from a technical point of view. In addition,
the closed procedure avoids staff members! exposure
to drugs during surgery. The results of this study
indicate that further investigation is warranted of the
place of laparoscopy in HIPEC as an innovative
application of laparoscopic surgery in gynecological
cancer, with the aim of reducing surgical trauma and
improving patient quality of life.
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TABLE 1. Oxaliplatin concentrations after heated intra-
peritoneal chemotherapy (460 mg/m2)
Variable Laparotomy Laparoscopy P value
Mean UF C2h (ng/mL) 2295.26 2994.17 .04
Mean plasma AUC2h
(ng/mL · min)
1102.01 1292.65 .23
Median peritoneal T½ (min) 59.3 37.5 .02
UF, ultrafiltrate; AUC, area under the curve; T½, half-life
elimination.
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Letter to the Editor
Increased Tissue Diffusion of Oxaliplatin During
Laparoscopically Assisted Versus Open Heated
Intraoperative Intraperitoneal Chemotherapy
(HIPEC)
To the Editor:
In the January 15, 2008 issue of the Annals of Surgical
Oncology we reported the results of an experimental study
comparing heated intraoperative intraperitoneal chemo-
therapy (HIPEC) performed by laparotomy versus laparo-
scopically hand-assisted.1 The technical feasibility of the
closed technique (laparoscopic) was explored in a previous
work2 and the major purpose of this second experimental
study was to compare the pharmacokinetics of oxaliplatin
with both techniques in adult pigs. The dose of oxaliplatin
administered was 460 mg/m2, heated in the abdominal
cavity for 30 min. The results supported the laparoscopic
approach since the mean half-life (T1/2) of oxaliplatin in
peritoneal perfusion was significantly shorter in the lapa-
roscopic group than in the laparotomy group (median
37.5 min versus 59.3 min, respectively), suggesting faster
tissue absorption of oxaliplatin. Since that time, the tissue
oxaliplatin concentration has been determined.
This present work brings new results of platinum deter-
mination in tissue samples from the pigs used in the pre-
vious study. Indeed, liver, peritoneum, and omentum
biopsies were realized 30 min after T0 (i.e., the start of
HIPEC when the peritoneal fluid reached 43!C), which
corresponds to the end of the procedure. Tissues were kept
frozen at -20!C until analysis. Biopsies were desiccated by
low-pressure centrifugation using a Speed Vac at 60!C for
few hours, until constant weight was reached. Tissue was
then digested in 65% nitric acid at 95!C and evaporated to
dryness. The solid residue was dissolved in 1 ml of a mix-
ture of Triton X100 (0.1%) and nitric acid (0.2%). Plati-
num levels were measured by means of flameless atomic
absorption spectrophotometric analysis according to a
previously described method.3 Oxaliplatin concentration
was determined in liver, omentum, and peritoneum of
20 pigs (i.e., 10 pigs in the laparotomy group and 10 pigs in
the laparoscopy group). The mean oxaliplatin level was
higher in the three types of tissues from the laparoscopy
group compared with the laparotomy group, as shown in
Fig. 1. This difference was significant in the liver
(P = 0.001, bilateral t-test). We previously showed that, at
the time of completion of HIPEC, 41.5% of the molecule
was ‘‘absorbed’’ in the laparoscopic group, compared with
33.4% in the laparotomy group, based on the disappear-
ance of the drug in peritoneal perfusion, which arises from
both better absorption and diffusion of oxaliplatin in tis-
sues.
These results confirm our previous hypothesis that the
‘‘closed’’ HIPEC technique (i.e., laparoscopy) allows better
penetration of the drug in tissues and, thus, probably in
tumors. Esquis et al.4 published results of platinum con-
centration in intra- and extraperitoneal organs after intra-
peritoneal (IP) cisplatin with high intra-abdominal pressure
(IAP). They observed higher levels of platinum in perito-
neal tumors and diaphragm but not in liver, kidney, and
heart with the IAP technique compared with intravenous or
classical IP. In this work, increased penetration in tumors
produced a better antitumor effect with increased survival
in rats treated with IAP. The next step would be to validate
the superiority of laparoscopic HIPEC in animals with in-
duced peritoneal carcinomatosis to determine platinum
levels in tumors and evaluate the clinical benefit in terms of
survival.
These results might stimulate us to investigate tissue drug
concentrations in patients that benefit from both techniques
in common practice to confirm our observations and eval-
uate the consequences in term of therapeutic effect and
toxic side effects.
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FIG. 1. Oxaliplatin concentration in liver, omentum, and perito-
neum in the laparotomy and laparoscopy groups. Each point is the
average of ten determinations; bars indicate standard deviations.
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Laparoscopically Assisted Heated 
Intra-Operative Intraperitoneal 
Chemotherapy (HIPEC): Technical 
Aspect and Pharmacokinetics Data
Gwenaël Ferron, Amélie Gesson-Paute, Laurence Gladieff, 
Fabienne Thomas, Etienne Chatelut, and Denis Querleu
Abstract Hyperthermic intraperitoneal chemotherapy (HIPEC) is being evaluated 
for patients with minimal residual or no residual disease after complete cytoreductive 
surgery. An experimental study on the porcine model was carried out to demonstrate 
the feasibility of the laparoscopic approach and to compare oxaliplatin pharmacoki-
netics during a laparoscopic assisted vs. the “coliseum” technique for HIPEC.
In the first step, feasibility of the peritonectomy procedure followed by HIPEC 
was evaluated in five adult pigs. In the second step, ten adult pigs were selected 
to receive laparoscopic assisted HIPEC procedure and ten pigs were selected for 
standard HIPEC in laparotomy. The HIPEC procedure was based on 460 mg/m2 
of oxaliplatin for 30 min with a heated perfusate at 41–43 °C. HIPEC drains were 
placed in the upper and lower quadrants of the abdomen. Peritoneal fluid and blood 
samples were collected every 10 min during the procedure and the pharmacokinetics 
of oxaliplatin was studied.
For the first step, the procedure was successfully completed with an adequate 
intrabdominal temperature and distribution. For the second step, no major technical 
problems were encountered. At the end of the HIPEC, 41.5% of the chemotherapy 
was absorbed in the laparoscopic group compared to 33.4% in the laparotomy group 
(p = 0.0543). The peritoneal oxaliplatin half-life (T1/2) was significantly shorter in 
the laparoscopic procedure (median value of 37.5 min vs. 59.3 min, p = 0.02). The 
area under the curve ratio for peritoneal/plasma reflects a faster oxaliplatin absorp-
tion through the peritoneal barrier in the laparoscopic procedure (ratio: 16.4 in the 
laparoscopic group vs. 28.1 in the laparotomy group, p = 0.03).
This study confirms the technical feasibility and reliability of the laparoscopic 
approach for HIPEC, and improves understanding of peritoneal drug absorption. 
Oxaliplatin absorption is significantly higher with laparoscopy, regarding time course 
in the peritoneal perfusion. Clinical application in selected patients may be expected 
after further experimental investigation designed to define adequate drug dosage.
G. Ferrron(!), A. Gesson-Paute, L. Gladieff, F. Thomes, E. Chatelut, and D. Querleu
Department of Surgical Oncology, Institut Claudius Regaud, 20-24 Rue du Pont Pierre, 
31052 Toulouse Cedex, France
e-mail: ferrongwenael@claudiusregaud.fr
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Introduction
Hyperthermic intraperitoneal chemotherapy (HIPEC) based on platinum compounds 
administration is being evaluated in patients with peritoneal carcinomatosis and 
sometimes in patients with previous intravenous chemotherapy. HIPEC has been 
proposed following advantage of IP vs. IV in randomized trials in patients with 
colorectal, gastric, peritoneal and ovarian cancer (1). We assume that HIPEC can 
be applied without performing a laparotomy, particularly when no bulky disease is 
present especially as a consolidation treatment after standard adjuvant chemotherapy 
or in cases of high risk of peritoneal recurrence. This may be  applicable during a 
second look laparoscopy in high risk cases. In addition, laparoscwopic surgery is 
adapted for adhesiolysis and comprehensive examination of the peritoneal cavity 
with acceptable accuracy and morbidity (2, 3).
To reinforce this approach, we performed a two step experimental study on the 
porcine model. The first step demonstrates the feasibility of laparoscopic peritonec-
tomy and heated intraperitoneal chemohyperthermia (HIPEC) (4). The second step 
compares the pharmacokinetics of oxaliplatin between an open vs. a laparoscopi-
cally assisted intraperitoneal hyperthermic chemotherapy (5).
Materials and Methods
A total of twenty five adult pigs were used. During the first step we performed 
five laparoscopic procedures to evalue the feasibility of peritonectomy followed 
by HIPEC. A 12 mm trocar was placed in the umbilical area to accommodate 
the endoscope. Four additional 12 mm Versastep® (Tyco Healthcare Group LP, 
Norwalk, Connecticut USA) trocars were placed in each quadrant of the abdomen 
(Fig. 1). The positioning of trocars in the four quadrants was planned to perform a 
complete peritonectomy and later to place the HIPEC drains. The umbilical trocar 
was then replaced by a Lapdisc® (Ethicon Endo Surgery Inc, Cincinnati, USA) 
allowing placement of the hand and forearm in the abdomen without any gas or 
liquid leakage. Four drains were placed under laparoscopic guidance: in the right 
and left upper quadrants with an inflow and an outflow circuit respectively. For 
the lower abdomen, the outflow drain was placed in the pelvis. The hand of the 
surgeon manipulated the inflow drain in order to evenly distribute the flow within 
the abdominal cavity. For the first step, no anticancer drug was used. At the end of 
the procedure, methylene blue was injected in order to check the completeness of 
peritoneal exposure to the heated fluid.
Twenty adult pigs were used for the second step. Half of the group under-
went HIPEC via laparotomy as previously described by Elias et al. (6) using the 
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“coliseum” technique. The other group of pigs underwent laparoscopically assisted 
HIPEC featuring the same dosage and physical parameters. Oxaliplatin was deliv-
ered at a dose of 460 mg/m2 filled heated (43 °C) in the abdominal cavity with a fixed 
volume (dextrose 5%–2L/m2) during 30 min (7). Knowing that the therapeutic index is 
optimal at 41–43 °C, the goal for achieving the adequate intraabdominal temperature 
was fullfilled using a perfusate heated at 46–52 °C, with a 1,360 mL/min flow that 
resulted in outflow temperature at 41–43 °C.
Blood and Peritoneal Fluid Sampling
Nine blood samples were collected from each animal at different times: before 
HIPEC, at time zero (T0) when the peritoneal fluid reached 43 °C, and every 
10 min during the procedure. Blood samples were then collected after the HIPEC 
at 45 min, 1 h, 1.5 h and 2 h after T0. Samples were immediately centrifuged at 
+4 °C, for 10 min at 1,500 g. For samples collected at the end of the procedure 
(i.e. 30 min after T0), at 1 and 2 h after the HIPEC beginning, an aliquot of plasma 
was ultrafiltered by centrifugation at +4 °C for 20 min at 2,000 × g through a 
Amicon MPS1 micropartition system with YMT membranes (cut-off 30,000 Da).
Five 5 ml samples of peritoneal fluid were collected from each animal at different 
time points: before the temperature reached 43 °C, at the beginning of the HIPEC and 
then every 10 min during the procedure. All samples were frozen at –20 °C until assay.
Fig. 1 Positioning of HIPEC drains with the surgeon’s right hand through the Lapdisc®
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Platinum Determination
Platinum levels in the plasma and in the plasma ultrafiltrate were measured by 
means of flameless atomic absorption spectrophotometric analysis according to 
a previously described method. Nominal values of platinum controls were 21, 
105 and 210 ng/mL for plasma ultrafiltrate and 20.9, 104.7 and 209.3 ng/mL for 
plasma samples. Platinum determination in samples was validated when measured 
control values were comprised within 10% for the medium and high level control 
and 20% for the low level control.
Results
In the first step, the peritonectomy procedure was successfully completed in all 
five animals. Active permanent manipulation of the bowel and viscera, and manual 
adaptation of the direction of the inflow by the surgeon’s hand, allowed us to obtain 
a homogeneous intraabdominal temperature. The distribution of blue dye was even 
in the abdominal cavity in all the pigs. Exposure of all peritoneal surfaces to heated 
perfusate, including the root of the mesentery and the omental bursa, was achieved.
In the second step, no noticeable technical problems were encountered in the 
laparotomy group as a result of our experience in human clinical practice. The 
most frequently encountered complication during laparoscopic procedures was 
circuit obstruction by the contact of small bowel and omentum with the tips of the 
drains in three procedures. As a result, target temperature was reached after 8 min 
(median value) in the laparotomy group vs. 12.5 min in the laparoscopic group 
(p = 0.03) (Fig. 2).
Pharmacokinetics of Heated Intraoperative 
Intraperitoneal Oxaliplatin
A decrease in platinum concentration was observed in the peritoneal perfusion during 
HIPEC in both groups (Fig. 3). Analysis of T1/2 of the drug showed a significantly 
faster tissue absorption of oxaliplatin in the laparoscopic group (median value: 
37.5 min vs. 59.3 min, p = 0.02), giving evidence that the “closed” technique seemed 
to influence and raise platinum absorption through the peritoneal barrier. At the time 
of completion of HIPEC, 41.5% of the chemotherapy was absorbed in the laparo-
scopic group, compared to 33.4% in the laparatomy group (p = 0.05).
Time Course of Oxaliplatin in the Peripheral Blood
Peak plasma concentration of platinum was observed on average 30 min after 
starting HIPEC in the laparotomy group whereas peak plasma concentration was 
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obtained after 46.4 min (p = 0.87) in the laparoscopic group (Fig. 4). Platinum 
concentration then dropped rapidly in both groups, resulting in a limited systemic 
area under the curve (AUC). The AUC2h was higher for the laparoscopic procedure, 
as was C2h in ultrafiltrat (Table 1). The AUC ratio peritoneal/plasma (at 30 min) 
was larger in the laparotomy group (28.1 vs. 16.4, p = 0.03), reflecting the fact 
that oxaliplatin was kept in the abdominal cavity with less penetration through the 
peritoneal barrier to the blood compartment compared to the laparoscopic group. 
During HIPEC, oxaliplatin was more rapidly absorbed in the laparoscopic group: 
41.5% of oxaliplatin was absorbed in the laparoscopic group, compared to 33.4% 
in the laparotomy group at the end of the HIPEC procedure (p = 0.0543).
Discussion
Development of intraperitoneal drug therapy is one of the main areas of research 
to improve the long-term survival for patients with peritoneal carcinomatosis. 
Encouraging results of a randomized controlled study of HIPEC in the manage-
ment of peritoneal carcinomatosis in colorectal cancer patients have been published 
(8). HIPEC has also been proposed in ovarian cancers, mesothelioma and pseu-
domyxoma peritonei (9, 10). Laparoscopic techniques may prove to be an optimal route 
Fig. 2 Temperature curve of optimal procedure in each group
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Fig. 3 Decrease in oxaliplatin concentrations in heated peritoneal instillation (460 mg/m2). First 
point (t = 0 min) corresponds to concentration in the peritoneal fluid before the HIPEC (i.e. before 
the temperature of 43 °C was reached)
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to administer intraperitoneal chemotherapy especially after complete cytoreductive 
surgery and adjuvant chemotherapy as a consolidation treatment. This approach can 
also be utilised in cases at high risk of peritoneal recurrence in patients with color-
ectal cancer or gastric cancer. HIPEC administered in only one session, under direct 
surgical monitoring, might be more applicable in clinical practice than sequential 
intraperitoneal chemotherapy using permanent catheters.
The possibility of using a closed technique, while manipulating the viscera using 
the hand-assisted technique and/or laparoscopic instruments, combines advantages 
of both laparotomy techniques.
In this study, we developed techniques to overcome the limitations of a “closed” 
HIPEC procedure in terms of intraabdominal temperature homogeneity and complete 
exposure of all peritoneal surfaces, including the root of the mesentery and the omen-
tal bursa, to heated perfusate. Considering that manual mobilisation of the bowel by 
the surgeon’s hand is an essential component of even distribution of the drug and 
complete exposure of the bowel (6), the use of hand-assisted technique has proved to 
be useful. Xiphopubic laparotomy is no longer required. In this regard, the laparoscopic 
hand-assisted HIPEC is superior to standard “closed” HIPEC procedure that has been 
Table 1 Oxaliplatin concentrations after heated intraperitoneal chemotherapy (460 mg/m2)
Laparotomy Laparoscopy p
Mean ultrafiltrate C2h (ng/ml) 2295.26 2994.17 0.04
Mean plasma AUC2h (ng/ml × min) 1102.01 1292.65 0.23
Median peritoneal T1/2 (min)  59.3  37.5 0.02
AUC Area under the plasma concentration-time curve; T1/2 Half life elimination
Fig. 4 Oxaliplatin pharmacokinetics in plasma after heated intraperitoneal chemotherapy (460 mg/m2)
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proposed for palliation of debilitating malignant ascites in a series of 14 patients 
(11). Hand-assisted surgery mimicks the Sugarbaker modification of the “coliseum” 
technique using an impermeable disposable drape covering the entire operative field 
with a cruciate cut in its central portion to open the access site to the surgeon’s arm 
(12). In addition, the laparoscopic technique avoids exposure of the operative room 
staff from droplets of chemotherapy and aerosols that may escape into the environ-
ment (13). This study provides evidence that laparoscopic HIPEC is feasible, and was 
successfully completed in all animals after resolution of minor technical problems 
(15 cases with a laparoscopic approach). The minimal additional time to reach target 
temperature is likely to disappear with experience.
From the pharmacokinetic point of view we demonstrated that laparoscopic 
HIPEC provides equivalent exposure of the peritoneum compared to an open one. 
Evidence is given that high intraabdominal pressure facilitates drug penetration into 
the blood compartment. A massive crossing of the molecule through the peritoneal 
barrier has been observed, but these results must be interpreted with caution, as they 
are significant only for ultrafiltrat values. Further experimental studies are required, 
to investigate tissue concentrations of platinum in the peritoneum, liver and omentum, 
assess the role of peritoneal pressure, and define appropriate dosage of drug, taking 
into account higher blood concentrations of drug during laparoscopic procedures.
Conclusions
This experimental study provides further evidence of the feasibility and reliability 
of HIPEC laparoscopic approach. We obtained optimal conditions in terms of tem-
perature and agent distribution in the laparoscopy group as well as the laparotomy 
group. The hand-assisted concept is revolutionary compared to classic “closed” 
techniques and matched the requirements of the open approach from the technical 
point of view. In addition, the “closed” procedure avoids drug exposure to the staff 
present in the operative room. The results of this study favours further investiga-
tion of the role of laparoscopic HIPEC as an innovative application of laparoscopic 
surgery in surgical oncology, with the aim of reducing surgical morbidity and hope-
fully improving the quality of life of patients.
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!2.1.3:!Discussion!and!future!prospect!!Knowledge! has! profoundly! changed! during! the! two! last! decades! about! peritoneal!carcinomatosis.! Initially! palliative! treatment! was! the! only! one! issue! for! patients,!associated!with! a! shortGterm! survival! and! a! bad! quality! of! life,! resulting! in! intestinal!obstruction! over! months! and! a! fatal! outcome! with! progression! of! intraperitoneal!disease.! The! new! approach! combining! cytoreductive! surgery! and! intraperitoneal!carcinomatosis!offers!hope!for!longGterm!survival!in!selected!patients.!Peritoneal! carcinomatosis! can! be! quantified! using! a! recommended! score,! with! the!extend!directly!correlating!with! treatment!success.!Limited!carcinomatosis,!with!a! low!PCI! (Peritoneal!Cancer! Index)!represents!a! therapeutic!challenge!regarding! to! the!real!possibility!to!cure!these!patients.!As! previously! described,! the! introduction! of!minimal! invasive! surgery! has! completely!modified! the! recruitment! of! patients.! Currently,! patients! are! referred! with! limited!peritoneal! extension! after! a! laparoscopic! evaluation! and! sometime! a! laparoscopic!resection!of!the!tumor.!Laparoscopy!represents!the!recommended!surgical!approach!for!exploration! of! adnexal! mass,! ascitis! or! for! resection! of! early! colorectal! cancer.!Prophylactic!HIPEC!for!patient!with!a!high!risk!of!developing!PC!from!colorectal!cancer!is!currently!on!evaluation!in!France!(ProphyloCHIP!trial).!Using!laparoscopic!represents!the! best! way! to! deliver! HIPEC! without! the! need! to! extensive! peritonectomy.! The!necessity! of! adhesiolysis! determines! the! complexity! of! the!procedure! and! requires! an!operating!team!with!experience!in!minimally!invasive!abdominal!surgery.!We!described!the!first!application!of!laparoscopy!for!peritonectomy!and!HIPEC.!PK!data!published,! with! a! favorable! modification! of! the! ratio! between! peritoneal! AUC! and!!plasma! ultrafiltrated! AUC,! has! confirmed! the! difference! observed! between! open! and!close! abdomen! technique.! According! to! these! results,! a! 30%! decreasing! dose! rate! is!recommended! when! using! a! close! abdomen! technique! compared! to! its! open!counterpart.!This!difference!was!confirmed!by!OrtegaGDebalon!in!an!experimental!study![63].!Our!hypothesis!concerning!the!increased!tissue!diffusion!during!laparoscopic!HIPEC!was!the! role! of! intraGabdominal! pressure.! It! was! confirmed! in! two! consecutive! works!published! by! Facy! [64].! The! authors! shown! that! the! association! of! hyperthermia! and!highGpressure!(25!cm!H2O)!increased!tissue!penetration!of!oxaliplatin!better!than!either!of! them! alone! and! did! not! significantly! increase! systemic! absorption.! The! interest! to!enhance!the!intraGabdominal!pressure!up!to!40!cm!H2O!was!also!evaluated.!Despite!an!enhancing! effect! on! the! concentration! of! drug! in! the! peritoneum,! very! high! intraGabdominal! pressure! (40! cm!H2O)!does!not! improve! the!depth!of! penetration! into! the!tissue! [65].! Increasing! the! pressure! to! the! maximal! tolerated! pressure! in! the! closed!procedures!seems!to!be!without!benefit,!because!the!drug!concentrations!at!25!and!40!cm! H2O!were! not! different.! IntraGabdominal! highGpressure! was!well! tolerated! in! this!experimental!model.!In!human!application,!highGpressure!pneumoperitoneum!caused!a!significant! decrease! in! static! respiratory! system! compliance! and! an! increase! in!inspiratory!resistance,!and!represents!a!limitation!for!obese!patients.!!
! 31!
On!the!other!hand,!adverse!impact!on!the!surgical!peritoneal!environment!during!a!CO2!pneumoperitoneum! has! been! described! [66],! with! an! increased! expression! levels! of!connective! tissue! growth! factor,! matrix! metalloproteinaseG9,! EGselectin,! chemokine!ligand! 2! (CXCLG2),! HyalG1! and! HyalG2.! HighGpressure! laparoscopy! has! a! negative!oncologic! impact! increasing! postoperative! tumor! growth! and! dissemination! [67],! and!facilitated!implantation!of!malignant!cells!and!port!site!metastases![68].!After!we!reported!the!feasibility!of!laparoscopic!peritonectomy!and!HIPEC,!Facchiano!et!al! [69]! reported! the! first! human! application,! in! palliative! care,! for! treatment! of!malignant! ascites! secondary! to!unresectable!peritoneal! carcinomatosis! from!advanced!gastric! cancer.! Esquivel! et! al! [70]! reported! in! 2009! the! first! case! of! combined!laparoscopic! cytoreductive! surgery! and! HIPEC! with! curative! intent! in! a! patient! with!limited! peritoneal! mesothelioma! using! our! published! technique.! The! same! team!published![71]!a!10!cases!consecutive!!series!and!demonstrated!the!feasibility!and!safety!of!cytoreductive!surgery!and!HIPEC!via!the!laparoscopic!route!in!selected!patients!with!lowGtumor! volume! and! no! small! bowel! involvement! mainly! from! appendiceal!malignancies.! Fagotti! et! al! [72]! confirmed! the! feasibility! of! this! technique! in! selected!platinumGsensitive!single!recurrent!ovarian!cancer!patients.!Rettenmaier!et!al.![73]!has!used! laparoscopic! carboplatin! based! HIPEC! as! a! consolidation! treatment! for! ovarian!cancer! patient! with! a! complete! response! after! neoadjuvant! chemotherapy.! Its!reproducibility! and! safety!were! confirmed!by!Passot! ! [74]! and!Esquivel! [75].! Patients!with! low!grade!pseudomyxoma!peritonei!and! limited!peritoneal!disease!(PCI! less! than!10)! underwent! a! laparoscopic! cytoreductive! surgery! and! HIPEC.! The! authors! have!concluded!that!laparoscopic!CRS!combined!with!HIPEC!is!feasible!and!safe!for!curative!treatment! of! strictly! selected! patients! with! peritoneal! surface! malignancy! and! might!reduce! postoperative! complications! and! length! of! hospital! stay.! As! prophylaxis! for!patients! with! high! risk! of! developing! peritoneal! carcinomatosis,! Sloothaak! et! al! has!confirmed!the!safety!and!the!short!hospital!stay! in!a!monocentric!pilot!study!by!using!laparoscopic! mitomycin! C! based! HIPEC! [76].! In! 2012,! a! review! was! published!concerning!laparoscopic!HIPEC![77].!Eight!studies!encompassing!a!total!of!183!patients!were! reported.! Indication! for! laparoscopic! HIPEC! was! neoadjuvant! in! 5! patients,!adjuvant!in!102!patients,!and!palliative!in!76!patients.!Using! nebulizers,! the! pneumoperitoneum! may! become! a! new! way! to! administer!intraoperative! treatments! [78].! It! have! been! developed! by! a! german! team! and! called!PIPAC! (Pressurized! intraperitoneal! aerosol! chemotherapy).! The! principle! is! to! apply!chemotherapy! as! a! pressurized! aerosol! within! the! abdominal! cavity! allowing! a!homogeneous!repartition!of!the!cytotoxic!agent.!For!the!authors,!it!generates!a!pressure!gradien,! which! counterbalances! tumoral! interstitial! fluid! pressure.! Ten! studies,!including!2!ex!vivo!and! in!vitro!studies,!6!clinical! studies,!and!2!ongoing!clinical! trials!using!PIPAC! in!women!with! recurrent!ovarian! cancer!have!been! identified.!PIPAC!has!demonstrated! antitumor! activity! based! on! histological,! radiological,! and! clinical!evidence![79].!The!toxicity!of!PIPAC!is!manageable.!The!ongoing!development!of!PIPAC!is! currently! dedicated! to! recurrent! disease! and! palliative! intent.! Using! neoadjuvant!PIPAC!will!be!the!next!step,!with!an!evaluation!of!the!postoperative!morbidity.!Effective! precautions! have! to! be! taken! in! order! to! minimize! workers! exposure.! The!members!of!the!operating!room!staff!are!usually!familiar!with!the!risks!of!exposure!to!various!infectious!agents,!to!various!solvents,!to!the!anesthetic!gases!and!to!XGrays.!The!management! of! PC! adds! exposure! to! surgical! smokes! and! to! cytotoxic! drugs.! A! few!
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publications! have! confirmed! a! possible! drug! contamination! of! surface’s! workplace,!especially! around! the! operating! table! [80].! Risk! of! exposure! is! minimized! in! Close!Abdomen!HIPEC! than! in!Open! abdomen.! ! Several! reports! have!documented! identified!drugs!in!the!urine!of!health!care!workers,!and!measured!genotoxic!responses!in!workers![81].!No!detectable!levels!of!the!cytotoxic!agent!were!present!in!any!of!the!samples![82].!A!residual!risk!is!mainly!due!to!the!possibility!of!direct!or!indirect!skin!exposure!and!can!be!prevented!by! the! correct!use!of! personal!protective! equipment! [83].!The! failure! to!detect! chemotherapy! residues! depends! on! the! measuring! techniques! used,! taking! on!board!the!chosen!detection!threshold![84].!Many!of!the!antineoplasic!agents!are!known!or!suspected!human!carcinogens,!effects!on!fertility!and!reproduction!are!documented![85,!86].!Chromosomal!aberrations,!micronuclei! induction,!DNA!damage! represent! the!most! frequent! abnormities! for! occupational! exposure.! Although! limited,! some!publications!exist!on!the!relationship!of!occupational!exposure!to!cytotoxic!agents!with!cancer! in! health! care! workers! [87].! Data! are! missing! concerning! the! real! impact! to!HIPEC!exposure.!There!are!not!currently!any!formal!European!Guidelines!about!the!type!of! PPE! to! be!used! for! the!HIPEC!procedure.! Some! teams! follow! the! recommendations!made!by!the!National!Institute!for!Occupational!Safety!and!Health![88].!!After! a! first! article! concerning! either! environmental! contamination! risk!management,!personal! protective! equipment,! or! occupational! health! supervision! [89],! a! practices!survey! was! carried! out! in! France,! via! the! RENAPE! Network.! This! publication! was!recently!submitted!to!the!Annals!of!Surgical!Oncology.!!!Considering!the!advantages!of!close!abdomen!HIPEC!on!safety!environmental!aspects,!the!laparoscopic!technique!avoids!exposure!of!the!operative!room!staff!from!droplets!of!chemotherapy!and!aerosols.!!!!!
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2.2:) EVALUATION) OF) THE) PHARMACOKINETIC) INTERNPATIENT) VARIABILITY) OF)
OXALIPLATIN)BASED)OPEN)ABDOMEN)HIPEC)AND)COMPARISON)OF)THE)IMPACT)
OF)TWO)PROCEDURES)OF)DRUG’S)DELIVERY)ON)OXALIPLATIN)PK.)A)POPULATION)
PHARMACOKINETIC)APPROACH.)!!Pharmacokinetics! (PK)! of! heated! intraperitoneal! oxaliplatin!was! previously! published!by!the!Gustave!Roussy!PK!team![90].!However,!no!model!was!used!to!analyze!the!data.!The! aim! of! this! study! was! to! develop! a! PK! model,! which! is! able! to! simultaneously!describe!peritoneal!and!plasma!oxaliplatin!concentrations!versus!time!in!order!to!obtain!mean!PK!parameters!and!their!interGindividual!variability.!!2.2.1:To!develop!a!PK!model!and! to!compared! the! impact!of! two!procedures!of!drug’s!delivery!This!model! was! applied! to! compare! the! impact! of! two! procedures! of! drug’s! delivery!during! HIPEC! on! oxaliplatin! PK.! Indeed,! European! Community! approved! reheaters! –!recirculators! have! been!marketed.! Two! different! procedures! for! drug’s! delivery!were!also!used,!depending!to!the!“school”!of!HIPEC!training,!related!to!the!marketing!of!new!European!Community!approved!reheaters:!! G!for!the!first!procedure!(12!patients):!the!solution!instilled!within!the!peritoneal!cavity! contained! oxaliplatin,! and! a! delay! of! 8G10!minutes!was! necessary! to! reach! the!targeted!temperature!(42G43°C)!! G!for!the!second!procedure!(12!patients):!the!cavity!was!initially!filled!only!with!the!carrier!solution.!Oxaliplatin!was!added!to!the!peritoneal!instillate!when!the!targeted!temperature!was!reached.!Plasma! and! peritoneal! fluid! oxaliplatin! concentrations! were! analyzed! according! to! a!population!PK!approach!using!NONMEM!according!to!a!threeGcompartment!model.!An! interGindividual!variability!was!reported,! larger! for!plasma!PK!parameters! than! for!peritoneal! parameters.! The!percentage!of! oxaliplatin!dose! absorbed!during! the!HIPEC!procedure!may!vary!from!40!to!68%.!The!heated!intraGoperative!procedure!did!not!have!any!impact!on!oxaliplatin!PK.!This!PK!model!is!useful!to!implement!PK!evaluation!of!further!oxaliplatin!based!HIPEC!clinical!trails.!This!work!was!published!in!Cancer!Chemotherapy!and!Pharmacology.!Ferron!G,!Dattez!S,!Gladieff!L,!Delord!JP,!Pierre!S,!Lafont!T,!Lochon!I,!Chatelut!E.!!
Pharmacokinetics)of)heated)intraperitoneal)oxaliplatin.)Cancer!Chemother!Pharmacol.!2008!Sep;62(4):679G83.!
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Abstract
Objective To evaluate the pharmacokinetic inter-patient
variability of 30-min hyperthermic intraperitoneal oxalipla-
tin chemotherapy.
Patients and methods Data were obtained from 24
patients who were treated according to two procedures of
heated intra-operative intraperitoneal oxaliplatin. For the
Wrst procedure (12 patients), the solution instilled within the
peritoneal cavity contained oxaliplatin, and a delay of 8–
10 min was necessary to reach a temperature of 42–43°C.
For the second procedure (12 patients), the cavity was ini-
tially Wlled only with the dextrose solution, and oxaliplatin
was added to the peritoneal instillate when temperature
reached 42–43°C. Plasma and peritoneal Xuid oxaliplatin
concentrations were analyzed according to a population
pharmacokinetic approach using NONMEM.
Results Peritoneal and total plasma data were simulta-
neously analyzed according to a three-compartment phar-
macokinetic model. The peritoneal half-life ranged between
18 and 42 min. The mean peritoneal clearance was 5.47 L/h
(§21%), and the mean plasma clearance was 3.71 L/h
(§47%). The heated intra-operative procedure did not have
any impact on oxaliplatin pharmacokinetics.
Conclusion The inter-individual variability was larger for
plasma pharmacokinetic parameters than that for peritoneal
parameters. However, the percentage of oxaliplatin dose
absorbed during a 30-min hyperthermic intraperitoneal
chemotherapy may vary from 40 to 68%. The present
pharmacokinetic model will be useful to implement phar-
macokinetic evaluation of further clinical trials of hyper-
thermic intraperitoneal chemotherapy based on platinum
compounds’ administration.
Keywords Population pharmacokinetics · 
Intraperitoneal chemotherapy · Oxaliplatin · HIPEC · 
Carcinomatosis
Introduction
In the past two decades, the evolution of loco regional ther-
apy has changed the management of peritoneal surface
malignancies. Encouraging results of a randomized con-
trolled study of hyperthermic intraperitoneal chemotherapy
(HIPEC) in the management of peritoneal carcinomatosis
in colorectal cancer patients have been published [10].
HIPEC has also been proposed in ovarian cancers, perito-
neal mesothelioma and pseudomyxoma peritonei [9].
HIPEC administered in only one session, after complete
cytoreduction under direct surgical monitoring, might be
more applicable in clinical practice than in sequential intra-
peritoneal chemotherapy using permanent catheters [7].
Pharmacokinetics (PK) of heated intraperitoneal oxalipl-
atin have been previously reported [2–4]. However, no
model has been used to analyze the data. The aim of the
current study was to develop a PK model which is able to
simultaneously describe peritoneal and plasma oxaliplatin
concentrations versus time in order to obtain mean PK
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parameters and their interindividual variability. This model
has been applied to compare the impact of two procedures
of HIPEC on oxaliplatin PK.
Patients and methods
Patients and oxaliplatin administration
Data were obtained from 24 patients who were treated from
June 2005 to January 2007 for primary or recurrent perito-
neal carcinomatosis with debulking surgery and HIPEC.
Their primitive tumor type was ovarian (n = 17), colorectal
(n = 5), mesothelioma (n = 1), or pseudomyxoma (n = 1). All
except the two patients with mesothelioma, or pseudomyx-
oma, were previously treated by intravenous chemotherapy.
All patients provided written informed consent before
study enrolment. The main patient characteristics are
shown in Table 1. HIPEC procedures were conducted as
previously described by Elias et al. [4] with the “coliseum”
technique. Oxaliplatin was administered in a 5% dextrose
solution (2 L/m2) at a dose of 460 (n = 17) or 360 mg/m2
(n = 7). The initial dose (i.e., 460 mg/m2) was reduced for
the Wnal seven patients treated due to toxicity. The Wrst 12
patients were treated according to the Wrst HIPEC proce-
dure (group 1), and the following 12 patients to the second
procedure (group 2). For the Wrst procedure, the solution
instilled within the peritoneal cavity contained oxaliplatin,
and a delay of 8–10 min was necessary to reach a tempera-
ture of 42–43°C. For the second procedure, the cavity was
initially Wlled only with the dextrose solution, and oxalipla-
tin was added to the peritoneal instillate when the tempera-
ture reached 42–43°C. The extracorporeal circulation of the
Xuid was realized using the Performer LRT® System
(Medolla, MO, Italy). Perfusion duration was exactly
30 min from the time when optimum temperature (42–
43°C) was reached.
Sampling and platinum assay
Seven peritoneal Xuid samples were collected (every 5 min
during the 30-min HIPEC) per patient. An additional peri-
toneal sample was obtained just before the warm-up period
for the Wrst 12 patients (HIPEC procedure 1). Eleven blood
samples (5 mL) were collected: before the HIPEC, 0.167,
0.333, 0.5, 0.75, 1, 2, 4, 6, and 8 after the beginning of the
HIPEC. Blood samples were immediately centrifuged at
2,000£g for 10 min at 4°C. One milliliter of plasma was
ultraWltered using an Amicon MPS1 micro partition system
with YMT membranes (30,000 MW cut-oV) at 4°C for
20 min at 2,000£g.
Peritoneal Xuid samples were collected: at the beginning
of the perfusion (for the 12 Wrst patients only), at the begin-
ning of HIPEC, and every 5 minutes during HIPEC.
Samples were kept at ¡20°C until analysis by Xameless
atomic absorption spectrophotometry, according to a previ-
ously described method [8]. The limit of quantiWcation was
10 ng/mL for both peritoneal Xuid and ultraWltrate, and
20 ng/mL for plasma.
Pharmacokinetic analysis
Peritoneal and total plasma data
Peritoneal and plasma data from the 24 patients were
simultaneously analyzed using NONMEM (version V,
level 1.1 running on Pentium 200 pro) [1] according to a
three-compartment pharmacokinetic model (Fig. 1) and a
Wrst-order conditional estimation (FOCE) method. A pro-
portional error model was used for residual and inter-
patient variability. Individual pharmacokinetic parameters
were obtained by Bayesian estimation using the POSTHOC
option. The impact of the HIPEC technique (TECH = 0,
or = 1 for the Wrst or the second procedure, respectively) on
absorption rate from peritoneal compartment to plasma,
Ka, was tested according to the following equation:
TVKa = !5 £ (1 ¡ !7 £ TECH) where !5 is the typical
value of Ka (TVKa) of patients for whom TECH = 0, and
!5 £ (1 ¡ !7) that of patients for whom TECH = 1. A Wrst
analysis was done by allocating a constant value of TECH
(either 0 or 1) for all samples during the HIPEC procedure.
A second analysis was done by coding TECH = 1 only for
samples during the warm-up period and then TECH = 0.
The two models with the covariate TECH were compared
to that without covariate by the "2 test of diVerence
between the respective objective function values (OBJs);
OBJ equal to minus twice the log likelihood of the data. A
change of at least 3.84 (P < 0.05, one degree of freedom)
was required to consider Ka as signiWcantly dependent of
the covariate TECH.
UltraWltrate plasma data
Since ultraWltrate (uf) plasma concentrations observed at
time 6 and/or 8 h were higher than those observed at previ-
ous sampling time for 12/24 patients, no attempt was made
to obtain a structural pharmacokinetic model to describe the
Table 1 Characteristics of the 24 patients 
Characteristics Mean Range
Gender (male/female) 2/22
Age (years) 53 32–68
Body weight (kg) 65 50–90
Dose of oxaliplatin (mg) 711 460–880
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observed uf plasma data. The pharmacokinetic parameters
corresponding to uf plasma concentrations were obtained
by model independent method using Kinetica software
(version 4.1, InnaPhase, Waltham, MA, USA). Mixed lin-
ear and logarithmic trapezoidal rule was used to calculate
the area under the curve of the uf plasma concentrations
versus time from time 0 to 8 h after the beginning of the
HIPEC (AUC0-8 h).
Results
Pharmacokinetics
Peritoneal and total plasma data
The structural pharmacokinetic model was found to
describe the data very accurately with a residual variability
of 8 and 13% for peritoneal and plasma concentrations,
respectively. Figure 2 shows the mean observed peritoneal
(Fig. 2a) and total plasma (Fig. 2b) concentrations versus
time, and concentrations corresponding to mean pharmaco-
kinetic parameters obtained by the model. The mean phar-
macokinetic parameters and their interindividual variability
are shown in Table 2. The inter-individual variability was
larger for plasma pharmacokinetic parameters than that for
peritoneal parameters. Figure 3 shows that the absorption
rate (Ka) of oxaliplatin from peritoneal compartment to
plasma was not dependent on the administered dose. The
mean peritoneal half-life (=ln 2/Ka) ranged between 18 and
42 min.
By considering the covariate TECH during either the
whole HIPEC procedure or only during the warm-up
period, no signiWcant decrease of the OBJ was observed
indicating that there was no change in Ka due to the HIPEC
technique. Figure 3 conWrms that individual values of Ka
were not dependent on the procedure.
UltraWltrate plasma data
The mean uf plasma AUC0-8 h was 13.7 !g/mL £ h (range:
8.0–20.0 !g/mL £ h). As previously stated to justify the
model-independent method to analyze these data, the mean
uf concentration (Fig. 4) at T + 8 h was slightly higher than
that at T + 6 h.
Fig. 1 Pharmacokinetic model with Ka = 0 when time > duration of
the peritoneal infusion, and peritoneal and plasma concentrations
corresponding to the peritoneal and central compartment, respectively
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Fig. 2 Mean (§SD) observed peritoneal (a) and total plasma (b)
oxaliplatin concentrations, and curve of concentrations versus time
corresponding to the mean pharmacokinetic parameters
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Toxicity
Major morbidity (grade 3 and 4) occurred in eight patients in
group 1 (Wrst HIPEC procedure), and in four patients in
group 2 (second HIPEC procedure). The most signiWcant
morbidities were abdominal bleeding, anastomotic leaks,
sensory alteration or paresthesia, infection complications,
systemic inXammatory response syndrome, and thrombocy-
topenia. Eight patients in group 1 and one patient in group 2
developed abdominal bleeding. Grade 3–4 thrombocytopenia
occurred in ten patients in group 1, and one patient in group
2. Systemic inXammatory response syndrome associated
with clinical peritonitis and a high level of C reactive protein
was seen in nine patients in group 1, and none in group 2.
Discussion
Pharmacokinetics of oxaliplatin given by HIPEC has been
previously reported, but this study was the Wrst based on a
population approach allowing to analyze all peritoneal and
plasma data from 24 patients simultaneously. The mean
value of 29 min (range 18–42 min) obtained for the perito-
neal half-life was consistent with those previously reported
(i.e., 30 min [2] or 40 min [3]). The absorption process was
not dependent on the dose (Fig. 3). The NONMEM meth-
odology also allowed us to evaluate if the procedure had an
impact on the absorption speciWcally during the warm-up
period: Ka was not signiWcantly diVerent during this period
in comparison with the period with peritoneal liquid at 42–
43°C. Since the pharmacokinetic model well described the
peritoneal data it is possible to estimate the mean absorbed
dose of oxaliplatin according to the mean Ka and the dura-
tion of the HIPEC procedure: half of the dose is absorbed
after 30 min of HIPEC. However, although the interindivid-
ual variability on Ka was limited (i.e., coeYcient of varia-
tion of 22%), there was a ratio of 2 between the extreme
values indicating that for some patients the percentage of
dose absorbed during a 30-min HIPEC may vary between
40 and 68%. This diVerence contributed to the variability of
the plasma oxaliplatin concentrations that was also the con-
sequence of the interindividual variability in plasma phar-
macokinetic parameters (i.e., 47% for plasma clearance).
The proWle of ultraWltered plasma oxaliplatin concentra-
tions was unexpected. For most of the patients, concentra-
tions at time 6 or 8 h were higher than those at previous
sampling time. This was also observed in the experimental
model of HIPEC in pigs [5]. We can make the hypothesis
that platinum compounds are released from the peritoneal
membranes lately after the end of the HIPEC. This fraction
does not necessarily correspond to unchanged oxaliplatin.
Indeed, we could make the hypothesis that oxaliplatin may
be conjugated with glutathione by the glutathione-S-trans-
ferase within the cells constituting the peritoneal mem-
branes and then transported out of the cells to the plasma
compartment by the MRP transporters. Since platinum glu-
tathione S-conjugates are relatively small molecules [6],
they would contribute to this rebound of the uf plasma con-
centrations.
A signiWcant correlation was observed between uf
plasma AUC and platelet count at nadir (r = ¡0.58,
P < 0.01, data not shown). However, the diVerence in
hematologic toxicity may be explained by considering only
the oxaliplatin dose: mean (§SD) nadir count of platelets
was signiWcantly lower (P < 0.001) after 460 mg/m2 of oxa-
liplatin than after 360 mg/m2: 86,900 (§69,600)/mm3 and
198,400 (§29,700)/mm3, respectively. The previous
hypothesis relative to platinum glutathione S-conjugates
could explain why pharmacokinetic–pharmacodynamic
relationship is not stronger than that between dose and tox-
icity. Moreover, thrombopenia was also the consequence of
post-operative hemorrhage that was more frequent for
patients for whom the Wrst HIPEC procedure was
Table 2 Mean peritoneal and plasma oxaliplatin pharmacokinetic
parameters
CV coeYcient of variation
* Harmonic mean
** Extreme values
Parameter Mean CV (%)
Peritoneal
Volume of distribution (L) 3.95 17
Clearance (L/h) 5.47 21
Ka (h¡1) 1.40 22
T1/2 (h) 0.49* 0.30–0.70**
Plasma
Central volume of distribution (L) 15.3 27
Clearance (L/h) 3.71 47
T1/2!((h) 0.21* 0.18–0.22**
T1/2"((h) 12.9* 5.33–38.08**
Fig. 4 Mean (§SD) observed ultraWltered plasma oxaliplatin concen-
trations
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performed. Since all of them received 460 mg/m2 of
oxaliplatin, whereas 7 of 12 patients with second HIPEC
procedure received 360 mg/m2, HIPEC procedure probably
contributed as much as the oxaliplatin doses or plasma con-
centrations to this hematological toxicity. Besides the phar-
macokinetic results, this study showed the impact of the
HIPEC procedure on toxicity. Detailed clinical (both toxic-
ity and eYcacy) results will be reported elsewhere.
In conclusion, the present pharmacokinetic model
allowed us to quantify the respective interindividual vari-
ability to peritoneal and systemic processes. It will be use-
ful to implement pharmacokinetic evaluation of further
clinical trials of HIPEC based on oxaliplatin administration
that is planned.
Acknowledgment We thank Miss Tracy Chapman for editorial
assistance with the English.
References
1. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit
Rev Biomed Eng 8:195–222
2. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA,
Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002)
Heated intra-operative intraperitoneal oxaliplatin after complete
resection of peritoneal carcinomatosis: pharmacokinetics and
tissue distribution. Ann Oncol 13:267–272
3. Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L,
Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P,
Ducreux M (2004) Heated intra-operative intraperitoneal oxalipl-
atin plus irinotecan after complete resection of peritoneal carcino-
matosis: pharmacokinetics, tissue distribution and tolerance. Ann
Oncol 15:1558–1565
4. Elias D, Raynard B, Bonnay M, Pocard M (2006) Heated intra-
operative intraperitoneal oxaliplatin alone and in combination with
intraperitoneal irinotecan: pharmacologic studies. Eur J Surg
Oncol 32:607–613
5. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E,
Querleu D (2007) Pharmacokinetics of oxaliplatin during open
versus laparoscopically assisted Heated Intraoperative Intraperito-
neal Chemotherapy (HIPEC): an experimental study. Ann Surg
Oncol (available online)
6. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas
M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin:
a critical review. Clin Cancer Res 6:1205–1218
7. Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the
initial management of primary epithelial ovarian cancer. Cochrane
Database Syst Rev CD005340
8. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE,
Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA
(1977) Analysis of platinum in biological materials by Xameless
atomic absorption spectrophotometry. Biochem Med 18:184–191
9. Sugarbaker PH (2007) Adjuvant intraperitoneal chemotherapy:
a review. Recent Results Cancer Res 169:83–89
10. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren
H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduc-
tion and hyperthermic intraperitoneal chemotherapy versus systemic
chemotherapy and palliative surgery in patients with peritoneal
carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743
! 34!
!!2.2.2:!Discussion!and!future!prospect!Standardization! of! HIPEC! technique! represents! an! important! challenge! in! order! to!conduct! multiGinstitutional! and! international! trials.! According! to! the! results! to! our!practices!survey,!a!relative!homogeneity!of!the!practices!was!shown!in!France,!linked!to!the!“schools”!of!HIPEC,!with!more!than!half!of!the!teams!having!been!in!practice!for!over!10! years.!Whatever! an! open!or! closed!method! for!HIPEC! is! used,! is! still! based!on! the!surgeon’s! preference! and! training.! The! most! frequently! performed! open! abdomen!procedure! was! established! by! Sugarbaker,! and! soGcalled! “Coliseum! technique”.! Open!HIPEC! technique! allows! a! manual! distribution! of! the! perfusate.! Two! European!Community!approved!reheaters!–!recirculators!are!commonly!used! in!France! for!open!abdomen! technique,! with! two! different! ways! to! deliver! hyperthermia! and! IP!chemotherapy:!!G!First,!by!using!the!SunCHIP!reheater:!increasing!of!temperature!occurred!quickly,!the!solution!instilled!within!the!peritoneal!cavity!contain!immediately!oxaliplatin.!!G! Second,! by! using! the! Performer! LRT! reheater:! increasing! of! temperature! occurred!slowly,!8!to!10!minutes!are!necessary!to!reach!42G43°C.!When!the!targeted!temperature!is!reached,!oxaliplatin!is!instilled.!!We! have! demonstrated! that! the! heated! intraGoperative! procedure! did! not! have! any!impact!on!oxaliplatin!PK.!!Our!work! has! contributed! to! improve! the! homogeneity! of! technique.! For! clinical! trial!enrollment,!data!of!patients!and!PK!studies!may!be!substantially! similar!whatever! the!device!and!the!technique!used.!!!!!
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2.3:)EVALUATION)OF)THE)TOXICITY)FOR)PATIENTS)WHO)UNDERWENT)COMPLETE)
CYTOREDUCTIVE)SURGERY)ASSOCIATED)TO)CISPLATIN)AND)OXALIPLATIN)BASED)
HIPEC.)CLINICAL)AND)PHARMACODYNAMIC)STUDIES)!!The!use!of!HIPEC!was!initially!developed!as!a!treatment!for!rare!peritoneal!disease!and!has! continuously! gain! interest.! But! at! the! beginning! of! our! experience,! 13! years! ago,!there!was!an!important!lack!of!data!regarding!toxicity!and!PKGPD!studies.!First!reported!experiences! were! focused! on! reproducibility! in! small! sample! size.! Moreover,! these!series! were! retrospective! with! heterogeneous! patients! cohorts! and! technique.! For!example,!the!dose!of!IP!cisplatin!ranged!from!25!mg/m2!to!150!mg/m2.!!Now,! numbers! of! case! series! publications! are! available! in! ovarian! cancer,!gastrointestinal!cancer!and!rare!peritoneal!disease!reporting!an!acceptable!morbidity!While! waiting! for! results! from! some! prospective! phase! III! clinical! trials,! a! HIPEC!program! was! developed! at! the! Institut! Claudius! Regaud,! with! a! strong! interest! for!clinical!trail!involvement!and!PKGPD!studies.!Paradoxically,!data! regarding!drug!dose! rate,! volume!and! type!of! carrier! solution,! and!duration!of!hyperthermia!were!missing!at! the!beginning!of!our!experience.!Our!HIPEC!program! has! started! with! the! application! of! early! experience! published! by! some!pioneers.!Refinements!have!been!secondarily!applied!explicating!that!dose!escalation!PK!studies!were!usually!available!after!the!first!toxicity!related!publications.!!Toxicity! varies,! depending! to! the! drug! used.! In! our! center,! two! cytotoxic! agents! are!predominantly! used! for! HIPEC:! cisplatin! and! oxaliplatin,! with! different! side! effects,!respectively,!renal!toxicity!and!abdominal!bleeding.!2.3.1:!Cisplatin!based!HIPEC!related!toxicity!Three!different!works!were!performed!to!evaluate!the!renal! toxicity!of!cisplatin!based!HIPEC.! Cisplatin! represents! the! cornerstone! of! chemotherapy! for! ovarian! cancer.! As!previously!described,!in!patients!with!minimal!residual!disease!after!surgery,!sequential!adjuvant! intraperitoneal! cisplatin! based! chemotherapy! has! been! to! produce! the! best!results! thus! far! observed! in! terms! of! survival! phase! III! clinical! trials.! A! number! of!institutions!around!the!world!have!begun!to!offer!cisplatin!HIPEC!for!ovarian!cancer.!Evaluation! of! the! renal! toxicity! represents! a! crucial! point! because! it! limits! the!therapeutic! option! for! recurrences! and!had! an! important! impact! on!patient! quality! of!life.!!2.3.1.1:!First!step!PK! data! from! 12! patients! who! underwent! a! CRS! and! Cisplatin! based! HIPEC! were!recorded! according! to! the! renal! function! in! a! retrospective! dose! deGescalation! study!
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using!a!three!compartmental!model.!Three!different!dose!levels!were!used:!100,!80!and!70! mg/m2,! with! 2! l/m2! NaCl! 0.9%! solution,! heated! during! 60! min! at! 42G43°C.!Postoperative!acute!renal!failure!was!evaluated!according!to!the!RIFLE!score.!!The!mean!maximum!fraction!of!the!dose!absorbed!was!69%!with!an!interGindividual!variability!at!7%.!The!mean!ratio!AUCIP/AUCUF!was!4.3,!confirming!the!pharmacokinetics!advantage!of! the! procedure.! Acute! renal! failure!was! reported! in! 83%! of! patients,! 58%! of!which!with!high!grade!(failure,!loss!or!endGstage).!!Occurrence!of!renal!failure!is!not!dose!dependant,!and!due!to!a!different!mechanism!as!known!with!using!intravenous!cisplatin.!!This! unpublished! work! was! presented! at! the! “13ème! journées! du! Groupe! de!Pharmacologie!Clinique!Oncologique”!–!Nîmes!2010!and!represents!the!base!for!the!next!step.! !Civade!E,!Ferron!G,!Pierre!S,!Lochon!I,!Rouge!P,!Gladieff!L,!Chatelut!E.!!Chimiohyperthermie!Intraperitoneale!à!base!de!Cisplatine:!Pharmacocinétique!et!tolerance!rénale.!!!2.3.1.2:!Second!step!Based! to! this! first! report! of! high! frequency! of! renal! toxicity,! a! large! bicentric!retrospective! study! was! performed.! Data! from! 66! patients! treated! with! CRS! and!Cisplatin! based! HIPEC! have! been! recorded! in! two! cancer! centers:! Institut! Claudius!Regaud! GToulouse!and! Institut!du!Cancer!–!Montpellier.!Decrease!glomerular! filtration!rate!more!than!25%!at!day!7!postoperative!was!reported!for!48%!of!patients:!1/3!were!classified!in!the!Risk!group,!1/3!in!the!Injury!group!and!1/3!in!the!Failure!group.!!Variables! significantly! associated! with! renal! failure! occurrence! were! treatment! by!angiotensin!converting!enzyme!inhibitors!and!preGexisting!hypertension.!Intraoperative!diuresis!represents!a!important!factor!for!acute!renal!injury!in!multivariate!analysis.!This!work!was!presented!at!the!French!Society!of!Gynecologic!Oncology!Annual!Meeting!–!Toulouse!–!Nov!2014!–!and!is!actually!submitted!at!the!European!Journal!of!Surgical!Oncology.!Vieille!P,!Quenet!F,!Gladieff!L,!Rougé!P,!Chaltiel!L,!Querleu!D,!MD,!Saint!Aubert!B,!Martinez!A,!Carrere!S,!Ferron!G.!!
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Abstract 
 
Introduction: 
Hyperthermic intraperitoneal Chemotherapy (HIPEC) is the standard treatment for some 
peritoneal disease such as pseudomyxoma peritonei, peritoneal mesothelioma advanced colon 
cancer. Cisplatine bsed CHIP seems to improve the treatment of peritoneal carcinomatosis from 
ovarian cancer and can have a significant impact on the patient’s survival. One of the important 
adverse effects of cisplatin administration is nephrotoxicity. 
 
Design of the study: 
Bicentric retrospective study. 
 
Patient and method: 
Data from patients treated with cytoreduction surgery (CRS) plus HIPEC have been recorded in 
two French centres. Patients characteristics were noted such as data concerning cytoreductive 
surgery and HIPEC and pre-, intra and postoperative management. Patients were divided into 
two groups according to the occurrence of a postoperative acute kidney injury. A univariate and 
a multivariate analysis were performed. 
 
Results: 
This study included 66 patients with a median age of 57, 43,9% underwent a first-line treatment 
and 56,1% were treated for recurrent disease.. A decrease in glomerular filtration rate (GFR) 
>25% at day-7 postoperative compared to day-0 was reported for 48,4%. Variables significantly 
associated with AKI occurrence were treatment by angiotensin converting enzyme inhibitors 
(ACEI) and/or angiotensin receptors blockers (ARBs), pre-existing high blood pressure. 
Intraoperative crystalloid volume and diuresis were statistically lower in the AKI group. The 
multivariate analysis identified high blood pressure and intraoperative diuresis as significant 
factors for acute renal injury. 
 
Conclusion: 
Cisplatin based HIPEC is possible with a low AKI rate if hydration is adequate in order to 
maintain a high diuresis level. Largest prospective study should be leaded to confirm these 
results. 
 
Keywords: Peritoneal carcinomatosis, Ovarian cancer, HIPEC, Cisplatin, nephrotoxicity, acute 
kidney injury, hydration 
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INTRODUCTION  
Ovarian cancer represents 22,240 new cases in 2013 
in united states which represent 3 % of new cases of 
all sites cancer (1). In France, a 2013 cancer 
incidence and mortality assessment reported 4615 
annual new cases of ovarian cancer with 3140 deaths 
in 2012 (2).  Ovarian cancer generally affects older 
women, and reduced life expectancy observed in the 
developing countries explains that the incidence rates 
range from over 11 cases out of 100,000 in Europe to 
less than 3 cases out of 100,000 in Africa (3). 
Ovarian cancer is the fifth leading cause of cancer-
related deaths after lung, breast, colon and pancreas 
(United States, 2013) (1). 
Because of the poverty of symptoms, around 75% of 
women  are diagnosed with an extension of the 
disease outside the pelvis (FIGO stage III/IV) (4).  
The standard treatment for these advanced stages is 
laparotomy with primary complete cytoreductive 
surgery followed by platinum-based chemotherapy. 
The principles of surgical management of peritoneal 
surface malignancies have been widely described and 
the quality of surgery is evaluated by the 
completeness of cytoreduction (CC) score established 
depending on the remaining macroscopic lesions size 
(5,6). 
The completeness of cytoreduction is one of the most 
important factors influencing recurrence of epithelial 
ovarian cancer (EOC). A complete surgery 
debulking, irrespective of primary treatment, 
significantly improves overall survival compared to 
patient undergoing uncomplete surgery (7). Di 
Giorgio et al. in 2013 showed that CC score 
(p<0.002) and degree of colorectal-wall involvement 
(p<0.037) are the most important predictive factors of 
long-term (five-year) survival, these results were 
confirmed by multivariate analysis (8).  A Cochrane 
review in 2013, showed a direct correlation between 
degree of cytoreduction and overall survival (9). 
Platinum anticancer drugs introduction into the 
clinical treatment of cancer has resulted in dramatic 
improvements in ovarian carcinoma. (10). The intra 
peritoneal (IP) drug administration in advanced 
ovarian cancer has been demonstrated to be efficient 
but cisplatin seems to be superior to carboplatin in IP 
delivery (11–13). The combination of hyperthermia 
with IP drugs administration improve the anti tumoral 
effect of chemotherapy and hyperthermia has also an 
anti tumoral effect, which acts in synergy with the 
pharmacological action of drugs(14,15). 
Hyperthermic intraperitoneal Chemotherapy (HIPEC) 
is the standard treatment for rare peritoneal disease 
(pseudomyxoma peritonei and peritoneal 
mesothelioma) but has also an interest in the 
management of peritoneal carcinomatosis from 
colorectal tumor.  
Intraperitoneal chemotherapy combined to 
intravenous therapy seems to improve the survival 
rate in advanced ovarian cancer compared to 
intravenous chemotherapy alone among the patient 
with and without residual disease after surgical 
debulking (16,17). 
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One of the most important adverse effect of cisplatin 
systemic and intraperitoneal administration is 
nephrotoxicity by activation of multiple cell death 
and survival pathways and initiation of a robust 
inflammatory response in renal tubular epithelial 
cells, which is responsible for acute renal injury 
(AKI) (18). Kusamura et al. found cisplatin dose for 
HIPEC of 240 mg or more as having a significant 
correlation with an increase of serum creatinine high 
or equal to 3,0 x ULN (upper limit normal) (> grade 
3 systemic toxicity) during the postoperative period, 
but they did not find any independent risk factor 
during the postoperative period (19). AKI rate 
reported is variable in literature(17–19).  
 
The aim of this study is to highlight risk factors to 
develop a postoperative AKI for women undergoing 
cytoreductive surgery (CRS) followed by HIPEC. 
Patient’s characteristics have been registred; 
information on surgery and pre-, intra- and 
immediately postoperative management of patient to 
determine which elements could influence or reduce 
the risk to develop acute kidney injury. 
 
 
 
PATIENTS AND METHODS 
This bicentric study is a retrospective analysis from a 
prospective database. Data from patients treated with 
CRS plus HIPEC based on cisplatin between 2007 
and 2013 for peritoneal carcinomatosis from 
advanced or recurrent EOC were collected. The 
patients were treated in two French centres: Institut 
Claudius Regaud, Toulouse and ICM Val d’Aurelle, 
Montpellier. A database was created using 
Microsoft® Access database management system. 
A computer generated search of two institional 
patient database was performed to retroscpectively 
identify all patients who was treated with CRS plus 
platinum based HIPEC  from advanced ovarian, 
fallopian or primary peritoneal cancer between 2007 
and 2013 at two Comprehensive Cancer Centers: 
Institut Claudius Regaud (Toulouse – France) and 
Institut du Cancer de Montpellier (Montpellier – 
France) 
The patient’s characteristics noted were the 
following: age, size, weight, comorbidities (diabetes, 
hypertension), treatment by angiotensin converting 
enzyme inhibitors (ACEI) and/or angiotensin 
receptors blockers (ARBs) and ASA score. The type 
of treatment was noted: recurrence or first line and 
the previous treatments (surgery, chemotherapy or 
both). The extent of peritoneal carcinomatosis was 
assessed intraoperatively with Sugarbaker’s 
Peritoneal Cancer Index (PCI) (20). The preoperative 
amount of crystalloid administrated was recorded. 
The principle of surgical procedures in the two 
centers were the same, consisting in a complete CRS 
(CC0 or CC1) followed by Platinum based HIPEC, 
heated between 41 and 43°C for 60 minutes using the 
“coliseum” open technique. The CRS was evaluated 
by the number of visceral resections and 
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peritonectomy procedures, as described by 
Sugarbaker (5) with into three levels according to the 
number of procedures performed: level I, 1 or 2 
procedures; level II, 3 or 4 procedures; level III, 5 or 
6 procedures (21). The completeness of the cancer 
resection was evaluated with the CC-score: CC-0 
correspond to no macroscopic residual disease, CC-1 
to residual tumour nodules less than 2.5 mm, and CC-
2 to residual tumour nodules more than 2.5 mm (20). 
Datas recorded for HIPEC were dose, body 
temperature 5 to 30 minutes before and after the 
intraperitoneal chemotherapy perfusion. 
Intraoperatives data were collected: epidural 
analgesia, diuresis, fluid loss (blood and ascites), 
continued intravenous noradrenalin administration 
and seven first postoperative days management and 
treatment (red blood cell units (RBCU), albumin, 
crystalloid and colloid, noradrenalin, 
aminoglycosides and non-steroidal anti-
inflammatories (NSAIs)).  Pre operative (day-0) 
blood sampling, at 24 hours, at day-7 and at the end 
of hospitalization was noticed. The postoperative 
complications identified were hemoperitoneum, 
ascites, sepsis, septic shock and the necessity of 
reintervention or dialysis. 
Patients were divided into two groups according to 
normal renal function or acute kidney injury at day 7 
but they were also compared too, according to their 
renal failure degree using RIFLE classification of 
decrease of glomerular filtration rate (GFR) (22) : 
Risk, Injury or Failure (GFR decrease >25%, >50% 
or >75%, respectively). GFR was calculated using 
MDRD (Modification of Diet in Renal Disease) 
equation. The aim was to determine which factor(s) 
among the data recorded could influence 
postoperative acute kidney injury occurrence. 
 
Data is summarized by frequency and percentage for 
categorical variables and by median and range for 
continuous variables. Differences between groups 
were analysed using χ2 test or Fisher’s exact test for 
qualitative variables and Mann Whitney test for 
continuous variable. Multivariate logistic regression 
with backward variable selection was performed to 
determine variables significantly associated with the 
outcome, the renal failure. All factors considered 
significant at the P<0.10 level were included in the 
logistic model. P-values <0.05 were considered as 
statistically significative. All statistical analyses were 
conducted using the STATA 13.0 software. 
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RESULTS 
Sixty-six patients undergoing CRS and HIPEC based 
on cisplatin for an EOC during this period were 
identified. The characteristics of the patients are 
listed in table 1. None included of the patients died in 
the 30 postoperative days.  
The median Follow-up was 35.9 months (95%CI: 
[28.2; 43.2]). The 3 year-survival rate  is 69.17% 
(95%CI: [54.0; 80.21]). Recurrence occurred for 47 
patients (74,2%), with a median relapse free survival 
of 12.8 months (95%CI : [7.6 ; 18.4]) and a Relapse 
Free Survival (RFS) rate at 3 years of 22.85% 
(95%CI: [12.98; 34.41]). 
A decrease in GFR >25% at day-7 postoperative 
compared to day-0 was reported for 48,4% of patients 
(n=30), data were missing for four patients. 
According to RIFLE classification, 32 patients 
(51.6%) were considered with no kidney injury, 11 
(17.7%) were classified in the Risk group, 10 
(16.1%) in the Injury group and 9 (14.5%) in the 
Failure group. Among patients with GFR decrease 
>25% at day-7, 14 (60.9%) suffer from chronic 
kidney disease six months later (GFR 
<60mL/min/m2) (data were missing for seven 
patients) and among these patients, 4 (28.6%) 
required dialysis. 
A univariate analysis was performed between the two 
groups: NRF group (normal renal function) and AKI 
group (acute kidney injury) corresponding 
respectively to a GFR decrease ≤ 25% and > 25% at 
day-7 (table 2). A high blood pressure and a 
treatment with ACEI and/or ARBs were statistically 
significant in the AKI group.  Intraoperative 
crystalloid volume perfusated and diuresis were 
significantly higher in the NRF group. Even if 
preoperative crystalloid volume perfused was more 
important in the NRF group, the difference was not 
statistically significant. 
Intraoperative noradrenalin administration was not 
significantly different, but it must be noted that 
among the patients without epidural analgesia, none 
of them needed intraoperative noradrenalin 
(p<0.0001). 
Regarding biologic datas, patients with AKI at day-7 
seemed to have a higher preoperative plasmatic urea 
level but it was not significant. At day-1 a plasmatic 
urea increase as a GFR decrease was correlated with 
AKI occurrence at day 7 (table 3). 
None of the identified postoperative complications 
was significantly associated with acute kidney injury: 
no patient needed a reintervention, one case of 
hemoperitoneum occurred in AKI group (p=0.48), 
one case of postoperative ascites in NRF group and 
two in AKI group (p=0.61), one case of sepsis in 
each group (p=1.00) and one septic shock in NRF 
group (p=0.49).  
No difference was found  for postoperative 
treatments between the two groups (NRF vs. AKI): 
red blood cells units; 0.0(0.0: 6.0) vs. 0.0(0.0: 4.0) (p 
= 0.39), albumin (dose: 20%, 100mL); 4.0(0.0:  10.0) 
vs. 5.0(0.0: 12.0) (p = 0.93), Aminoglycosides; 1 
(3.1%) vs. 0 (p = 1.00), NSAIs; 9 (29%) vs. 6 
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(22.2%) (p = 0.55), diuretics; 14 (43.8%) vs. 16 
(57.1%) (p = 0.30) and 4 patients (12.5%) received 
noradrenalin in the NRF group vs. 5 (18.5%) in the 
AKI group (p = 0.72). 
The comparison of the different variables according 
to RIFLE classification (table 4) did not allow to 
demonstrate significant differences because of the 
small sampling in each group, but it suggests that 
acute kidney injury severity increases with the 
reduction of pre and intraoperative amount of 
crystalloids. Similar results are observed for diuresis: 
low intraoperative urine volume seems to be linked to 
more severe renal function degradation. The number 
of peritonectomies seems to be important too:   
43.7% of the patients in the NRF group, 54.6% in the 
Risk group, 70% in the Injury group and 77.7% in the 
failure group underwent level 2 or 3 procedures 
(more than three procedures). The median cisplatin 
doses in the same groups were respectively 75, 75, 60 
and 80 mg/m2. 
Two significant factors for acute renal injury were 
identified in the multivariate analysis: high blood 
pressure (OR=18.59; 95%CI [1.90-182.31]; p=0.012) 
and intraoperative diuresis (OR=0.54; 95%CI [0.37-
0.77]; p=0.001). Variables used for this test were 
high blood pressure, preoperative crystalloid volume, 
intraoperative diuresis and crystalloid volume, 
number of peritonectomy procedure, body 
temperature before HIPEC and preoperative 
plasmatic urea level.  
 
 
DISCUSSION 
CRS associated with HIPEC is getting an important 
role in the treatment of recurrent EOC, its place must 
be most clearly defined in the case of advanced EOC 
frontline treatment. Most studies reporting the use of 
HIPEC for EOC are retrospectives and concern small 
samples with relatively low levels of evidence, no 
randomized controlled trial is available. Cisplatin acts 
by binding DNA and generating lesions causing 
cancer cells death (14). The combination of 
hyperthermia with IP drugs administration improve 
the anti tumoral effect of chemotherapy, this has been 
shown in rats models. Higher intratumour platinum 
concentrations are available with drug heat 
combination than with cisplatin at 37°C (15,23,24) 
Hyperthermia has also an anti tumoral effect, which 
acts in synergy with the pharmacological action of 
drugs. These effects of hyperthermia are known for a 
long time. The study of supranormal temperatures 
upon normal human cells (derived from normal adult 
and embryonic tissues) and neoplastic human cells 
(derived from biopsies of malignant tumors) exposed 
to temperatures of 42.5-43°C, shows an highest 
thermo sensitivity of neoplastic cells compared to 
normal cells with an higher cells died rate in tumoral 
cultures (15,25). 
Hyperthermic intraperitoneal Chemotherapy (HIPEC) 
is the standard treatment for pseudomyxoma 
peritonei and peritoneal mesothelioma. The overall 
survival rate is more important in pseudomyxoma 
peritonei and peritoneal mesothelioma than in other 
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histology (26,27).  
Several drugs are used in HIPEC for treatment of 
EOC, cisplatin is the most widely used. Oxaliplatin 
have an interesting pharmacokinetic in HIPEC but 
variability in peritoneal and systemic oxaliplatin 
exposures are observed between patients (28). A 
potential benefit of Oxalipaltin based HIPEC for the 
treatment of peritoneal carcinomatosis from 
colorectal origin had been shown, an effective 
antitumor activity and a favorable toxicity profile in 
EOC seems to exist. Oxaliplatin at the dose of 460 
mg/m2 during 30 min with a 42-44°C of temperature 
had not shown any survival benefit and was 
responsible for an high rate of intraperitoneal 
bleeding (29). HIPEC with cisplatin seems logical as 
the standard chemotherapy used in EOC but no study 
with high level of evidence justified the use of 
cisplatin and the widely used dose of 75 mg/m2 (30).  
HIPEC seems to be interesting treatment of ovarian 
cancer and can have a significant impact on patient 
survival when the appropriate patients are selected 
(31). In 2013, the FROGHI (French Oncologic and 
Gynecologic HIPEC) Group, in a retrospective study, 
identified several prognostic factors being significant 
for overall survival in patients treated by HIPEC for 
advanced EOC (front line therapy) and for recurrent 
EOC: the period of treatment, the age, the PCI, the 
CC-score, the performans status, and the number of 
HIPEC drugs The multivariate analysis identified 2 
significant factors: the performans status and the 
Peritoneal Cancer Index (PCI)> 8 (32). 
A review published in 2014, exposed several results 
concerning chemotherapy in frontline for stage III or 
IV EOC: overall survival was 22.8 months vs 24.5 
months respectively in the PS group (primary surgery 
followed by six cycles of platinum based 
chemotherapy) and in the NACT group (Neoadjuvant 
chemotherapy) and the median progression-free 
survival (PFS) time was respectively 10.2 vs. 11.7 
months with no difference between the two groups. 
In case of platinum resistant recurrent ovarian cancer, 
the adjunction of bevacizumab (BEV) to 
chemotherapy (CT) significantly improves RFS from 
3.4 vs. 6.7 months (p<0.001), but the overall survival 
was respectively 13.3 vs. 16.6 months (33). In a 
recent study, 566 patients underwent CRS and 
HIPEC, the median overall survival was 35,4 months 
for patients with peritoneal carcinomatosis from 
advanced EOC treated with CRS and HIPEC as 
front-line therapy and for recurrent EOC, the median 
overall survival was 45.7 months. They did not find 
any difference between patients with chemoresistant 
and chemosensitive recurrence, suggesting HIPEC 
may increase the potential effect of intraperitoneal 
cisplatin in platinum-resistant patients. Median 
recurrence-free survival was 11.8 months for 
advanced EOC (32). Another study in 2007, on 81 
patients undergoing CRS and HIPEC using 
abdominal closure technique for chemoresistant and 
recurrent advanced EOC reported median overall and 
disease-free survivals of 28.4 and 19.2 months, 
respectively (34). These results suggest an 
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improvement of survival with this treatment but must 
be confirmed by larger studies. We reported in this 
study a survival rates at 3 years of 69.17% with a 
median Follow-up of 35.9 months. Recurrence 
occurred for 47 patients (74,2%), and RFS rate at 3 
years was 22.85% (95%CI: [12.98; 34.41]). Similar 
results are observed in the literature, but the doses of 
chemotherapy are variable.  
A postoperative acute kidney injury was observed for 
48.4% of patients with 14.5% in the Failure group 
(GFR decrease> 75%) according to RIFLE 
classification, which corresponds to grade 3 and 
higher of NCI CTCAE V4.0 (National Cancer 
Institute, Common Terminology Criteria for Adverse 
Events; Version 4.0, May 2009). In 2007, a study was 
reporting systemic toxicity after peritonectomy and 
HIPEC, 242 patients were undergoing 247 
procedures for pseudomyxoma peritonei, colorectal 
and gastric carcinomatosis, peritoneal mesothelioma, 
ovarian carcinomatosis and abdominal sarcomatosis. 
All HIPEC regimens used cisplatin associated either 
with doxorubicin or mitomycin, the median dose of 
cisplatin was 204 mg (100-300). Ten (4%) cases of 
grade 3 and 4 (1,6%) cases of grade 4 serum 
creatinine alteration were observed with an onset on 
day 3 (1-6) and a maximum on day 8 (3-15) (19).  
Bakrin et al. observed 51 renal insufficiency (8%) 
with 15 (2%) developping chronic renal insufficiency 
and 6 patients (1%) requiring long-term dialysis (25).  
Schmidt et al, reported a study of 67 patients among 
which 51 underwent HIPEC with cisplatin at the dose 
of 75 to 150 mg/m2. Only one case of grade 3/4 
toxicity occurred in this study, but they reported a 
low overall morbidity rate of 34% while their 
literature review exposed rates from 27 to 65 % (35). 
Di Giorgio et al., in a prospective single center study 
of 47 patients undergoing surgical procedure 
followed by HIPEC based on cisplatin at the dose of 
75 mg/m2, reported 24 patients (51,1%) presented 
grade 1 complication, 10 patients (21,3%) grade 2, 10 
patients (21,3%) grade 3 and 2 (4,2%) grade 4. No 
renal function alteration was reported (36). A part 
from extracellular expansion using at least 1 liter of 
normal saline with 3 g of magnesium sulfate and 40 g 
of mannitol intravenously (17), authors, in these 
study, did not report sodium thiosulfate or other 
nephroprotectant. Sodium thiosulfate allows 
increased doses of cisplatin by reducing toxicity (37) 
but a potential reduction antitumor activity is unclear 
(38,39). Acute renal injury rate post Cisplatin-HIPEC 
is difficult to assess because of the very varied data 
given in the literature. A very few articles had 
especially study this complication.  
The only patient characteristics, which appear to be 
risk factors in our study, are high blood pressure and 
treatment by ACEI and/or ARBs. Renin Angiotensin 
system (RAS) blockers, ACEI and ARBs, have been 
evaluated as risk factors of adverse events after 
cardiothoracic surgery, preoperative RAS-blocker use 
was associated with increased odds, for both, 
postoperative AKI (OR, 1.17; 95% CI, 1.01-1.36; P = 
0.04) (40). Furthermore, the same assessment has 
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been done on patient developing a septic shock: 
patients who developed AKI were more likely to 
have been on ACEIs or ARBs and to have a pre-
existing high blood pressure. It is interesting in this 
study to notice that platinum-based chemotherapy 
was not a risk factor to develop AKI. 
Aminoglycosides and NSAIs use, as in our study, 
were not significantly associated with AKI but the 
data for which our results differ are important BMI, 
lower baseline GFR which are associated with an 
increased risk of AKI (41). These results are in 
agreement with ours, the difference could be 
explained by the low number of sepsis (n=2; 33%) 
and of septic shock (n=1; 1,5%) that we reported and 
which could be added on factors of AKI. Concerning 
high blood pressure, a recent study on cisplatin and 
mannitol used as nephroprotectant, has shown that 
patients who had a history of hypertension had a 
higher likelihood of developing nephrotoxicity: (OR 
= 3.219 (95% CI = 1.228, 8.439; P = 0.017)) (42). 
The doses of cisplatin more likely to be responsible 
for AKI reported are 100 mg/m2 intravenous and 
>240 mg intraperitoneal (19,42). We did not find any 
significant difference between the two groups (NRF 
and AKI) for the median cisplatin dose. The highest 
dose use in our study was 100 mg/m2 intraperitoneal, 
but the dose of 240 mg would correspond to 150 
mg/m2 if we consider the median BSA (body surface 
area) of 1,6m2 (1.4; 2.1) in our population and no 
patient received such an important dose. However, 
according to RIFLE classification, cisplatin dose 
seems to be higher in the Failure group (median: 80 
mg; range: 70; 100). 
Patient with AKI at day-7 seemed to have received 
less pre and intraoperative crystalloid volume, the 
only difference appearing significant was 
intraoperative perfusion. Preoperative perfusion of 
crystalloid seemed different between the two groups 
but was at the border of significance. This is 
correlated with the difference in urine output, more 
important in the NRF group. Kadji et al., in a 
retrospective study on 54 patients undergoing 57 
CRS + HIPEC with various types of chemotherapy 
including cisplatin, did not find any negative effects 
of crystalloids on renal function but the amount of 
hydroxyl-ethyl starch (HES) given had a significant 
negative effect on postoperative GFR in patients 
younger than 60 (p  <0.001).  Intraoperative blood 
loss and urine output had no significant impact on 
postoperative GFR, in their study (43).  There was a 
disparity in our population because of different pre- 
and intraoperative management of patients between 
the two centers: either preoperative hyperhydration 
(4000 to 6000 mL perfused 48 hours before 
procedure) and intraoperative hyperhydration with 
furosemide administration to maintain a diuresis 
during HIPEC phase at least of 250mL per 15 
minutes or lower hydration with largest noradrenalin 
use to maintain a correct hemodynamic variables. 
Noradrenalin use did not appear like a significant 
factor of acute kidney injury but hyperhydration 
seemed to improve postoperative renal function, as a 
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high level of urine output. Pili-Floury et al. describe 
postoperative alteration of renal function after 
reductive surgery associated with cisplatin-based IPC 
intraperitoneal chemotherapy) and risk factors for 
moderate to severe acute renal failure using two 
strategies according to the absence or presence of 
epinephrine in the IPC baths. They reported that the 
absence of epinephrine in the IPC bath, is 
significantly associated with the occurrence of acute 
renal injury as a higher duration of severe 
hypotension, a lower blood protein level on arrival in 
ICU (intensive care unit) and a lower volume of 
intraoperative diuresis (44). Vasopressive drugs use, 
systemic or intraperitoneal, must be studied to clarify 
their influence on chemotherapy pharmacokinetic, in 
terms of anti tumoral effect but also in term of 
toxicity. 
Preoperative hypoalbuminemia did not appear as a 
significant risk factor in this work, this could be due 
to a lack of subject in our population to evidence this 
variable, because a low plasmatic albumin level has 
been found to associate with increased risk of 
cisplatin nephrotoxicity, like pre-existing renal 
insufficiency (18), but none of the patients we 
included present a preoperative renal function 
degradation. 
After multivariate analysis, the only significant risk 
factors for AKI due to cisplatin were pre-existing 
high blood pressure and intraoperative diuresis. 
These results are linked to literature data, but this 
analysis suffers from a lack of data, which explained 
a very large 95% confidence interval for high blood 
pressure, and the non-significance of variables like 
intra- and preoperative crystalloid volume. 
Despite a GFR decrease persistence at 6 months, a 
low number of patient needed dialysis. This suggests 
that most of renal function degradations are moderate 
and not responsible for important decrease of quality 
of life. Cisplatin based HIPEC seems possible with 
low morbidity rates but antitumor activity needs to be 
proved. In tumor samples surgically removed from 
human donors diagnosed with colorectal or ovarian 
peritoneal carcinomatosis before and after HIPEC 
treatment, it was not possible to detect any known 
cisplatin-related molecule by MALDI MS (Matrix-
Assisted Laser Desorption Ionization-Mass 
Spectrometry). ICS MS (Inductively Coupled 
Plasma- Mass Spectrometry) allowed detecting 
cisplatin in tumor samples but oxaliplatin response 
was twice higher (45). 
 
CONCLUSION 
In this study, risk and protective factors for renal 
function degradation were identified and others as 
potential risk factors were supposed. The 
retrospective data collection raises an issue in terms 
of missing data. Despite that, it is worth mentioning 
that adjustable variables could affect postoperative 
renal function, like crystalloid volume perfused. 
Larger prospective multicentric studies should be 
performed, and could lead to established standardized 
protocol of pre and intraoperative management of 
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patient undergoing CRS + HIPEC. Indeed, even if 
this treatment increases the patient’s survival with 
advanced or recurrent EOC, there is still much to do 
concerning its morbidity rate.  
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Tables 
 
Table 1: Patient’s characteristics 
 
 
 
 
Characteristics Data 
Age: median (Range) 57.0 (20.0:  75.0) 
Body mass index 
    <18   
 [18-25[ 
    [25-30[ 
>=30  
 
2 (3.0%) 
43 (65.2%) 
14 (21.2%) 
7 (10.6%) 
Score ASA      
    1  
    2  
    3  
    4  
  
 
23 (35.4%) 
39 (60.0%) 
 2 (3.1%) 
1 (1.5%) 
1(-) 
Type of treatment 
First line 
Recurrence 
 
29 (43.9%) 
37 (56.1%) 
Comorbidities and treatment 
Diabetes                                                   3 (4.5%) 
High blood pressure  11 (16.7%) 
IEC/ARA II  4 (6.1%) 
Intraoperative parameters 
PCI: median (range) 8 (0.0:  33.0) 
Visceral resections 
0 
1-2 
>3 
Peritonectomy procedures 
0 
Level 1 
Level 2 
Level 3 
 
26 (39.4%) 
32 (48.5%) 
8 (12.1%) 
 
8 (12.1%) 
22 (33.3%) 
25 (37.9%) 
11 (16.7%) 
Completeness of cytoreduction 
CC0 
CC1 
 
63 (95.5%) 
3 (4.5%) 
Median operating time (min) (range) 320  
(147.0: 720.0) 
1(-) 
Cisplatin (dose in mg/m2)  
median (range) 
 
 
75 (34.0: 100.0) 
1(-) 
Epidural analgesia 29 (45.3%)     
 2(-) 
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Table 2: Univariate analysis for risk factors of acute kidney injury (GFR decrease > 25%) at 
day-7 postoperative. 
Variables NRF (n=32) AKI (n=30) p-values 
Age  58 (20.0:  75.0) 57 (41.0:  65.0) 0.3005 
BMI 21.3 (17.8:  38.1)  22 .6 (18.2:  33.3) 0.1831 
ASA Score 
1-2 
3-4 
 
 
30 (96.8%)     
1 (3.2%) 
1(-) 
 
29 (96.7%) 
1 (3.3%) 
0(-) 
1.0000 
PCI 
>8 
≤8 
 
15 (51.7%)   
14 (48.3%)  
3(-) 
 
14 (50.0%) 
14 (50.0%) 
2(-) 
0.8964 
ACEI/ ARBs 0 (0.0%)     4 (13.3%) 0.0491 
Diabetes 1 (3.1%)  2 (6.7%) 0.6066 
HBP 2 (6.3%) 8 (26.7%) 0.0400 
    
Input 
Preoperative crystalloids (mL/kg) 
 
67.8 (0.0: 127.7) 
1(-) 
45,8 (5.3: 109.1) 
4(-) 
0.0598 
Intraoperative colloids (mL/kg) 15.6 (0.0: 216.7) 14.8 (0.0:  38.5) 0.4769 
Intraoperative crystalloids (mL/kg) 92.1 (49.0: 186.4) 66.6 (16.3: 147.4)  < 0.001 
RBCU 0.0 (0.0: 3.0) 0.0 (0.0: 3.0) 0.8769 
 
Albumin (20%; 100mL) 
0 
1 
2 
 
28 (87.5%)   
2 (6.3%)         
2 (6.3%)      
 
28 (93.3%) 
1 (3.3%) 
1 (3.3%) 
 
1.0000 
    
Output 
Blood loss 787.5 (100.0: 3650.0) 700.0 (100.0: 3300.0) 0.7675 
Diuresis (ml/kg/h) 5,8 (1.6:  27.3) 2.8 (1.2:  9.7)  < 0.001 
    
Surgical and HIPEC procedures 
Peritonectomy procedures 2.0 (0.0: 6.0) 3.0 (0.0: 6.0) 0.0681 
Visceral resections 
0 
1-2 
>3 
 
14 (43.8%)     
14 (43.8%)    
4 (2.5%)      
 
11 (36.7%) 
15 (50.0%) 
4 (13.3%) 
 
0.8826 
Cisplatin dose (mg/m2) 75.0 (34.0: 100.0) 
1(-) 
75.0 (34.5: 100.0) 
0(-) 
0.1392 
Cytoreduction score 
CC0 
CC1 
 
31 (96.9%) 
1 (3.1%)      
 
28 (93.3%) 
2 (6.7%) 
 
0.6066 
Median operating time (min) 337.5 (147.0: 690.0) 317.5 (228.0: 720.0) 0.1449 
 
Intraoperative data 
Body temperature 
PreHIPEC 
 
PostHIPEC 
 
35.0 (32.0:  37.6) 
0 (-) 
37.9 (35.8:  39.4) 
0 (-) 
 
35.8   (34.5:  37.6) 
5(-) 
37.8 (35.6:  39.3) 
1(-) 
 
0.0162 
 
0.5962 
Noradrenalin (qualitative) 
Dose (µg/kg/min) 
5 (15.6%)      
0.1 (0.0: 0.2) 
9 (30.0%) 
0.1 (0.0: 0.2) 
0.1761 
0.5708 
    
Aminoglycosides 1 (3.1%)      2 (6.7%) 0.6066  
NSAI 13 (40.6%)      8 (26.7%) 0.2458 
Epidural analgesia 12 (37.5%) 
0(-)   
16 (55.2%) 
1(-) 
 
0.1666 
  Predictive factors of acure kidney injury 
 
 15 
Table 3: Univariate analysis for biologic data according to acute kidney injury (GFR decrease > 
25%) at day-7 postoperative. 
 
Biologic data  NRF (n=32) AKI (n=30) p-values 
    
Day-0 
Albumin (g/L) 40.0 (21.0: 46.0) 
7(-) 
40.0 (19.4:  49.0) 
3(-) 
0.3272 
 
GFR (mL/min/1.73m2) 87.6 (58.5: 155.9) 88.0 (57.3: 137.8) 0.6370 
Urea (mmol/L) 4.5 (1.3:   8.8) 
8(-) 
5.7 (3.1:  46.0) 
3(-) 
0.0508 
C-reactive protein (mg/L) 1.4  (0.0:  37.0) 
18(-) 
3.0 (0.0:  23.0) 
17(-) 
0.7895 
    
Day-1 
Albumin (g/L) 27.0 (12.0:  40.0) 
1(-) 
24.5 (13.0:  35.0) 
0(-) 
0.2698 
GFR (mL/min/1.73m2) 97.3 (49.2: 174.3) 85.4 (36.2: 177.6) 0.0285 
Urea (mmol/L) 2.5 (0.7:  28.0) 4.0 (1.6: 8.0) 0.0070 
C-reactive protein (mg/L) 94.0(36.0: 231.0) 85.0 (23.0: 194.6) 0.2262 
 9(-) 9(-)  
ΔHb D-0 /Hb D-1 (g/dL) 1.6 (-3.7:   6.0) 
2(-) 
2.1 (-2.5:   6.2) 
3(-) 
0.2499 
ΔHb D-0 /Hb D-1 : difference in haemoglobin rate between Day-0 and Day-1 
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Table 4 : Variable distribution according RIFLE classification. 
Variables  NRF (n=32) Risk (n=11) Injury (n=10) Failure (n=9) 
Age  58 (20.0: 75.0) 56 (41.0: 65.0) 58.5 (46.0: 64.0) 57 (41.0: 61.0) 
BMI 21.3 (17.8:  
38.1) 
 
22.3 (19.5:  
29.0) 
27.4 (19.7:  
33.3)  
21.6 (18.2:  
30.5) 
ASA Score 2.0(1.0:  4.0) 
1(-) 
2.0 (1.0: 3.0) 
0(-) 
2.0 (1.0:  2.0) 
0(-) 
2.0 (1.0:  2.0) 
0(-) 
PCI 
>8 
≤8 
 
15 (51.7%)  
14 (48.3%)  
3(-) 
 
5 (55.6%) 
4 (44.4%) 
2(-) 
 
6 (60.0%)   
4 (40.0%)  
0(-) 
 
3 (33.3%) 
6 (66.7%) 
0(-) 
     
ACEI/AA-2R 0 (0.0%)  1 (9.1%) 1 (10.0%)      2 (22.2%) 
Diabetes 1 (3.1%)  1 (9.1%) 1 (10.0%)      0 (0.0%) 
HBP 2 (6.3%)  3 (27.3%) 3 (30.0%)    2 (22.2%) 
   
 
  
Input 
Preoperative crystalloids (mL/kg) 
 
67.8  
(0.0: 127.7) 
1(-) 
37.9  
(7.4: 81.6) 
1(-) 
54.4  
(5.3: 109.1)   
0(-) 
16.5  
(6.8: 66.7) 
3(-) 
Intraoperative colloids (mL/kg) 15.6 (0.0: 216.7) 18.2 (0.0: 38.5) 9.4 (0.0: 21.7) 13.7 (0.0: 36.4) 
Intraoperative crystalloids 
(mL/kg) 
 
92.1  
(49.0: 186.4) 
 
 
 
73.5  
(42.0: 147.4) 
 
45.0  
(24.0: 130.4)  
 
61.2  
(16.3:  88.3) 
RBCU 
0 
1 
2 
3 
 
25 (78.1%)  
1 (3.1%)  
4 (12.5%)  
2 (6.3%)  
 
8 (72.7%) 
1 (9.1%) 
2 (18.2%) 
0 (0.0%) 
 
7 (70.0%)     
1 (10.0%)  
0 (0.0%)  
2 (20.0%)  
 
9 (100.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
Albumin (20%; 100mL) 
0 
1 
2 
 
28 (87.5%)  
2 (6.3%) 
2 (6.3%)  
 
11 (100.0%) 
0 (0.0%) 
0 (0.0%) 
 
8 (80.0%)   
1 (10.0%)   
1 (10.0%)            
 
9 (100.0%) 
0 (0.0%) 
0 (0.0%) 
   
 
  
Output 
Blood loss 787.5 
(100.0: 3650.0) 
2(-) 
950.0  
(200.0: 3300.0) 
1(-) 
702.5  
(100.0: 2240.0) 
0(-) 
617.0  
(100.0: 2090.0) 
1(-) 
Diuresis (ml/kg/h) 5.8  
(1.6: 27.3) 
0(-) 
2.8  
(1.7: 9.7) 
0(-) 
3.0  
(1.2: 6.7)  
0 (-)      
1.8  
(1.5: 4.7) 
1(-) 
   
 
  
Surgical and HIPEC procedures 
Peritonectomy procedures 
0 
Level 1 
Level 2 
Level 3 
 
5 (15.6%)  
13 (40.6%) 
9 (28.1%) 
5 (15.6%)  
 
3 (27.3%) 
2 (8.2%) 
4 (36.4%) 
2 (8.2%) 
 
0 (0.0%) 
3 (30.0%) 
6 (60.0%) 
1 (10.0%)      
 
0 (0.0%) 
2 (22.2%) 
4 (44.4%) 
3 (33.3%) 
Visceral resections 
0 
1-2 
>3 
 
14 (43.8%) 
14 (43.8%)  
4 (12.5%)  
 
4 (36.4%) 
4 (36.4%) 
3 (27.3%) 
 
4 (40.0%)  
6 (60.0%) 
0 (0.0%)         
 
3 (33.3%) 
5 (55.6%) 
1 (11.1%) 
Cisplatin dose (mg/m2) 75.0  
(34.0: 100.0) 
75.0  
(35.2: 100.0) 
60.0  
(34.5: 100.0) 
80.0 
(70.0: 100.0) 
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1(-) 0(-) 0(-) 0(-) 
     
Intraoperative data 
Body temperature 
preHIPEC 
 
 
PostHIPEC 
 
35.0  
(32.0:  37.6) 
0(-) 
37.9  
(35.8: 39.4) 
0(-) 
 
36.0  
(34.8:  37.6)  
0(-) 
37.5  
(35.6: 39.3) 
1(-) 
 
35.5  
(34.5:  36.9) 
2(-) 
37.8  
(37.4: 38.8) 
2(-) 
 
35.5  
(35.0:  36.3) 
3(-) 
38.3  
(36.3: 39.0) 
3(-) 
Noradrenalin (qualitative) 
dose (μg/kg/min) 
5 (15.6%)  
0.1 (0.0: 0.2) 
1(-) 
3 (27.3%) 
0.0 (0.0: 0.0) 
1(-) 
1 (10.0%) 
0.1 (0.1: 0.1) 
0(-) 
5 (55.6%) 
0.1 (0.1: 0.2) 
1(-) 
Aminoglycosides 1 (3.1%)  1 (9.1%) 0 (0.0%)     1 (11.1%) 
NSAI 13 (40.6%)  2 (18.2%) 4 (40.0%)      2 (22.2%) 
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FIGURES 
 
Figure 1: Overall survival rate of patients at 3 years 
 
 
 
Figure 2: Relapse Free Survival rate of patients a 3 years. 
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Abstract 
Purpose: Hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the 
outcome of patients with initially inoperable ovarian cancer who are offered complete 
cytoreductive surgery (CCRS) after responding to neoadjuvant chemotherapy. The 
aim of this multicenter phase I study was to identify the recommended dose of 
cisplatin for HIPEC at CCRS after neoadjuvant carboplatin and paclitaxel (CP). 
Methods: Patients were treated with 6 cycles of CP followed by CCRS and HIPEC 
using cisplatin heated for one hour at 42°C+/-1°C. Four cisplatin dose levels were 
evaluated, between 50 to 80 mg/m². Dose-limiting toxicities (DLTs) were defined as a 
grade ≥IIIb adverse event (Dindo classification). The Continual Reassessment 
Method was used for this dose-finding study, with a target percentage of DLT set at 
20%. Twenty-two cycles (15 mg/kg/cycle) of maintenance bevacizumab therapy were 
planned after surgery. 
Results: From 08/11 to 10/12, 30 patients were recruited. No DLT occurred at the 
first three dose levels (4, 4 and 5 patients at 50, 60 and 70 mg/m² respectively). At 
dose level 4 (80 mg/m², 17 patients), four DLTs occurred: renal failure (n=2), 
peritonitis (n=1) and hemorrhage (n=1). Eight weeks after surgery, creatinine 
clearance was reduced to <30 ml/min in 3 patients treated at 80 mg/m², and between 
30 and 60 ml/min in 6 patients (2, 1, 1 and 2 at the four dose levels respectively). 
Twenty patients started maintenance bevacizumab, and 7 received 22 courses. 
Conclusions: Based on the DLT observed and prolonged impairment of renal 
function, we recommend a dose of 70 mg/m² of cisplatin for HIPEC.  
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Introduction 
In most cases, ovarian cancer is discovered at an advanced and initially unresectable 
stage. The standard of care in advanced stage ovarian cancer (ASOC) combines 
complete cytoreductive surgery (CCRS) and systemic chemotherapy with a platinum 
agent. Unfortunately, progression-free survival is usually short, with an estimated 
median duration of 17 months in a French multicenter study.1 To improve the 
prognosis of ASOC, three therapies were considered promising: intra-peritoneal 
chemotherapy, hyperthermic intraperitoneal chemotherapy (HIPEC) and 
bevacizumab. HIPEC is an attractive therapy against peritoneal carcinomatosis from 
ovarian cancer: after CCRS resecting the macroscopic peritoneal implants, HIPEC 
treats the remaining microscopic peritoneal implants. However, the exact place and 
modalities of HIPEC in ASOC remain to be defined. Intraperitoneal cisplatin 
chemotherapy has been shown to be significantly efficient as frontline treatment for 
ASOC in three large randomized studies.2-4 Those three studies used intraperitoneal 
cisplatin capitalizing on its favorable peritoneal plasma gradient. Cisplatin is currently 
the reference agent for the treatment of ovarian cancer, as demonstrated in the meta-
analysis reported by Aabo et al.5 Adding hyperthermia to intraperitoneal cisplatin 
yielded direct cytotoxic and synergistic effects.6,7 However, the dose of cisplatin 
ranged from 25 mg/m2 to 150 mg/m2 in the series which used HIPEC to treat ASOC. 
Moreover, these series were retrospective with heterogeneous patient cohorts.8 
Bevacizumab administered as maintenance adjuvant therapy significantly increased 
the progression-free survival of patients with peritoneal carcinomatosis from ovarian 
cancer, as shown by two international randomized phase III trials (GOG0218 and 
ICON 7).9,10 
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Considering the therapeutic impact of adding maintenance bevacizumab and the 
interest of HIPEC, the CHIPASTIN trial proposed a new therapeutic approach for 
ovarian cancer with initially unresectable peritoneal carcinomatosis. This new 
strategy combines CCRS with HIPEC, followed by bevacizumab maintenance 
therapy over 15 months (22 courses, 15 mg/kg/course). The CHIPASTIN trial 
included a dose-finding study for cisplatin administered in HIPEC.  
 
Patients and methods 
The study is an investigator-driven trial conducted in seven French comprehensive 
cancer centers for initially unresectable ASOC. The trial comprised two parts:  a 
dose-finding study of cisplatin for HIPEC (phase I), and evaluation of the efficacy of 
the entire strategy combining CCRS+HIPEC followed by maintenance bevacizumab.  
The protocol was approved by the Ethics Committee and by the Competent Health 
Authority, and was registered in the ClinicalTrials.gov registry (NCT02217956). 
Written informed consent from the patient was mandatory before surgery. This trial 
was sponsored by the Gustave Roussy Institute. 
 
Patient eligibility 
Patients aged between 18 and 65 with a confirmed histologic diagnosis of epithelial 
ovarian cancer were screened for the study if their disease was deemed 
unresectable at diagnosis (stage IIIC according to the International Federation of 
Gynecology and Obstetrics).11 After 6 cycles of neoadjuvant chemotherapy, they 
were included in the study if macroscopically complete CCRS was considered 
feasible, providing all eligibility criteria were fulfilled. The main criteria were: 1) 
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adequate renal function (creatinine <140 μmol/L, clearance >60 mL/min), bone 
marrow function (neutrophil count >1,500/μL, platelets 150,000/μL), hepatic function 
(bilirubin <1.5xULN, AST/ALT <1.5xULN) and nutritional status (albumin >25 G/l); 2) 
No grade >1 neuropathy (CTC-AE v4.0 classification); 3) No contraindication to 
bevacizumab administration. 
 
Treatment plan 
All patients were treated with 6 cycles of neoadjuvant chemotherapy combining 
carboplatin (area under the curve, 5) and paclitaxel (175 mg/m2 every three weeks or 
80 mg/m2 weekly). CCRS+HIPEC had to be performed within 10 weeks after the last 
injection of carboplatin. Cisplatin was administered as HIPEC, heated for one hour at 
42°C+/-1°C. The dose of cisplatin was defined according to the dose escalation 
method. Four dose levels were planned: 50, 60, 70, and 80 mg/m2. Maintenance 
bevacizumab (15mg/kg every 3 weeks ×22 cycles) was started 10 to 14 weeks after 
CCRS+HIPEC, for a total duration of maintenance therapy of 15 months. 
 
Study endpoints 
The primary endpoint of the trial was dose-limiting toxicity (DLT) within 30 days 
following CCRS+HIPEC. The following adverse events were classified as DLT: 
1) Death; 2) Grade IV toxicity according to the Dindo classification; 3) Digestive, 
hepato-biliary or a pancreatic fistula requiring resurgery; 4) Severe bleeding (>30% 
blood mass) requiring resurgery; 5) an adverse event deemed life-threatening or 
resulting in a permanent disability.12 
The safety of CCRS+HIPEC was evaluated during hospitalization and at the visit 
planned at week 8 after CCRS+HIPEC, and included clinical assessment and 
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biological tests on days 1, 3 and 5, then twice a week during hospitalization, then at 
week 8 (+/-2 weeks). The safety of maintenance bevacizumab was evaluated before 
each new cycle and 4 weeks after the last administration. Creatinine clearance 
computed with the Cockroft formula was monitored over the whole study duration 
according to the same schedule. 
Toxicity occurring after CCRS+HIPEC was graded using the Dindo classification and 
adverse events that occurred later were graded using the CTC-AE v4.0 
classification.13 
To monitor the disease status, a clinical follow-up was performed at week 8, then 
every 3 weeks during maintenance therapy and every 4 months after the end of 
treatment until disease progression or death. CA125 and CA19.9 biomarkers were 
measured at week 8, at cycle 11, at the end of treatment, and every 4 months 
thereafter. A thoraco-abdominal CT scan was performed at the end of treatment and 
12 months later, or when progression was suspected. Disease-free survival (DFS), 
defined as the time to relapse or death from any cause, and overall survival (OS), 
computed from the date of CCRS+HIPEC, were used as efficacy endpoints.  
 
Statistical considerations 
The dose-finding study was performed using the Continual Reassessment Method 
(CRM), with a one-parameter logistic model in a Bayesian framework.14 After each 
new observation, the model was reassessed using all data previously collected. The 
dose level recommended for the next patient was the one nearest to the 20% target 
percentile. Patients were included at the best ongoing estimate of the recommended 
dose (RD). Additional allocation rules were applied to ensure patient safety. The 
technical details are available in the appendix. 
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Based on the literature on the CRM and considering the number of levels to be 
explored, the targeted number of patients was set at 30, allowing for acceptable 
accuracy of the toxicity probability estimate at the dose identified as the 
recommended dose. 
Descriptive statistics were used to describe the patient population and outcomes. 
DFS and OS curves were estimated with the Kaplan-Meier method. An exploratory 
prognostic factor study was conducted to identify risk factors for renal impairment, 
given the level of creatinine clearance observed at week 8, reflecting the stabilized 
value. We first performed a covariance analysis (ANCOVA) of creatinine clearance 
over the covariables using the SAS proc glm procedure. We then modeled the risk of 
grade II-IV toxicity (clearance<60 mL/mn) using logistic regression. The dose level 
was forced into the models. All p values are two-sided and estimates are provided 
with their 95% confidence intervals (95%CI). Analyses were performed using SAS 
9.3 and R software programs. 
 
Results 
From June 2011 to September 2012, 30 of the 39 patients screened for the study 
were enrolled in the trial (Figure 1). All eligible patients were included at the date they 
were considered eligible for CCRS+HIPEC, regardless of the number of patients still 
under evaluation at the time of study entry, because the dose-escalation method 
allowed continuous recruitment. All patients included were evaluable for DLT 
assessment.  
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Patient baseline characteristics 
The median age and body mass index of the 30 patients were respectively 58 years 
(range, 26-65) and 22 kg/m2 (range, 16-40). Twenty-six patients (87%) had an 
ovarian carcinoma and 4 patients, a primary peritoneal carcinoma. The histologic 
subtype was serous in 29 and undetermined in one patient. The tumor was grade 1 
in 2 cases (7%), grade 2 in 10 (33%), grade 3 in 12 cases (40%), and undetermined 
in 6 cases (20%). All patients received 6 cycles of a weekly regimen of neoadjuvant 
carboplatin-paclitaxel chemotherapy (N=19, 63%) or a standard every-three-week 
regimen (N=10, 33%). One patient received three cycles of each regimen. The 
median time interval between the diagnosis and start of neoadjuvant chemotherapy 
was 24 days (range, 7-58). In most cases, patients had preoperative immunonutrition 
with oral impact® (3 bags/day) over 7 days (87%), bowel preparation (97%) and 
preoperative hydration (87%). The median preoperative plasma albumin level was 41 
g/L (range, 27–44). The median interval between the last carboplatin injection and 
CCRS+HIPEC was 41 days (range, 24-81). 
 
Surgical procedures 
All study patients underwent exploration of the abdominal cavity and a 
macroscopically complete resection of their disease. Surgical procedures and HIPEC 
are detailed in Table 1. The dose of cisplatin was adhered to in all cases. The median 
operative time was 360 min (range, 214-780) and the median hospital stay was 19 
days (range, 10-69). Pathological reports of surgical specimens indicated tumor 
sterilization in 5 patients (17%), persistence of active cells but with major sterilization 
in 15 patients (50%), and a considerable portion of persistently active disease in 10 
patients (33%). Fifteen patients (50%) had retroperitoneal lymph node involvement, 
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with capsular rupture in 4 patients. Among the 16 patients (53%) with at least one 
bowel resection, 8 had mesocolon and/or mesorectum lymph node involvement, 
including one patient with capsular rupture.  
 
Dose escalation and safety of CCRS+HIPEC 
As illustrated in Figure 2, the dose was escalated from the first level (50 mg/m2) to 
the highest dose level (80 mg/m2), with 4, 4, 5 and 13 patients at the four dose levels 
respectively. 
Overall, four patients experienced a toxic event considered as a DLT during the 30 
days after CCRS+HIPEC (Figure 2). All DLTs were observed at the 80 mg/m2 dose 
level. Two patients experienced HIPEC-related renal failure requiring dialysis (grade-
IV in the Dindo classification, as well as in the CTC-AE v4.0 classification). In one 
case, creatinine clearance was evaluated at 101 mL/mn before CCRS+HIPEC, 
19 mL/mn at day 3 after CCRS+HIPEC, 9 mL/mn at day 7, and 13 mL/mn a year 
later. In the second case, creatinine clearance was evaluated at 61 mL/mn at the 
screening visit, 57 mL/mn just before CCRS+HIPEC, 13 mL/mn at day 6 after 
CCRS+HIPEC, 10 mL/mn at day 7. A partial recovery was observed at week 10 with 
creatinine clearance at 24 mL/mn, but the patient then relapsed and died of cancer. 
The other two DLTs were surgical complications requiring further surgery (Dindo 
grade IIIb): one patient sustained small bowel perforation with peritonitis related to 
both CCRS and HIPEC. Another patient with two anastomoses (colorectal and 
ileocolic) experienced active bleeding of the ileocolic anastomosis, related to CCRS, 
and required a transient stoma. In addition to the four DLTs, 23 adverse events 
occurred in 14 patients during the first 8 weeks after CCRS+HIPEC (Table 2). 
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Regarding the evaluation of renal function (Table 3), we observed wide variations in 
creatinine clearance during the post-HIPEC days, in both directions. Compared to the 
clearance measured before HIPEC, creatinine clearance decreased by 30 mL/mn or 
more in 15 out of the 30 patients, leading to grade II renal insufficiency in 10 patients 
(30≤clearance<60 mL/mn), grade III renal insufficiency in 2 patients 
(15≤clearance<30 mL/mn) and grade IV renal failure in 2 patients (clearance<15 
mL/mn). Levels stabilized at week 8 in most cases. At that point in time, creatinine 
clearance was lower than the initial value (30 mL/mn) in 6 patients. Three of them, 
experienced grade III renal insufficiency: in addition to the two patients with a DLT 
previously described, one patient did not require dialysis and partially recovered, but 
had persistent grade II renal insufficiency (clearance=35 mL/mn).  
In the model adjusted on the dose level, the creatinine level at week 8 was 
significantly correlated with the baseline value (p=0.001) and diuresis before HIPEC 
(p=0.001). The trend towards lower clearance with an increasing cisplatin dose 
(-5.0/10 mg/m2) was not significant (p=0.20). No significant association was 
observed between the creatinine level and body mass index (p=0.62), Sugarbaker’s 
peritoneal cancer index (p=0.24), maintenance fluid requirement and blood loss 
during surgery (p=0.82 and 0.88, respectively). The results are shown in Figure 3.  
In the logistic regression analysis, the risk of grade II-IV renal failure (creatinine 
clearance <60 mL/mn, N=9) was exclusively associated with low diuresis before 
HIPEC (p=0.026). No significant association was observed with the cisplatin dose 
level (p=0.39). 
Based on all these observations, the estimated probability of DLT associated with a 
cisplatin dose of 80 mg/m2 was 19% (95%CI, 7-38%) which is the closest to the 
target probability set at 20%. However, considering both the DLT observations and 
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prolonged impairment of renal function in several patients, we recommend a cisplatin 
dose of 70 mg/m2. 
 
Maintenance treatment with bevacizumab 
Among the 30 patients who underwent CCRS+HIPEC, 20 patients started 
maintenance bevacizumab. The median interval between CCRS+HIPEC and the first 
bevacizumab injection was 78 days (range, 52-93). Overall, 10 patients did not start 
bevacizumab due to DLT (N=4), pulmonary embolism (N=1), early recurrence (N=2), 
the patient’s choice (N=2) and the physician’s decision (N=1). 
Among the 20 patients who started maintenance bevacizumab, 7 completed the 
treatment (22 cycles) and 13 stopped before completing the 22 cycles. The reasons 
for early stopping were progression in 6 cases, adverse events in 6 cases (entero-
cutaneous fistula requiring hospitalization for medical treatment after 3 cycles, grade 
III arthralgia after 4 cycles, eventration complicated by a small bowel fistula after 9 
cycles requiring immediate surgery, grade II diarrhea after 11 cycles, subocclusion 
after 12 cycles, grade II renal insufficiency after 20 cycles) and the physician’s 
decision after 19 cycles in one case. The adverse events documented during 
maintenance bevacizumab are detailed in Table 4. The median change in creatinine 
clearance during maintenance bevacizumab was -9 mL/mn (range, -38 to + 58). 
 
Survival analysis and recurrence 
With a median follow-up of 29.3 months since the diagnosis (range, 23–37) and 23 
months after CCRS+HIPEC (range, 17-31), disease progression or a relapse has 
occurred in 23 patients, leading to death in 9. Among the 23 patients, 12 had a 
recurrence exclusively in the abdominal cavity, 6 had a metastatic recurrence (nodes, 
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n=3; nodes and liver n=1; pleura, n=1; lung, n=1) and 5 patients had a combined 
recurrence (peritoneal associated with nodes, n=3; liver, n=1; and lung, n=1). Among 
the 21 patients alive at the last follow-up visit, 7 were in first continuous complete 
remission more than 26 months since the diagnosis. Median DFS since 
CCRS+HIPEC was 16.7 months (95%, 10.6-21.0) and after CCRS+HIPEC, 2-year 
DFS and OS were 27% (95% CI, 14–46) and 71% (95%, 51–85), respectively. 
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Discussion 
The CHIPASTIN trial comprised 30 homogeneous patients (stage IIIC serous 
carcinoma and a macroscopically complete resection of the disease) over a short 
period of time (18 months versus the 24 months initially planned), which demonstrate 
the interest of this trial. To our knowledge, CHIPASTIN is the first phase I dose 
escalation trial of front-line hyperthermic intraperitoneal cisplatin after neoadjuvant 
chemotherapy and CCRS in initially unresectable ovarian cancer. CHIPASTIN 
provided crucial information. Firstly, considering the prolonged renal function 
impairment observed, we recommend a dose of 70 mg/m2. Indeed, compared to the 
clearance measured before HIPEC, creatinine clearance decreased by 30 mL/mn or 
more in 15 of the 30 patients. Furthermore, three patients experienced grade III renal 
insufficiency, 8 weeks after CCRS+HIPEC. Among them, 2 required dialysis and did 
not recover normal renal function and the third patient did not require dialysis but 
experienced persistent grade II renal insufficiency. In addition, another patient 
stopped maintenance bevacizumab after 20 cycles due to grade II renal insufficiency. 
This point is crucial because renal insufficiency limits the therapeutic options if a 
recurrence occurs and has an impact on patient quality of life. In the largest series of 
CCRS+HIPEC published to date, comprising 566 patients with ASOC, 92 for front-
line treatment and 474 for treatment of a recurrence, renal insufficiency was reported 
in 51 patients (8%) including 15 patients (2%) who developed chronic renal 
insufficiency, requiring long-term dialysis in 6 patients. However, in that series, 
various drugs were used during HIPEC : cisplatin in 76% of cases, alone or in 
combination, with doses ranging from 30 to 100 (median=50 mg/m²).15 Hakeam and 
al. recently estimated the incidence of cisplatin nephrotoxicity after CCRS+HIPEC 
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combining cisplatin 50mg/m2 and doxorubicin 15mg/m2. In that retrospective cohort 
of 53 patients, comprising 40 with ASOC, two patients with an ovarian cancer 
experienced postoperative renal insufficiency (5%). Both of them recovered a normal 
glomerular filtration rate at one and three months respectively, but serum creatinine 
failed to normalize in one patient.16 Royer et al., showed that an intraperitoneal 
concentration above 10 mg/L eradicated 100% of platinum resistant ovarian cells in a 
clonogenic assay.17 As 70 mg/m2 is deemed sufficient for maximum efficacy and is 
considered acceptable in terms of renal toxicity, we recommend a 70 mg/m2 dose of 
cisplatin during HIPEC for one hour at 42°C. In addition, our data suggest that 
pronounced diuresis should be maintained before HIPEC to reduce the risk of renal 
impairment. 
Regarding other toxicities after CCRS+HIPEC, we observed a low incidence of major 
morbidities: resurgery in 2 patients (6%, versus 8 % in the series reported by Bakrin 
et al.) and radiologic drainage of lymphoceles in 6 (20%, versus 27% in the largest 
series in the literature focused on this topic).15,18 
Concerning maintenance bevacizumab therapy, the percentage of patients who 
completed the 22 cycles of bevacizumab was consistent with that published in both 
phase 3 trials, GOG-0218 and INCON 7 (24% received 22 cycles and 42% received 
18 cycles, respectively).9,10 An increased risk of fistula related to bevacizumab after 
surgery has previously been reported by Burger et al.19 In CHIPASTIN, two patients 
developed a fistula during bevacizumab, requiring surgery in one case. Bevacizumab 
appears to be feasible after CCRS+HIPEC provided that patients with bowel 
resection are carefully screened. In addition, we observed a median reduction in 
creatinine clearance of 9 mL/mn during maintenance bevacizumab. An equivalent 
reduction in creatinine clearance (9.8 to 11.6 mL/min/1.73 m2) was also observed by 
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Levy et al., in a series of 72 patients with solid tumors who had been included in four 
Phase I trials testing antiangiogenics.20 
With the CHIPASTIN strategy, median PFS was 16.7 months (95%, 10.6-21.0) after 
surgery. Costa-Miranda et al. reported median chemotherapy-free survival attaining 
16 months with a similar strategy (six cycles of neoadjuvant chemotherapy followed 
by cytoreductive surgery and without adjuvant chemotherapy) but without HIPEC.21 
However, the populations differ between the two studies, with more advanced 
disease in our trial (no bowel resection in Costa-Miranda’s study). The relatively 
similar results with and without HIPEC as well as the cisplatin-related renal toxicity 
raise two questions : the interest of adding HIPEC in this setting for all patients and 
the choice of cisplatin for HIPEC. In order to achieve progress in this setting, further 
prospective trials are warranted to evaluate other drugs intraperitoneally such as 
paclitaxel and targeted treatments, and to better define patients who may benefit 
from HIPEC. 
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Table 1: Characteristics of cytoreductive surgery and HIPEC 
Characteristics N=30 
PCI (Peritoneal Cancer Index), median (range) 10.5 (1-35) 
Number of affected regions (/ 13 ), median (range) 7 (1-13) 
Standard procedures, N (%)  
Lymphadenectomy pelvic and para-aortic 30 (100%) 
Supracolic omentectomy 30 (100%) 
Extensive procedures, N (%)  
Splenectomy 12 (40%) 
Cholecystectomy  14 (47%) 
Diaphragmatic peritoneal surgery 23 (77%) 
Bowel resection 16 (53%) 
Details of the bowel resection, N (%)  
Small bowel resection 5 
Hemicolectomy 9 
Total colectomy 1 
Low anterior resection 11 
Number of intestinal anastomoses   
               1 11 
               2 5 
Transient stoma 2 
Complete macroscopic resection, N (%) 30 (100%) 
HIPEC procedure, N (%)  
Open wall 24 (80%) 
Closed wall 6 (20%) 
Average intraperitoneal temperature, °C, median (range) 42 (40-43) 
Cisplatin dose adhered to 30 (100%) 
Epidural anesthesia, N (%) 24 (80%) 
Operative time, minutes, median (range) 
Blood loss, mL, median (range) 
410 (256–780) 
950 (200-2720) 
Hospital stay, days, median (range) 
Intensive care unit stay, days, median (range) 
18.5 (10-69) 
10 (1-25) 
* CC0 according to Sugarbaker’s classification1  
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Table 2: Grade II-IV adverse events (AE) during the 8 weeks after CCRS+HIPEC 
according to the Dindo classification 
Dose level Toxicity 
II 
N=14 
IIIa 
N=9 
IIIb 
N=2 
IV 
N=2 
50 mg/m2 2 AE in 2/4 patients 1 1 0 0 
 Renal insufficiency 1 0 0 0 
 Lymphocele 0 1 0 0 
60 mg/m2 3 AE in 2/4 patients 1 2 0 0 
 Urinary infection 1 0 0 0 
 Lymphocele 0 1 0 0 
 Necrotizing enterocolitis 0 1 0 0 
70 mg/m2 7 AE in 4/5 patients 4 3 0 0 
 Renal insufficiency  2 0 0 0 
 Pulmonary embolism 1 0 0 0 
 Urinary infection 1 0 0 0 
 Lymphocele  0 3 0 0 
80 mg/m2 15 AE in 10/17 patients 8 3 2 2 
 Anemia 1 0 0 0 
 Klebsiella Pneumonia infection 1 0 0 0 
 Urinary infection 2 0 0 0 
 Septicemia  1 0 0 0 
 Wall collection 0 1 0 0 
 Lymphocele 0 2 0 0 
 Small bowel perforation with peritonitis 0 0 1 0 
 Rectal bleeding 0 0 1 0 
 Renal insufficiency 3 0 0 2 
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Table 3: Distribution of creatinine clearance at different time points 
Time Creatinine clearance (mL/mn) 
 Median (Range) <15 15-30 30-60 60-90 > 90 
Baseline 93.5 (55 - 179) 0 0 0 14 16 
Minimal value 63.5 (  8 - 138) 2 2 10 10 6 
At week 8 75.5 (17 - 146) 0 3 6 10 11 
No bevacizumab (N=10)       
- Latest measure  
(median time after 
CCRS+HIPEC, 83 days) 
54 (13 – 96) 1 1 4 3 1 
Bevacizumab (N=20)       
- At start of bevacizumab 87.5 (39 - 166) 0 0 5 7 8 
- Latest measure after the 
end of bevacizumab 
(median time after 
CCRS+HIPEC, 460 days) 
70 (41 - 170) 0 0 6 9 5 
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Table 4: Adverse events (AE) reported during bevacizumab treatment  
 CTC AE 
Grade 
No. cycle when AE occurred / total 
number of cycles administered 
Hypertension (N=3)   
 III 6 & 7/20 
 III 11/19 
 III 14/21 
Gastrointestinal AE (N=2)   
Eventration I 3/20 
Enterocutaneous fistula III 3/3 
Eventration complicated by a 
small bowel fistula 
IV 9/9 
Diarrhea II 11/11 
Epigastralgia & subocclusion III 12/12 
Pain (N=2)   
Arthralgia III 4/4 
Osteomuscular pain III 9/22 
Renal AE (N=1)   
Renal insufficiency II 20/20 
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Figures 
Figure 1: Participant flow diagram 
Figure 2: Dose-limiting toxicities and dose escalation 
Figure 3: Observed and predicted creatinine clearance level at week 8, according to 
the baseline value and main covariables  
The dots represent the observed values. The lines represent the values 
predicted by the model including the dose level, creatinine clearance before 
HIPEC and hourly diuresis during anesthesia before HIPEC. 
The diuresis before HIPEC was dichotomized at the median value, 143 mL/h, 
defining high diuresis if >143 mL/h versus low diuresis if <143 mL/mn. 
The coefficient of determination of the final model, R², was 0.64. 
Details are given in the appendix. 
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Screened for study entry
N=39
Registered in the study
N=30
Not eligible at the time of surgery
- Incomplete cytoreductive surgery, N=8
- Adenocarcinoma stage IV, N=1
CCRS + HIPEC performed
N=30
Bevacizumab maintenance started
N=20
Did not start Bevacizumab maintenance
- DLT, N=4
- Toxicity other than DLT, N=1
- Progression, N=2
- Patient choice, N=2
- Physician choice, N=1
Bevacizumab maintenance completed
as per protocol, N=7
Early stop of Bevacizumab, N=13
- Toxicity, N=6
- Progression, N=6
- Physician choice, N=1
Evaluable for the dose-finding study
N=30
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Appendix 
Dose-finding method 
Based on a preliminary simulation study, we used a one-parameter logistic model 
with a fixed intercept equal to 3, and a slope equal to exp(Beta) to be estimated in a 
Bayesian framework. The prior distribution of the Beta parameter to be estimated 
was a normal distribution with a mean of zero and variance of 1.34. The working 
model was set using the getprior function from the dfcrm R package, with a prior 
guess of recommended dose equal to 80 mg/m² and the indifference interval 
parameter set at 0.07, leading to a vector of initial guesses of the probability of DLT 
at the four dose levels of {0.01, 0.03, 0.08, 0.20}. 
This model was reassessed after each new observation, using all previous collected 
data, in order to predict the probability of experiencing a DLT at each level, and to 
define the current recommended dose. The target percentage of DLT was set at 
20%. 
In order to ensure patient safety, the following restrictions were applied: 
1. Skipping doses was not allowed. 
2. When the model recommended dose escalation, at least two patients fully 
evaluated for toxicity at the current dose level were required before allocating 
patients at the next higher dose level. 
3. When a new dose level was opened, if a new patient could be included within 15 
days after the start of treatment of a patient at a new dose level, she could not be 
enrolled at this new dose level but at the previous lower dose level. 
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A target accrual of 30 patients was set. A stopping rule was considered if the lowest 
dose was deemed too toxic. The trial would then have been stopped without a dose 
recommendation. 
 
Prognostic factor analysis of creatinine clearance 
Table 5: Prognostic factor analysis of creatinine clearance at week 8 
 Final model*  
 Coefficient SE p p to enter 
Dose level -5.0 3.8 0.20  
64Creatinine clearance before HIPEC +0.50 0.14 0.001  
Diuresis before HIPEC > 143 mL/h -33.3 8.9 0.001  
Body Mass Index>22 kg/m² -   0.62 
Sugarbaker’s Peritoneal Cancer Index>10.5 -   0.24 
Maintenance fluid requirement > 904 mL/h -   0.82 
Blood loss > 900 mL -   0.88 
*In this covariance analysis, the final model comprised the following three variables: 
dose level, creatinine clearance before HIPEC, and diuresis before HIPEC. The 
coefficient of determination of the final model, R², was 0.64. The variables in italics in 
the lower part of the table correspond to the covariables that were not retained in the 
final model. For these latter covariables, the “p to enter” was computed for each 
covariable separately, adjusted on the final model. Except for the dose level and 
creatinine clearance before HIPEC that were entered as continuous variables in the 
covariance analysis, the covariables were dichotomized considering their median 
value.  
SE: Standard Error 
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Abstract
Introduction: The aim of the present study was to prospectively evaluate morbidity of intra-peritoneal hyperthermic chemotherapy (HIPEC)
using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma and, secondly, to study peritoneal recurrence.
Methods: Between 2004 and 2007, 31 patients from 18 to 65 years with FIGO stage IIIC epithelial ovarian carcinoma were treated by sur-
gery and a total of 6 cycles of platinum based chemotherapy. Those patients were eligible for consolidation therapy. We performed a second
look laparotomy operation with intra-peritoneal hyperthermic chemotherapy. We used Oxaliplatin 460 mg/m2 with 2 l/m2 of dextrose in an
open medial laparotomy for a total of 30 min at a temperature of 42e44 !C.
Results: The grade 3 morbidity rate was 29% (95 CI: 14e45%). Nine patients experienced a total of 13 exploratory laparotomies for intra-
abdominal bleeding after HIPEC. Two-year disease free and overall survival were 27% and 67% respectively. As a result of this high level
of morbidity the trial was closed.
Conclusion: Using intra-peritoneal Oxaliplatin associated with hyperthermia as consolidation therapy for advanced ovarian cancer results in
a high risk of grade 3 morbidities with only a small benefit on survival.
! 2010 Elsevier Ltd. All rights reserved.
Keywords: HIPEC; Ovarian epithelial carcinomatosis
Introduction
Epithelial ovarian cancer (EOC) is usually discovered at
an advanced stage resulting in an overall poor prognosis for
this condition. Modern first line treatment with debulking
surgery which is as complete as possible and an intravenous
combination of Paclitaxel and Platinum chemotherapy can
result in remission in a majority of cases. Unfortunately,
50% of optimally debulked patients will recurre after a neg-
ative second look following 6 cycles of platinum based che-
motherapy.1 Thus, overall survival will depend upon on 2
conditions: first, chemosensitivity and secondly, quality of
cytoreductive surgery. Systemic treatment alone never
results in cure, and so optimising surgery continues to be
the best way to improve survival.2 Intra-peritoneal chemo-
therapy (IPC) after optimal debulking surgery has been
demonstrated as being beneficial in terms of overall and
* This trial was supported by the Gustave Roussy Institute, Villejuif,
France.
** Presented at the 16th International Meeting of the European Society
for Gynaecological Oncology (ESGO 16) Belgrade, Serbia, October
11e14, 2009.
* Corresponding author. Tel.: þ33 473278080.
E-mail address: christophe.pomel@cjp.fr (C. Pomel).
0748-7983/$ - see front matter ! 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejso.2010.04.005
Available online at www.sciencedirect.com
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disease free survival with acceptable quality of life.3e5 At
this time a search for an effective consolidation treatment
is required in order to control residual microscopic disease.
So far none of the intravenous consolidation treatments
have showed any survival benefits.6 The use of IPC as con-
solidation therapy is suggestive of a treatment benefit but
does not support a change in clinical practice.7 On the other
hand, IPC seems a very interesting and logical approach for
a disease involving the peritoneal cavity. A consensus has
emerged to support the potential benefit of hyperthermia
associated with intra-peritoneal chemotherapy (HIPEC)
for the treatment of peritoneal carcinomatosis from colorec-
tal origin.8 Recent studies suggest some interest for the use
of HIPEC in EOC patient.9 Standard HIPEC is used at the
time of debulking surgery. We have designed a study aimed
to evaluate the HIPEC related morbidity as consolidation
therapy for EOC patients.
Methods
Between September 2004 and January 2007, we con-
ducted a prospective non randomized multicentre phase 2
trial using hyperthermia and intra-peritoneal chemotherapy
as consolidation therapy for advanced EOC. The trial was
accepted by the local ethics committee. Informed consent
was obtained from all patients. Oxaliplatin was used as
a single agent. The main goal of the study was to examine
the morbidity of this process, the secondary goal was to ex-
amine the overall survival and recurrence free survival. The
design of the study was to enrol 67 patients for 2 years of
inclusion and 5 years of follow-up. Statistical analysis was
a Simon multistep “optimum design”. The expected 20%
grade 3 morbidity was considered to be acceptable. 40%
was considered unacceptable. Morbidity was defined by
Dindo classification.10 The study was planned in two steps
with a minimum of 67 patients. Twenty eight at the first
step and 39 at the second step. If the morbidity exceeded
ten patients after inclusion and evaluation of the first 28
patients, then the study would be stopped. To be eligible
for the study patients had Stage IIIC peritoneal carcinoma-
tosis from ovarian, tubal or primary serous peritoneal ade-
nocarcinoma including the following criteria:
-Patients aged from 18 to 65 years
-Patients that could not be optimally debulked at first look
laparotomy and/or patients with positive second look af-
ter 6 cycles of cisplatin/carboplatin based chemotherapy.
Exclusion criteria was limited to patients of ASA 3.
All the patients presented normal preoperative coagula-
tion state, normal preoperative platelets counts and no
patients was taking antiaggregant therapy before the sur-
gery. A laparotomy was performed after 6 cycles of plati-
num based chemotherapy. This procedure required a full
abdominal adhesiolysis including small bowel, large bowel,
posterior aspect of the liver and finally lesser sac to allow
a complete immersion of the entire peritoneal cavity with
HIPEC. The peritoneal extent was scored with the Peritoneal
Cancer Index (PCI). At this stage a secondary cytoreductive
surgery including peritonectomies according to Sugar-
baker’s techniques was accepted.11 If no disease remained
or disease not exceeding one mm in the greatest diameter
(volume) then an intra-peritoneal hyperthermic chemother-
apy was achieved. Four intra-peritoneal temperature detec-
tors were placed in the abdominal cavity, one in the right
hypochondrium, one in the left hypochondrium, one in the
pelvis and one in contact with the small bowel. We were
using Oxaliplatin 460 mg/m2 with 2 l/m2 of dextrose in
a open medial laparotomy for a total of 30 min with
a 42e44 !C of temperature. Anticoagulants such as fraction-
ated heparin were used as thrombotic prophylaxis.
Results
Patients underwent surgery in eight different institutions.
After 13 inclusions, 6 patients developed intra-abdominal
bleeding. Therefore the dose of Oxaliplatin was reduced
from 460mg/M2 to 350mg/M2. Analysis after 28 inclusions
demonstrated that 13 emergency procedures were performed
on 9 patients. The clinical trial was then closed. At the same
time 3 more patients were registered before we closed the
trial. Therefore our results involved 31 patients. Patient char-
acteristics are summarized on Table 1. Nine patients had
optimal debulking at first look laparotomy. Twenty two
patients had suboptimal debulking (more than 1 cm residual
tumour) at first look laparotomy. Thirty patients had 6 cycles
of platinum and paclitaxel chemotherapy prior to the HIPEC
and one patient had 8 cycles. PCI analysis observed at the be-
ginning of the HIPEC laparotomy are reported on Table 2.
Twenty two patients had persistent disease at the time of
the procedure. Nine patients had negative cytology with no
residual disease. Limited cyto reduction without bowel
resections performed at the time of the HIPEC could be com-
pleted for 16 patients. Six patients had less than 1 mm resid-
ual tumour. Median operative time before the HIPEC started
was 210mn (70-700mn). Six patients received a blood trans-
fusion at the time of the surgery.
Postoperative course
The grade 3 morbidity rate was 29% (95 CI: 14e45%).
Thirteen emergency laparotomies were performed on 9
Table 1
Patients characteristics.
Epithelial ovarian cancer 28
Primary peritoneal cancer 3
Median age 57 (36e64)
Median weight (kilos) 60 (49e95)
ASA score 0: 7
1: 10
2: 14
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patients for active intra-abdominal bleeding (IAB). Surgical
characteristics of all patients with IAB are summarized on
Table 3. These surgeries were performed between postoper-
ative day 3 and day 12 (with a median of 8 day). Six
patients had one exploratory laparotomy. Two patients
had two exploratory laparotomies. One patient had three
exploratory laparotomies. Among those 9 patients with
IAB, median platelet levels were 88,500 (54,000 to
191,000) This was not statistically different from the rest
of the group study (42,000e245,000). No active bleeding
was observed at the time of the exploratory laparotomies
and one patient developed disseminated intravascular coag-
ulapathy. One patient developed a coma with neurologic
disorders and needed a tracheostomy. Five patients devel-
opped pulmonary infections. Median post op stay was 18
days range from 9 to 46 days. There was no difference of
morbidity between 460 mg/M2 (13 patients) and
350 mg/m2 (18 patients) dose of Oxaliplatin. All patients
recovered completely. Overall and recurrence free survival
are summarized on Fig. 1. To date 24 patients have devel-
oped a recurrence.
Discussion
This trial assessing cytoreductive surgery plus HIPEC
with Oxaliplatin was prematurely closed as there had
been an unacceptably high rate of re-surgery for peritoneal
haemorrhage. To test this combined treatment for EOC was
logical when considering that HIPEC using Oxaliplatin and
surgical resection cured approximately 25% of patients
with peritoneal carcinomatosis from colorectal origin.
This strategy was mainly applicable to patients with limited
intra-peritoneal cancer volume and no extraperitoneal in-
volvement.12 Platinum remains the most active drug class
in ovarian cancer treatment. However, Oxaliplatin,
a third-generation platinum derivative, has shown effective
antitumour activity and a favorable toxicity profile in epi-
thelial ovarian cancer.13 Consolidation/maintenance ther-
apy in the standard management of EOC remains
controversial, primarily due to the unknown impact of
this strategy on overall survival. The use of HIPEC after
6 cycles of chemotherapy may represent an interesting ap-
proach as the peritoneal cavity has been previously treated
both surgically and medically. Therefore this could mini-
mize the amount of intra-peritoneal disease. This is ex-
tremely important as it has been demonstrated that the
effect of HIPEC reaches the centre of tumour deposits
Table 2
Peritoneal cancer index analysis observed at the beginning of the
laparotomy.
Index Nb pts
0 9
1e5 10
6e10 7
11e20 4
>20 1
Table 3
Characteristics of all 9 patients with intra-abdominal bleeding.
Patients Bigest deposit
(cm)
PCI Surgical procedure Residual deposit Experience of the
Centre in HIPEC
(years)
1 5 30 Peritonectomies, Diaphragmatic
stripping, cholecystectomy,
appendicectomy, infragastric
omentecomy, pelvic and PA
lymphadenectomy
0 10
2 1 2 Infragastric omentectomy 0 4
3 0 0 Adhesiolysis 0 15
4 0 0 Adhesiolysis 0 15
5 0 0 Adhesiolysis 0 15
6 0 0 Adhesiolysis 0 10
7 2 19 Peritonectomies, diaphragmatic
stripping, appendicectomy,
completion of omentectomy,
pelvic lymphadenectomy
0 4
8 0 0 Adhesiolysis 0 4
9 1 4 Infragastric omentectomy 0 8
812 8113 6231
272 81 2131
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30 Months
Patients at risk
93%
79%
67%
61%
41%
27%
Recurrence Free Survival
Overall Survival
8
Figure 1. Overall and recurrence free survival.
591C. Pomel et al. / EJSO 36 (2010) 589e593
less than 3 mm.14 Extensive surgery associated with HIPEC
usually impacts on morbidity. Therefore, our results reflect
the side effects of HIPEC alone. 5 of the 8 centres involved
in this study using HIPEC had more than 10 years of expe-
rience in this field. Unfortunately, in our series, surgical
morbidity was a major issue. 9 patients developed postop-
erative intra-abdominal bleeding (IAB) which was not inci-
dentally associated with a less than 50,000/ml platelets
level. Other studies using Oxaliplatin for HIPEC in colon
cancer patient regimen did not show such a dramatic risk
of IAB. In the Gustave Roussy Institute, 90 patients were
treated for peritoneal pseudomyxoma with intra-peritoneal
Oxaliplatin alone (460 mg/m2 in 2 l/m2 of iso-osmotic 5
per cent dextrose; 27 patients) or intra-peritoneal Oxalipla-
tin (360 mg/m2) plus intra-peritoneal irinotecan
(360 mg/m2) (63 patients), at a homogeneous intra-perito-
neal temperature of 43 !C for 30 min. These 90 patients re-
ceived an intravenous perfusion of 5-fluorouracil (5-FU)
(400 mg/m2) with leucovorin (20 mg/m2) before starting
HIPEC. Less than 5% of the patients developed postopera-
tive bleeding.15 Nevertheless, in a recent publication, Mar-
cotte et al. observed an 18% risk of haemorrhage in
a consecutive series of 38 patients treated by HIPEC with
Oxaliplatin at the same dose.16 Furthermore, Ceelin et al.
observed the case of one patient who developed unex-
plained repeated episodes of hemoperitoneum.17 This phe-
nomenum occured in three patients in our current series.
Recently, Fagotty et al. used the same dose of Oxaliplati-
num. After complete CRS they were submitted to intra-
peritoneal perfusion of Oxaplatinum (460 mg/m2) heated
to 41.5 !C for 30 min. The population of recurrent ovarian
cancer patients with a platinum-free interval of at least 6
months were prospectively enrolled. Interestingly they ob-
served 7 postoperative haemorrhage.18 Should we consider
that 6 cycles of paclitaxel-platinum based chemotherapy
prior to HIPEC may affect platelets toxicity? Does ovarian
peritoneal carcinomatosis alter the coagulation system? We
were unable to clearly answer to these questions. Unfortu-
nately, the choice of Oxaliplatin with HIPEC does not ap-
pear to be a good option for EOC patients. Gori et al.
investigated the effect of intra-peritoneal hyperthermic per-
fusion chemotherapy as consolidation therapy in stage
IIIBeIIIC epithelial ovarian cancer, following cytoreduc-
tive surgery and systemic chemotherapy (cispla-
tinecyclophosphamide e six cycles). In a multicentre
prospective trial, 29 patients with complete or optimal cy-
toreductive surgery and systemic treatment were included
in the consolidation group and received HIPEC using cis-
platin 100 mg/m2, for 60 min. The consolidation therapy
group showed a better 5-year survival rate and lower recur-
rent disease rate, but differences were not statistically sig-
nificant.19 Furthermore, Kim JH et al. reported the study
of 19 patients with stage IceIIIc EOC who received consol-
idation intra-operative HIPEC using 6 L of lactated
Ringer’s solution containing paclitaxel 175 mg/m,2 for
90 min in hyperthermic phase. The survival rates were
compared with 24 patients treated with conventional ther-
apy. The 8-year overall survival rates were 84.21% in the
HIPEC-paclitaxel group and 25.00% in the control group
with a significant P value.20
Our inclusion criteria included patients with poor prog-
nostic factors: suboptimal (incomplete) debulking at first
time laparotomy or positive second look. This could explain
that overall and disease free survival rates are disappointing
in this trial. Unfortunately HIPEC did not decrease the risk
of peritoneal recurrence as 80% of our patients developed
intra-abdominal recurrence. As claimed in the recent paper
of Helm et al. we still believe that HIPEC may be a future
option in the management of advanced epithelial ovarian
cancer. The choice of appropriate drugs will be the key point.
In conclusion, this phase II trial showed a dramatic rate
of morbidity that fortunately did not affect perioperative
mortality. We were unable to demonstrate any survival ben-
efit following this therapy. Physicians should be aware of
the possibility of acute intra-abdominal hematological
emergencies following intra-peritoneal Oxaliplatin admin-
istration associated with hyperthermia in epithelial ovarian
cancer patients. Therefore we would not recommend the
use of Oxaliplatin in this indication.
Conflict of interest
The authors declare that there are no conflicts of interest.
References
1. Copeland LJ, Gershenson DM. Ovarian recurrences in patients with no
macroscopic tumor at second look laparotomy. Obstet Gynecol 1986;
68(6):873–4.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ.
Survival effect of maximal cytoreductive surgery for advanced ovarian
carcinoma during the platinum era: a meta-analysis. J Clin Oncol
2002;20:1248–59.
3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus
intravenous cyclophosphamide versus intravenous cisplatin plus inrta-
venous cyclophosphamide for stage III ovarian cancer. N Engl J Med
1996;335(26):1950–5.
4. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard
dose intravenous cisplatin plus paclitaxel versus moderately high-dose
carboplatin followed by intravenous paclitaxel and intraperitoneal cis-
platin in small-volume stage III ovarian carcinoma: an intergroup
study of the gynaecologic oncology group, southwestern oncology
group, and eastern cooperative oncology group. J Clin Oncol 2001;
19(4):1001–7.
5. Armstrong DK, Bundy B, Wenzel L, et alGynecologic Oncology
Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
N Engl J Med 2006;354:34–43.
6. Markman M. Consolidation/maintenance chemotherapy for ovarian
cancer. Curr Oncol Rep 2003 Nov;5(6):454–8. [Review].
7. Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin ver-
sus no further treatment: 8-year results of EORTC 55875, a random-
ized phase III study in ovarian cancer patients with a pathologically
complete remission after platinum-based intravenous chemotherapy.
Int J Gynecol Cancer 2003;13(Suppl. 2):196–203.
8. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy in the management of
592 C. Pomel et al. / EJSO 36 (2010) 589e593
peritoneal surface malignancies of colonic origin: a consensus state-
ment. Ann Surgical Oncol 2007;14(1):128–33.
9. Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperther-
mic intraperitoneal chemotherapy with and without cytoreductive sur-
gery for epithelial ovarian cancer. J Surg Oncol 2008;98:283–90.
10. Dindo D, Demartines N, Clavien PA. Classification of surgical compli-
cations: a new proposal with evaluation in a cohort of 6336 patients
and results of a survey. Ann Surg 2004 Aug;240(2):205–13.
11. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am
2003 Jul;12(3):703–27.
12. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal
carcinomatosis arising from colorectal cancer by complete resection
and intraperitoneal chemotherapy. Cancer 2001;92:71–6.
13. Fu S, Kavanagh JJ, Hu W, Bast Jr RC. Clinical application of oxalipla-
tin in epithelial ovarian cancer. Int J Gynecol Cancer 2006 SepeOct;
16(5):1717–32.
14. Sugarbaker PH, Cuniffe W, Belliveau JF, de Bruin E, Graves T. Ra-
tionale for perioperative intraperitoneal chemotherapy as a surgical
adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1988;1:
66–79.
15. EliasD,Honor!eC,Ciuchend!eaR,et al. Peritoneal pseudomyxoma: results
of a systematic policyofcompletecytoreductive surgery andhyperthermic
intraperitoneal chemotherapy. Br J Surg 2008 Sep;95(9):1164–71.
16. Marcotte E, Sideris L, Drolet P, et al. Hyperthermic intraperitoneal
chemotherapy with oxaliplatin for peritoneal carcinomatosis arising
from appendix: preliminary results of a survival analysis. Ann Surg
Oncol 2008 Oct;15(10):2701–8. [Epub 2008 Jul 25].
17. Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F,
Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemo-
perfusion with high-dose oxaliplatin in patients with peritoneal carci-
nomatosis. Ann Surg Oncol 2008 Feb;15(2):535–41.
18. Fagotti A, Paris I, Grimolizzi F, et al. Secondary cytoreduction plus
oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian can-
cer patients: a pilot study. Gynecol Oncol 2009 Jun;113(3):335–40.
19. Gori J, Castan˜o R, Toziano M, et al. Intraperitoneal hyperthermic che-
motherapy in ovarian cancer. Int J Gynecol Cancer 2005 MareApr;15
(2):233–9.
20. Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperthermic intraper-
itoneal chemotherapy using paclitaxel in patients with epithelial ovar-
ian cancer. J Surg Oncol 2010 Feb 1;101(2):149–55.
593C. Pomel et al. / EJSO 36 (2010) 589e593
! 39!
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five-compartment PK model with irreversible nonlinear 
binding from UF to B according to a Michaelis–Menten 
equation. The mean (±SD) maximum fraction of dose 
absorbed and elimination half-life from the peritoneum was 
53.7 % (±8.5) and 0.49 h (±0.1), respectively. The mean 
(±SD) ratio AUCIP/AUCUF was 5.3 (±2) confirming the 
pharmacokinetic advantage of the procedure. Haemoperi-
toneum (22.7 %), neuropathy (18.7 %), grade 3/4 throm-
bocytopenia (13.3 %) were the most frequently reported 
toxicities. AUCUF accounts for approximately 12 % of the 
variation in the maximum percentage of platelet decrease 
(r = 0.35, p = 0.002). Thrombocytopenia was correlated 
with higher AUCUF, partly dependent on the extent and rate 
of oxaliplatin absorption.
Conclusions Despite a common dose administered, vari-
ability in peritoneal and systemic oxaliplatin exposures are 
observed, leading to differences in haematological toxicity 
between patients.
Keywords Oxaliplatin · HIPEC · Population 
pharmacokinetic · Thrombocytopenia · NONMEM
Introduction
Peritoneal carcinomatosis is caused by widespread metas-
tases in the peritoneal cavity. Until recently, the treatment 
of this terminal condition was limited to standard palliative 
surgery and chemotherapy with mediocre results in terms 
of survival. However, a recent meta-analysis has shown that 
the use of cytoreductive surgery (CRS) followed by hyper-
thermic intraperitoneal chemotherapy (HIPEC) signifi-
cantly increases survival in patients with colorectal cancer 
[1]. Experimental studies have shown that drug penetration 
is limited to a few cell layers beneath the tumour surface 
Abstract 
Purpose First, to evaluate the peritoneal (IP), plasma 
ultrafiltrated (UF) and protein-bound (B) pharmacokinet-
ics (PK) of oxaliplatin after intraperitoneal hyperthermic 
chemoperfusion (HIPEC) following cytoreductive surgery. 
Second, to evaluate the relationship between oxaliplatin 
exposure and observed toxicity.
Methods IP, UF, and B concentrations from 75 patients 
treated by 30-min oxaliplatin-based HIPEC procedures 
were analysed according to a pharmacokinetic modelling 
approach using NONMEM. Oxaliplatin was administered 
in a 5 % dextrose solution (2 L/m2) at 360 (n = 58) or 
460 mg/m2 (n = 17). The most frequently observed toxici-
ties were related to the peritoneal, systemic exposures and 
to the parameters corresponding to the oxaliplatin absorp-
tion from peritoneal cavity into plasma.
Results IP (n = 536), UF (n = 669) and B (n = 661) con-
centrations were simultaneously described according to a 
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[2] and consequently HIPEC must be administered imme-
diately after the CRS in order to achieve maximal cytotoxic 
activity on residual tumour cells before they are trapped in 
the post-operative fibrin adhesions [3]. This combination is 
the standard treatment for both pseudomyxoma peritonei 
and peritoneal mesothelioma [4]. There are ongoing clini-
cal trials in colorectal cancer [5] and advanced ovarian can-
cer [6, 7] as well as several phase I/II trials in gastric cancer 
[8].
Although other drugs such as cisplatin [9], carboplatin 
[10], paclitaxel [11], mitomycin C [12] or doxorubicin [13] 
have been used, the antineoplastic platinum-compound 
oxaliplatin is currently frequently employed because its 
cytotoxic activity is substantially improved by hyperther-
mia [14] and its intratumoural penetration is optimal [15]. 
However, these therapeutic advantages have to be put into 
balance with the associated risk of peripheral sensory neu-
ropathy and haematological toxicity which are the dose-
limiting toxicities of oxaliplatin administered intravenously 
[16]. Votanopoulos et al. [12] reported a 14.5 % incidence 
of grade 3–4 neutrophil toxicity and a 10.9 % incidence 
of grade 3–4 platelet toxicity among patients treated with 
oxaliplatin-based HIPEC. On the other hand, Elias et al. 
[17] found a grade 3–4 haematological toxicity rate of 58, 
41 % of grade 4 neutropenia and 26 % of grade 3 thrombo-
cytopenia, in 39 patients with peritoneal carcinomatosis of 
either gastro-intestinal or peritoneal origin who underwent 
CRS followed by HIPEC with oxaliplatin and irinotecan.
Several authors have examined the pharmacokinet-
ics (PK) of oxaliplatin during HIPEC [18–21] and found 
that oxaliplatin was linearly absorbed from peritoneum to 
plasma and linearly eliminated from a central compartment. 
On the other hand, Elias et al. [15] showed that intratu-
moural oxaliplatin penetration was high, similar to absorp-
tion at the peritoneal surface and 18 times higher than 
that in non-bathed tissues. In a previous study, we showed 
that inter-individual variability was larger for plasma PK 
parameters than for peritoneal parameters [18].
Two recent studies [20, 22] used semi-mechanistic pop-
ulation pharmacokinetic and pharmacodynamic (PK/PD) 
Friberg-type models to characterize the oxaliplatin PK 
in peritoneum and plasma (only total equal to ultrafiltra-
ble plus protein-bound concentrations were determined) 
in relation to absolute neutrophil counts over time on, 
respectively, 30 and 66 patients treated with CRS and 
oxaliplatin-based HIPEC. Valenzuela et al. [20] found that 
a peritoneum oxaliplatin exposure was associated with the 
incidence of severe neutropenia, which suggested that the 
use of primary prophylaxis with G-CSF to counterbalance 
the neutropenia should be considered when peritoneal con-
centrations of oxaliplatin administered in dextrose 5 % 
during 30–60 min are expected to be higher than 900 and 
660 mg/L [22].
In the present study, we simultaneously evaluated the 
pharmacokinetics of peritoneal (IP), plasma ultrafiltrated 
(UF) and protein-bound (B) oxaliplatin concentrations 
in 75 patients treated by HIPEC following CRS. We also 
related the most frequently observed toxicities to the peri-
toneal and systemic oxaliplatin exposures and to the param-
eters reflecting absorption into plasma.
Patients and methods
Patients and oxaliplatin administration
Seventy-five patients were treated by 30-min oxalipl-
atin-based HIPEC procedures conducted as previously 
described by Elias et al. [23] with the “coliseum” tech-
nique (open abdomen, closed circuit). Primary tumour type 
was colorectal carcinomatosis (n = 25), advanced ovarian 
cancer (n = 18), peritoneal mesothelioma (n = 9), pseu-
domyxoma peritonei (n = 20), and other (CUP, cervical 
cancer, n = 3). Oxaliplatin was administered in a 5 % dex-
trose solution (2 L/m2) at a dose of 460 mg/m2 (n = 17) 
or 360 mg/m2 (n = 58): the initial dose of 460 mg/m2 was 
reduced to 360 mg/m2 due to toxicity. The first twelve 
patients were treated according to the first HIPEC proce-
dures (group 1) and the following (n = 63) to the second 
procedure (group 2) [18]. For the first procedure, the solu-
tion was instilled within the peritoneal cavity contained 
oxaliplatin and a delay of 8–10 min was necessary to reach 
a temperature of 42–43 °C. For the second procedure, the 
cavity was initially filled only with the dextrose solution 
and oxaliplatin was added to the peritoneal instillate when 
the temperature reached 42–43 °C. We previously showed 
from the data of the 24 first included patients that the pro-
cedure did not impact on oxaliplatin pharmacokinetics 
[18]. The extracorporeal circulation of the fluid was real-
ized using the Performer LRT® system (Rand, Medolla, 
MO, Italy). Perfusion duration was exactly 30 min from the 
time when optimum temperature (42–43 °C) was reached. 
The study was approved by the institutional review board 
from our institution and performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments. All patients provided writ-
ten informed consent before study enrolment. Their main 
characteristics are shown in Table 1.
Pharmacokinetic data
Seven peritoneal fluid samples were collected (every 5 min 
during the 30-min HIPEC) per patient. One additional 
peritoneal sample was obtained just before the warm-up 
period for the first 12 patients who had undergone a differ-
ent warm-up procedure [18]. Oxaliplatin was added to the 
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peritoneal instillate before (first twelve patients) or when 
the temperature reached 42–43 °C (all the other patients). 
Ten blood samples (5 mL) were collected before HIPEC, 
0.167, 0.333, 0.5, 0.75, 1, 2, 4, 6, and 8 h after HIPEC. 
Blood samples were immediately transferred from the sur-
gical unit to the laboratory and then immediately centri-
fuged at 2,000×g for 10 min at 4 °C. One mL of plasma 
was immediately ultrafiltered using Amicon MPS1 micro-
partition system with YMT membranes (30,000 MW cut-
off) at 4 °C for 20 min at 2,000×g.
Samples were kept at −20 °C until analysis. Total 
platinum in peritoneum, plasma and ultrafiltrated plasma 
was measured immediately after thawing of samples by 
flameless atomic absorption spectrophotometry accord-
ing to a previously described method [24]. Specific 
matrix and calibration were used for standard and qual-
ity control (QCs) samples: water for peritoneal or ultra-
filtrated plasma, and plasma for total plasma analysis, 
respectively. The limit of quantification was 5.25 ng/mL 
for both peritoneal fluid and plasma ultrafiltrated plati-
num concentrations, and 10.5 ng/mL for plasma plati-
num concentrations. Accuracy ranged between 95.2 and 
109.9 % for water QCs, and 87.1 and 109.5 % for plasma 
QCs. Precision within and between runs was lower than 
10 % for the 6 QCs (low, medium and high QCs in each 
matrix). Before conducting the pharmacokinetic analysis, 
platinum concentrations measured were converted into 
oxaliplatin concentrations according to their molecular 
weights. Consequently, all the results were expressed as 
oxaliplatin concentrations in nanograms per millilitre (ng/
mL), corresponding to the sum of unchanged oxaliplatin 
and all its platinum metabolites.
Pharmacodynamic data
The onset of toxicity (haemoperitoneum, ascites, neu-
ropathy and haematotoxicity) was monitored by the clini-
cal team until the patients were discharged from hospi-
tal. Haematotoxicity was evaluated by the neutrophil or 
platelet counts obtained once a day until the patients were 
discharged.
Pharmacokinetic analysis
A population pharmacokinetic approach was applied to 
simultaneously link up intra-peritoneal (IP) to plasma 
ultrafiltrate (UF) and to protein-bound (B) oxaliplatin con-
centrations. The protein-bound concentrations (PtB) were 
obtained by subtracting the ultrafiltrated plasma oxaliplatin 
concentrations (PtUF) to the total plasma (PtT) ones [25], at 
the same sampling time, as follows:
For each type of data, the structural PK model was 
selected between 1-, 2- or 3-compartment models. The 
intra-peritoneal oxaliplatin was assumed to be absorbed 
into the plasma through a first-order process. To model the 
irreversible binding of ultrafiltrated plasma oxaliplatin to 
plasmatic proteins, a first-order process [26] or a nonlinear 
binding through a Michaelis–Menten equation [25] model 
were tested. A first-order elimination was assumed for both 
ultrafiltrated and protein-bound oxaliplatin concentrations. 
Inter-individual variability (IIV) in the pharmacokinetic 
parameters was assumed to follow a log-normal distribu-
tion, and consequently, an exponential error model was 
used. Different error models (i.e. additive, proportional and 
combined) were tested to describe the three IP, UF and B 
residuals errors.
Model selection
The likelihood ratio test was used to discriminate two 
nested models. A difference greater than 3.84 for one 
additional parameter, corresponding to a significance 
level of 5 %, was used. Non-nested models were discrimi-
nated by computing the Bayesian Information Criterion 
(BIC = OFV + k × Ln(n), with n, the number of observa-
tions; k, the number of estimated parameters; and OFV, the 
objective function value). The model with the lowest BIC 
value was selected. Model development was guided by pre-
cision in parameter estimates [i.e. relative standard error 
(RSE)], visual inspection of the classic goodness-of-fit 
plots (GOFs) and normalized prediction discrepancy errors 
(NPDE) [27, 28]. One thousand simulations of the build-
ing dataset based on the dose regimen and sampling time-
points of each patient were performed using the parameter 
PtB = PtT − PtUF
Table 1  Characteristics of the 75 patients studied
BSA body surface area, BMI body mass index, ALB serum albumin 
concentration, PLATINCL platelet count before surgery, PROT serum 
total protein concentration, PCI Sugarbaker’s peritoneal index, SCr 
serum creatinine concentration, REG number of impacted regions, 
CLCr Cockcroft–Gault creatinine clearance
Characteristics Mean SD Median (min–max)
Weight (kg) 67.5 14.4 65 (37–106)
Height (m) 1.647 5.18 1.65 (1.5–1.85)
Age (years) 55.83 9.65 57.02 (32.6–73.27)
BSA (m2) 1.72 0.18 1.69 (1.32–2.09)
ALB (g/L) 20.67 5.48 21 (10–34)
PROT (g/L) 40.87 8.62 42 (19–58)
SCr (µmol/L) 79.79 28.61 75 (35–155)
CLCr (mL/min) 85.1 31.84 82.3 (23.3–199.6)
BMI (kg/m2) 24.90 5.18 23.88 (14.45–42.46)
PLATINCL (×109/L) 293.21 90.62 289 (94–635)
PCI (n) 11.49 8.71 9 (0–39)
REG (n) 6.6 4.3 6 (0–13)
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estimates in order to compute NPDE. These were plotted 
versus time and versus population prediction concentra-
tions (PRED) for each type of data (UF, IP and B) in order 
to identify a possible bias in the structural model. The best 
model according to the LRT, acceptable parameter preci-
sion supported by the goodness-of-fit plot and NPDE, was 
finally selected.
Covariate analysis
In order to explain part of the IIV, a covariate analysis was 
performed. Only covariates with a biologically plausible 
effect were tested. The empirical Bayesian estimates (EBE) 
obtained using the POSTHOC option in NONMEM were 
used to screen the influence of covariates on PK parameter 
estimates. Nonparametric statistical tests were first applied 
to discriminate the covariate statistically correlated (i.e. 
Wilcoxon, Spearman or Kruskal–Wallis tests for, respec-
tively, binary, continuous or categorical covariates) only on 
PK parameters with an η-shrinkage lower than 30 % [29]. 
Only covariates with a statistically significant association 
(p < 0.05) with a model parameter were further tested in 
NONMEM in order to be incorporated into the population 
model. For parameters with an η-shrinkage higher than 
30 %, all the covariates were tested in NONMEM. A step-
wise analysis was performed with sequentially a forward 
inclusion (p < 0.05, leading to a drop of 3.84 in OFV after 
addition of one covariate parameter) and backward elimi-
nation (p < 0.01, leading to an increase of 6.63 in OFV 
after removal of one parameter covariate). Continuous 
covariates were evaluated using power equations after cen-
tring on the median of the covariate; categorical covariates 
were incorporated into the model as indicator variables. 
The covariates tested included body surface area, age, sex, 
serum total protein concentration, creatinine clearance (cal-
culated according to Cockcroft and Gault equation), first 
treatment or relapse and the primary tumour site. The lat-
ter was divided into four categories according to the global 
therapeutic management strategy: (1) colorectal cancer; (2) 
advanced ovarian cancer; (3) peritoneal mesothelioma; and 
(4) pseudomyxoma peritonei or other. The extent of perito-
neal carcinomatosis was assessed by intraoperative explo-
ration, using Sugarbaker’s peritoneal cancer index [30], and 
the distribution of implant throughout the abdomen regions. 
The surgical procedure was evaluated with the number of 
peritonectomy procedures required to achieve a complete 
cytoreductive surgery and the duration of the surgery.
Model evaluation
NPDE versus time and NPDE versus PRED were com-
puted, according to the same procedure as described 
above, to evaluate the final model including covariates. 
By construction, the NPDE should follow a standard 
normal distribution, and consequently, a Kolmogorov–
Smirnov test was performed to check normality [27, 28]. 
Visual predictive checks (VPC) were also used to evalu-
ate the final model. For each type of data (IP, UF and B), 
one thousand simulations, based on the dose regimen and 
sampling timepoints of each patient, were performed with 
the final parameter estimates. The 5th, 50th and 95th per-
centiles of the observed concentrations were calculated at 
each theoretical sampling time and plotted versus theoreti-
cal sampling time. The 5th, 50th and 95th percentiles of 
the predicted concentrations were calculated at each theo-
retical sampling time and for each of the 1,000 simulations. 
Therefore, the 5th, 50th and 95th percentiles for the 1,000 
model-based predicted percentiles were calculated at each 
theoretical sampling time and plotted versus theoretical 
sampling time. The observed concentrations were added on 
the respective plots to evaluate the ability of the model to 
describe peritoneal, plasma ultrafiltrate and plasma protein-
bound oxaliplatin concentrations.
Secondary pharmacokinetic parameters
The peritoneal half-life was calculated as t1/2(IP) = ln 2/ka. 
The oxaliplatin maximum bioavailability (MB), correspond-
ing to the maximum fraction of absorbed dose, was calcu-
lated for each patient as MB = (Conct=0−Conct=last)Conct=0 × 100, 
with Conct=0 and Conct=last the individual prediction of peri 
toneal concentrations (IPRED in NONMEM), respectively, 
at the beginning and at the end of the CHIP.
The areas under the curve (AUC) for concentration ver-
sus time values were computed with the trapezoidal rule for 
both the intra-peritoneal (AUCIP) and plasma ultrafiltrated 
compartments (AUCUF) considering the individual Bayes-
ian predictions concentrations (Conc) over time. Indeed, 
thanks to the final model, Conc were computed after adding 
numerous lines into the dataset (EVID = 2 in NONMEM 
dataset) with time from t = 0 to t = last, respectively, every 
0.1 h for the IP compartment, and every 0.5 h until 48 h for 
the UF compartment.
Pharmacokinetic–pharmacodynamic (PKPD) analysis
The pharmacodynamics of oxaliplatin were evaluated by 
the toxicity. Different variables reflecting the most fre-
quently observed toxicities in treated patients (onset of 
haemoperitoneum, ascites, sepsis, neuropathy and depth 
of thrombocytopenia) were related to the peritoneal (i.e. 
AUCIP and individual prediction of initial peritoneal con-
centrations Conct=0) exposures, systemic (i.e. AUCUF) 
exposures and to the parameters reflecting the absorp-
tion into the plasma (i.e. ka, MB). Thrombocytopenia was 
described by the maximum percentage of platelet decrease 
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(relative percentage between the value determined before 
the surgery and the observed nadir). Statistical tests were 
applied to identify relationships between PK and toxi- 
city. For the qualitative binary toxicity variables, Stu-
dent’s t tests or Wilcoxon comparison of mean tests were 
performed, whereas for the quantitative toxicity variables, 
Pearson’s or Spearman’s correlation coefficients and corre-
sponding significance tests were used. Logistic and linear 
regressions were then performed to aid the clinical inter-
pretation of the observed associations.
Software
Concentration–time profiles of these three types of concen-
tration were analysed using nonlinear mixed effects mod-
els with NONMEM version 7.2. The subroutine ADVAN13 
and the first-order conditional estimation method with 
interaction (FOCE-I) was used. Pirana 2.7.1 was used as an 
interface for NONMEM procedure. Graphical evaluation 
was performed using plots produced by R 2.14.0.
Results
The data from 75 patients are integrated in the present data-
set. Overall, 1,866 data were simultaneously analysed with, 
respectively, 536 intraperitoneal, 669 plasma ultrafiltrated 
and 661 plasma protein-bound oxaliplatin concentrations.
Clinical results
Patients had a mean Sugarbaker’s peritoneal cancer index 
of 11.5 [median (min–max): 9 (0–39)] for an average 
of 6.6 affected regions [median (min–max): 6 (0–13)]. 
Twenty-one per cent of patients were previously treated 
by a protocol of chemotherapy containing oxaliplatin 
(e.g. FOLFOX). A complete cytoreductive surgery was 
reached in all patients: 70 patients exhibited no residual 
disease (cytoreductive score of CC0), and 5 had a remain-
ing disease <1 mm (cytoreductive score of CC1), respec-
tively. The mean duration of surgery and number of proce-
dures of peritonectomy were, respectively, 4.71 h [median 
(min–max): 4.25 (2.32–9)], and 3.4 [median (min–max): 4 
(0–10)]. Mean perioperative total insensitive losses (includ-
ing blood loss) was 1,057 mL [median (min–max): 732.5 
(87–5, 131)] based on 52 patients. The mean hospital stay 
was 21.7 days [median (min–max): 17 (6–90)] based on 
73 patients. Haemoperitoneum (22.7 % of patients), neu-
ropathy (18.7 %), thrombocytopenia [13.3 % of grade 3 
(n = 5) and 4 (n = 5)] and ascites (4 %) were the most 
frequently reported toxicities. Patients who exhibited grade 
3–4 thrombocytopenia had a mean nadir of 27.2 × 109 
platelets per litre [median (min–max): 26 (7–47)] and a 
mean maximum percentage of platelet decrease of 89.4 % 
[median (min–max): 91.8 (76.5–98.2)]. The observed nadir 
appeared on average 7 days after the end of the treatment 
[median (min–max): 7 (3–10)]. Interestingly, neutropenia 
were rarely observed (only two patients exhibited grade 3 
neutropenia) which is why we decided not to include them 
in the current PKPD analysis.
Pharmacokinetic model
The structural pharmacokinetic model included five differ-
ent compartments (Fig. 1): the three compartments corre-
sponding to the available concentrations (i.e. VIP, VUF and 
VB), and two additional compartments corresponding to 
peripheral compartments of distribution of either UF or B 
Fig. 1  Pharmacokinetic compartment model linking intra-peritoneal 
(IP) oxaliplatin concentrations to plasma ultrafiltrated (UF) and pro-
tein-bound (B) oxaliplatin concentrations. Oxaliplatin was adminis-
tered in the peritoneal compartment. UF oxaliplatin was transferred 
to the central compartment according to the absorption constant rate 
ka. UF oxaliplatin can bind irreversibly to plasma proteins according 
to a nonlinear Michaelis–Menten equation (Km, Vm). Both UF and B 
oxaliplatin can change between the central and peripheral compart-
ments (QUF and QB, respectively) or be eliminated according to a 
first-order process from the central compartment (kEL-UF and kEL-B, 
respectively)
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oxaliplatin (VPeri-UF and VPeri-B). Absorption from perito-
neum to UF compartment as well as elimination from UF 
and B compartments were better described by first-order 
processes according to ka, kEL-UF and kEL-B, respectively. 
Binding of oxaliplatin to plasma proteins was described 
according to a nonlinear Michaelis–Menten equation 
parameterized in Vm (the maximum rate of drug transport), 
and Km (the ultrafiltrated oxaliplatin concentration at which 
the rate is half maximum). Proportional residual error mod-
els best fitted each of the three types of data with 10.9, 19 
and 22.8 % for the IP, UF and B oxaliplatin concentrations, 
respectively. As VB is not identifiable, we decided to fix it 
to 1. IIV were estimated on all parameters except on Km. 
The median population pharmacokinetic parameter esti-
mates and their inter-individual variability were reported 
in the Table 2. Goodness-of-fit plots, VPCs and NPDEs for 
the each type of data were depicted on the Figs. 2 and 3. 
The mean [95 % confidence interval (95 % CI)] and stand-
ard deviation (95 % CI) of the NPDE for peritoneal con-
centrations were −0.004 (−0.082; 0.075) and 0.931 (0.874; 
0.985), respectively; 0.088 (0.017; 0.158) and 0.924 
(0.873; 0.973) for the plasma ultrafiltrated concentrations, 
respectively; and 0.089 (0.021; 0.158) and 0.889 (0.84; 
0.936) for the plasma protein-bound concentrations, 
respectively.   
Forward inclusion followed by backward elimination of 
covariates within the population pharmacokinetic model 
identified two significant covariates: body surface area 
(BSA) on both VIP (IIV decreases from 20.9 to 16.6 %) 
and serum total protein concentration (PROT) on kEL-B (IIV 
decreases from 24.2 to 17.3 %). The covariate parameters 
and their precision of estimation were reported on Table 2.
Secondary pharmacokinetic parameters
The mean maximum bioavailability (MB) was 53.7 % 
[median (min–max): 53.6 (30.7–73.4)], and the mean elim-
ination half-life from the peritoneum was 0.49 h [median 
(min–max): 0.5 (0.3–0.9)]. The mean AUCIP and AUCUF 
was 84.8 µg.h/mL [median (min–max): 81.6 (51.9–136.7)] 
and 17.7 µg.h/mL [median (min–max): 16.4 (6.5–30.1)], 
respectively. The mean pharmacokinetic advantage (i.e. 
ratio AUCIP/AUCUF) was 5.3 [median (min–max): 4.9 
(2.6–12.7)].
Pharmacokinetic–pharmacodynamic analysis
The results of the statistical tests examining the association 
between the peritoneal or systemic exposure of oxaliplatin 
and the various toxicity variables are reported in Table 3. 
AUCUF accounts for approximately 12 % of the variation 
in the maximum percentage of platelet decrease [p = 0.002 
with a Pearson’s coefficient of correlation (r) of 0.35]. 
Furthermore, statistically significant correlations were 
found between MB and AUCUF (p = 1 × 10−7, r = 0.57), 
ka (p = 2.2 × 10−16, r = 0.83) and Conct=0 (p = 0.004, 
r = 0.32). Furthermore, Conct=0 was statistically corre-
lated with AUCIP (p < 2 × 10−16, r = 0.82) and AUCUF 
(p = 0.016, r = 0.28). No statistically significant associa-
tions were found between the onset of ascites or neuropa-
thy and oxaliplatin exposures (neither IP nor UF, results not 
shown). No statistically significant associations were found 
between a previous treatment with oxaliplatin and any tox-
icity (results not shown). No statistically significant associ-
ations were found between the surgery (duration of surgery 
or number of peritonectomy procedures) and oxaliplatin 
exposure (neither IP nor UF, results not shown).
Discussion
In the literature, publications reporting population 
PK models of oxaliplatin after HIPEC procedure in 
patients who underwent cytoreductive surgery are few. 
Here, we present the first population PK model able to 
Table 2  Population pharmacokinetic parameter estimates with their 
inter-individual variability (IIV) and associated relative standard error 
(RSE)
ERR refers to the respective residual errors for the intra-peritoneal 
(IP) oxaliplatin concentrations, plasma ultrafiltrated (UF) and protein-
bound (B) oxaliplatin concentrations
RSE (%) = (standard error/final parameter estimate) × 100
IIV (%) = (ωIIV) × 100
BSA (m2) body surface area, PROT (g/L) serum total protein concen-
tration
Parameters Population median  
estimates (RSE %)
IIV (%) 
[RSE (%)]
ka (h−1) 1.42 (4.3) 24.1 (12.7)
VIP (L) 3.73 (3.7) × (BSA/1.69)1.24 (21) 16.6 (11)
VUF (L) 22.1 (7.6) 26.9 (17.1)
kEL-UF (h−1) 0.191 (28) 70.4 (34.8)
QUF (h−1) 44.4 (7.2) 36.1 (14.2)
VPeri-UF (L) 163 (9) 26 (19.5)
Vm (ng/h) 124 (12.3) 27.9 (13.7)
Km (ng/mL) 5,980 (14.1) –
kEL-B (h−1) 4.58 (8.3) × (PROT/42)−0.75 (34.1) 17.3 (53.7)
QB (h−1) 19.4 (14.3) 62.1 (14.8)
VPeri-B(L) 17.5 (9.9) 25.4 (49.5)
ERRIP (%) 10.9 (5.8)
ERRUF (%) 19 (4.8)
ERRB (%) 22.8 (4.1)
ε-Shrinkage IP (%) 10.1
ε-Shrinkage UF (%) 15.1
ε-Shrinkage B (%) 10.9
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Fig. 2  Evaluation of the pharmacokinetic model by visual predic-
tive check (VPC) and goodness-of-fit plots [observations (DV) versus 
individual predictions concentrations (IPRED)] for intra-peritoneal 
(IP) oxaliplatin concentrations (a, b), plasma ultrafiltrated (UF) oxali-
platin concentrations (c, d) and plasma protein-bound (B) oxalipl-
atin concentrations (e, f). In the VPC plots, open circles represent 
the observed data, the dotted lines the 5th, 50th and 95th percentiles 
of the observed data associated with their 90 % prediction intervals 
(shaded areas). In DV versus IPRED plots, the solid lines represent 
the identity line (y = x)
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simultaneously describe peritoneal, plasma ultrafiltrated 
and protein-bound oxaliplatin concentrations after admin-
istration of oxaliplatin in the peritoneum. Moreover, this 
is, to our knowledge, the first population PK analysis 
of plasma ultrafiltrated oxaliplatin concentrations after 
HIPEC procedure, which is considered to be the pharma-
cologically active compound [31]. This PK model was 
built based on data from 75 patients (with a total of 1,866 
oxaliplatin concentrations), which is, to our knowledge, 
the largest HIPEC-treated patient population database 
to have been analysed using a pharmacokinetic model-
ling approach. Although the recent study by Pérez-Ruixo 
et al. [21] included 107 patients treated by oxaliplatin, 
only 57 of these underwent oxaliplatin-based HIPEC after 
CRS, while the remaining 50 patients received oxaliplatin 
intravenously.
The whole PK model comprised five different compart-
ments (Fig. 1). The ultrafiltrated oxaliplatin was eliminated 
from the systemic compartment by both a linear process 
and a nonlinear process corresponding to irreversible pro-
tein binding; the latter mimicking the binding of the free 
oxaliplatin to plasmatic proteins described by a nonlinear 
Michaelis–Menten equation [25]. As in Royer et al., the 
protein binding was only applied to the plasma UF con-
centration as IP oxaliplatin binding was shown to be very 
low [25, 32, 33]. Moreover, as the lost fraction correspond-
ing to this phenomenon is not identifiable, this could lead 
to an overestimation of the central volume (VUF) of plasma 
Fig. 3  Evaluation of the PK model by normalized prediction discrep-
ancy errors (NPDE) versus time and versus population predictions 
concentrations (PRED), for intra-peritoneal (IP) oxaliplatin concen-
trations (a, b), plasma ultrafiltrated (UF) oxaliplatin concentrations 
(c, d) and plasma protein-bound (B) oxaliplatin concentrations (e, f). 
The dashed lines represent the 95 % prediction interval of the 1,000 
simulations
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ultrafiltrated oxaliplatin. A covariate analysis was per-
formed leading to the addition of two covariates in the pop-
ulation model (BSA on VIP and PROT on KEL-B). The ratio 
between extreme predicted VIP corresponding to extreme 
BSA observed values was 1.8 which may have a clinical 
impact regarding the AUCIP—thrombocytopenia relation-
ship discussed below. For kEL-B, the ratio corresponding 
to extreme PROT values was even larger (i.e. 2.3), but no 
major clinical impact is expected as it refers to the elimina-
tion of biologically inactive compounds. All the PK param-
eters were correctly estimated with a maximum RSE of 
34.1 and 53.7 % for the fixed and random effects, respec-
tively (Table 2). Although, IIVs on IP were lower than IIVs 
on UF parameters, IIVs on IP were not negligible with 
24.1 % on ka and 16.6 % on VIP. According to the respec-
tive residual errors (10.9, 19 and 22.8 % for the IP, UF 
and B oxaliplatin concentrations, respectively), GOFs and 
VPCs (Fig. 2), the model adequately described each type 
of concentration and their associated variability in treated 
patients. NPDE (Fig. 3) versus time and versus PRED did 
not show any trend that evidences model inadequacy [27, 
28]. Although the Kolmogorov–Smirnov test was statisti-
cally significant (p < 0.05), implying the rejection of the 
normality of the NPDEs, the whole PK model showed 
good descriptive features. Furthermore, Comets et al. [34] 
suggested that a visual inspection of the aforementioned 
NPDE graphs was appropriate to evaluate the ability of the 
model to describe data.
The absorption parameters were close to the previously 
published parameters. The mean value of apparent oxali-
platin elimination half-life from the peritoneum to plasma 
was 29.6 min in the current study compared to 29.5 min 
[35], 30 min [15], 40 min [17] or 29 min in our previous 
analysis [18]. The mean maximum bioavailability was 
53.7 %. However, this value corresponds to the maximum 
fraction of absorbed dose from peritoneum to plasma, since 
a fraction of the oxaliplatin may irreversibly bind to pro-
teins in the peritoneal walls [15]. Pérez-Ruixo et al. [21] 
estimated an absolute bioavailability of oxaliplatin admin-
istered in peritoneum of 38 % using data from patients 
treated with oxaliplatin administered intravenously. Conse-
quently, the difference could be partly explained by a high 
uptake of oxaliplatin in local tissues [15].
Blood sampling was only conducted over an 8-h period, 
which results in an imprecise estimate of the terminal 
elimination phase (i.e. overestimation of the constant rate 
of elimination leading to an underestimation of the mean 
elimination half-life). However, even if a longer terminal 
half-life was expected, this terminal elimination phase con-
sists almost entirely of pharmacologically inactive plati-
num conjugates (e.g. albumin-bound platinum) [31]. Cotte 
et al. [36] studying HIPEC with cisplatin thought that the 
aggressiveness of the surgical procedure could influence 
the systemic transfer of the cytotoxic drug administered 
in the peritoneum during HIPEC. However, in the present 
study, no correlations were found between either AUCIP, 
AUCUF, ka, MB and the surgery (duration, number of peri-
tonectomy) or the PCI.
By comparing the median population Km estimated of 
5,980 ng/mL (Table 2) with the distribution of the observed 
ultrafiltrated oxaliplatin concentrations (mean ± SD: 
3,480 ± 3,084 ng/mL), there is no evidence of a complete 
saturable binding of oxaliplatin proteins, as previously 
mentioned by Graham et al. [31]. The protein binding pro-
cess seems to be principally located in the linear range of 
the Michaelis–Menten curve.
Peripheral sensory neuropathy and haematological 
toxicity are known to be the dose-limiting toxicities of 
Table 3  Pharmacokinetic–pharmacodynamic analysis. Pharmacoki-
netics was evaluated by the peritoneal exposure (Conct=0 and AUCIP), 
systemic exposure (AUCUF) and the rate (ka) and extent [maximum 
bioavailability (MB)] of the systemic absorption of oxaliplatin from 
peritoneum. Pharmacodynamics was evaluated by the toxicity (onset 
of haemoperitoneum and sepsis and depth of thrombocytopenia). 
Mean values (standard deviation) for each group as well Student’s or 
Wilcoxon’s test p values are given for haematoperitoneum and sepsis. 
Pearson’s or Spearman’s correlation coefficient and corresponding p 
value are given for depth of thrombocytopenia (maximum percentage 
of platelet decrease)
Bold refers to the associations statistically significant
Conct=0: individual peritoneal concentration predictions at t = 0
Variables Haemoperitoneum Sepsis Maximum  % 
of platelet 
decrease
No Yes p value No Yes p value r p value
AUCUF (ng.h/mL) 16,729 (5,526) 20,917 (4,506) 0.003 16,860 (5,394) 19,221 (5,673) 0.06 0.35 0.002
AUCIP (ng.h/mL) 83,488 (17,124) 89,303 (24,727) 0.50 84,291 (18,637) 85,776 (20,231) 0.76 0.36 0.001
MB (%) 52.3 (8.3) 58.3 (7.8) 0.01 52.3 (8.5) 56.3 (8.2) 0.05 0.41 0.0003
ka (h−1) 1.44 (0.3) 1.58 (0.3) 0.09 1.42 (0.3) 1.57 (0.3) 0.04 0.14 0.22
Conct=0 (ng/mL) 171,558 (26,470) 175,747 (31,478) 0.47 171,729 (29,047) 173,974 (24,850) 0.53 0.26 0.02
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oxaliplatin after intravenous treatment [16]. In the present 
study, neuropathy and grade 3–4 thrombocytopenia were 
observed in approximately 19 and 14 % of treated patients, 
respectively. The systemic exposure of oxaliplatin (AUCUF) 
was found to be linked with the severity of the observed 
thrombocytopenia, and more precisely with the maximum 
percentage of platelet decrease since inclusion (p = 0.002, 
r = 0.35). Linear regressions with observed platelet nadir 
as dependent variable and AUCUF (respectively AUCIP) as 
independent variable demonstrated a decrease of approxi-
mately 16 × 109 (respectively 19 × 109) platelets per litre 
for an increase of approximately 20 % of the mean AUCUF 
(i.e. 3,500 ng.h/mL) (respectively AUCIP; i.e. 17,000 ng.h/
mL). Moreover, a significant association was found 
between AUCUF and the occurrence of haemoperitoneum: 
logistic regression showed that for an increase of 20 % of 
the mean AUCUF (i.e. 3,500 ng.h/mL), we expect to see an 
increase of approximately 66 % in the odds of having hae-
moperitoneum. Three different mechanisms of action lead-
ing to oxaliplatin-related thrombocytopenia were reported 
[37]: a splenic sequestration of platelets related to oxalipl-
atin-induced liver damage, an immune thrombocytopenia, 
and a myelosuppression probably due to its direct toxicity 
on megakaryocytic progenitors leading to their apoptosis. 
Considering the kinetics of thrombocytopenia (mean time 
to nadir of 7 days), as well as the absence of statistical 
association between the depth of thrombocytopenia and 
a previous administration of oxaliplatin, chemotherapy-
induced myelosuppression seems to be the main cause of 
observed thrombocytopenia in these patients.
In our study, 17 and 58 patients received a dose of 
460 and 360 mg/m2, respectively. As the volume of solu-
tion (2 L/m2) and these doses were based on the body sur-
face area, the drug concentrations observed in the perito-
neum at t = 0 should be the same in all patients treated in 
each group of doses. However, surprisingly, an important 
inter-individual variability was observed [mean ± SD: 
189.6 ± 34.6 and 176.1 ± 53.4 µg/mL for the 460 mg/m2 
doses (n = 16) and 360 (n = 56), respectively]. A possi-
ble explanation for this variability is that two patients with 
an identical body surface area might have very different 
intraperitoneal volumes. The advantage of the Performer® 
LRT system is that it adapts the infused intraperitoneal 
volume according to the patient’s anatomy. However, this 
means that the oxaliplatin dose to which the patient is 
exposed will vary depending on the volume remaining in 
the device. This initial variability in concentration cou-
pled to that of ka and MB parameters lead to an important 
variability not only on AUCIP [mean ± SD: 108.6 ± 17.1 
and 77.8 ± 13.1 µg.h/mL(p = 9.6 × 10−8) for 460 and 
360 mg/m2, respectively] but also contribute to variability 
on AUCUF [mean ± SD: 22.9 ± 4.7 and 16.1 ± 4.9 µg.h/
mL(p = 3.4 × 10−5) for 460 and 360 mg/m2, respectively]; 
AUCUF is itself associated with haematological toxicity. 
Despite the lack of significant association between the 
depth of thrombocytopenia and the surgery (duration, num-
ber of peritonectomies), we cannot exclude perioperative 
haemorrhage as a factor of haematological toxicity. Indeed, 
a statistically significant correlation was found between the 
total perioperative insensitive losses and the maximum per-
centage of platelet decrease (p = 0.01, r = 0.35, n = 52).
Conclusions
In summary, the current work presents the first PK model 
of oxaliplatin after HIPEC procedure in patients who 
underwent cytoreductive surgery, which simultaneously 
describes the kinetics of peritoneal, plasma ultrafiltrated 
and protein-bound oxaliplatin concentrations. Thrombocy-
topenia was observed in approximately 14 % of patients. 
On the one hand, they seem to be related to the PK vari-
ability observed both in the peritoneum and in the sys-
temic compartment, depending on both the pharmacoki-
netic parameters of absorption from the peritoneum and 
the initial concentrations in the peritoneum. The higher the 
absorbed dose from the peritoneum, which is very depend-
ent on the initial concentration in the peritoneum and ka, 
the deeper the resultant thrombocytopenia. On the other 
hand, we cannot exclude perioperative haemorrhage as a 
factor of thrombocytopenia. A simple measure of the ini-
tial concentration in the peritoneum could dictate the pro-
phylactic administration of platelet concentrates, after the 
definition of a threshold. However, further prospective 
studies are necessary to confirm and better understand this 
observed variability in oxaliplatin exposure. In the future, 
the PKPD relationship between oxaliplatin exposure and 
the total platelet count over time could be investigated, as 
already done by others for neutrophils [20] in order to opti-
mize the peritoneal administration of oxaliplatin in such 
HIPEC procedures.
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!2.3.3:!Discussion!and!future!prospect!!Accumulation!and!analysis!of!data!from!patients!treated!with!approved!drugs!are!crucial!to! improve!therapeutic!management.!Despite!the!number!of!publications!about!HIPEC,!data! are! missing! regarding! drug! toxicities! and! related! morbidity,! which! have! been!probably!underGevaluated!at! the!beginning!of! the!experience.!Enrolment!of!patients! in!phase! I! or! phase! II! clinical! trial! is! required.! Important! information! to! improve!therapeutic!management!would!be!obtained!through!a!better!understanding!and!control!of! the! relationship! between! the! drug! exposition! and! the! observed! toxicities,! but! also!with!the!accumulation!and!analysis!of!data!from!patients!treated!with!approved!drugs.!Regarding! specific! toxicity! of! cisplatin! based! HIPEC,! risk! of! acute! renal! failure! was!difficult! to! assess! in! some! small! sample! size! heterogeneous! studies,! and!with! lack! of!standardization! of! HIPEC! technique.! Comparison! of! published! HIPEC! regimens! was!impossible! regarding! the!variability!of! volumes!and! concentrations!used,! the!different!modalities!of!HIPEC,! the!different!time!to!exposure,! the!different!optimal!temperature,!and! the! different! carrier! solutions.! A! consensus! on! technical! aspects! of! cytoreductive!surgery! and! HIPEC! was! obtained! through! the! Delphi! process! in! 2006! at! the! Fifth!International!Workshop!on!Peritoneal!Surface!Malignancy![91],!which!has!facilitate!data!and!publications!analysis.!!At! the! beginning! of! our! experience,! cisplatin! dose! rate!was! determinate! according! to!intraperitonal! treatment! without! concurrent! surgery! and! hyperthermia.! In! our!unpublished! deGescalation! study,! acute! renal! failure! according! to! RIFLE! score! was!reported!in!83%!of!patients,!58%!of!which!with!high!grade!(failure,! loss!or!endGstage)!after! CRS! and! cisplatin! based! HIPEC.! Because! of! low! plasma! dose! exposure,! we! have!concluded!that!occurrence!of!renal!failure!is!not!dose!dependant,!and!due!to!a!different!mechanism!as!known!with!using!intravenous!cisplatin.!!High!rate!of!renal!toxicity!was!described!in!different!retrospective!studies,!ranged!from!27%!to!65%![92],!depending!to!the!dose!of!cisplatin!used.!Hakeam!has!estimated!a!5%!of! acute! renal! failure! rate! after! CRS! and! HIPEC! combining! cisplatin! 50mg/m2! and!doxorubicin! 15!mg/m2! [93].! The! development! of! perioperative! acute! renal! failure! is!associated! with! a! high! incidence! of! morbidity! and! mortality.! In! a! population! PKGPD!study,!Cotte!has!reported!a!renal!toxicity!in!29%!of!patients!which!is!correlated!to!AUCp![94].!Acute!renal!failure!seems!to!have!been!more!frequent!in!patients!who!received!IP!cisplatin!only!compared!to!IP!association!of!drugs.!But!in!this!study,!these!patients!who!received!cisplatin!only!have!received!the!greatest!dose!of!cisplatin.!Royer!has!reported!a!threshold! of! 25!mg·h/l! for! the! AUCp! of! total! platinum,! above!which! the! risk! of! renal!toxicity! increases! [95].! Evaluation! of! renal! toxicity! is!more! effective! in! a! doseGfinding!prospective! study.! In! our! dose! escalation! study,! all!DLT!were! observed! at! the! highest!dose! level! (80! mg/m2)! with! HIPEC! related! renal! failure! requiring! dialysis.! A! wide!variation! in! creatinin! clearance! was! observed! during! post! HIPEC! days.! In! a! model!adjusted! on! the! dose! level,! the! creatinine! level! at!week! 8!was! significantly! correlated!with!the!baseline!value!and!diuresis!before!HIPEC.!In!our!retroscpective!bicentric!study,!we!have!shown!that!previous!hypertension,!renin!angiotensin!system!blockers!and!low!intraoperative! diuresis! represent! the!main! risk! factor! of! renal! failure.! For! Cotte,! [94]!
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renal! toxicity! may! be! due! to! multiple! factors,! such! as! surgical! complications! (sepsis,!hemodynamic!shock,!digestive!tract!occlusion)!and!medical!complications!(dehydration!and!comedication!toxicity).!How!to!prevent!acute!renal!failure?!!2.3.3.1:!By!using!sodium!thiosulfate:!It!allows!to!reduce!the!renal!toxicity!of!cisplatin!administered!locally!by!either!the!intraGarterial,!intraGperitoneal!or!intraGthoracic!routes.!However,!controversies!still!exist!as!to!the!effect!of! sodium!thiosulphate!on!cisplatin!antitumor!activity.! Sodium!thiosulfate! is!currently! not! available! in! France.! Thus! sodium! thiosulphate! may! be! most! useful! in!combination! with! intraperitoneal! cisplatin! where! it! confers! renal! protection! without!altering!local!effects!of!cisplatin!2.3.3.2:!By!using!low!dose!of!cisplatin:!Early!in!the!development!of!cisplatin,!more!than!70%!of!patients!developed!acute!renal!failure! that! appeared! to! be! cisplatin! doseGrelated.! Royer! [95]! has! shown! that! an!intraperitoneal! concentration! above! 10! mg/l! eradicated! 100%! of! platinum! resistant!ovarian!cells!in!a!clonogenic!assay.!Regarding!our!DLT!observed!at!the!level!80!mg/m2,!a!70!mg/m2!dose!of!ciplatin!for!HIPEC!is!recommended.!2.3.3.3:!By!maintaining!a!pronounced!diuresis!before!starting!cisplatin!based!HIPEC:!!The!clinical!use!of!cisplatin!is!hampered!by!nephrotoxicity,!expressed!by!a!reduction!in!glomerular! filtration! rate.! Despite! aggressive! hydration,! especially!with! normal! saline!solutions,!which!are! routinely!applied! in! the!clinical! setting! to!prevent!nephrotoxicity,!renal!failure!still!occurs.!For!intravenous!cisplatin!used,!some!authors!suggest!a!regimen!consisting!of!prehydration!using!100!ml/h!of!normal!saline!solution!for!the!12!h!prior!to!the! administration! of! the! compound! and! continuous! infusion! of! saline! during! and! at!least!1!day!after!cisplatin!treatment![96].!In!some!clinical!trial,!to!prevent!renal!toxicity,!a! hyperhydration! (≈12!ml/kg/h)! and! forced! diuresis! (≈2!ml/Kg/h)! during! HIPEC! are!required! (CHORINE! trial,! CHIPOR).! Several! experimental! reports! have! suggested! that!diuretics!(mannitol!and!furosemide)!decrease!cisplatin!nephrotoxicity.!But!others!have!shown!that!they!may!aggravate!it.!During!cytoreductive!surgery,!objective!of!euvolemia!is!mandatory!in!order!to!maintain!organ!perfusion,!which!represents!the!main!factor!to!prevent! related! cisplatin! renal! toxicity.! Perioperative! fluid! losses! can! be! recorded! in!terms! of! blood! and! intravascular! fluid! losses,! insensible! losses.! There! is! a! need! to!replace!both!blood!and!extracellular!fluid!losses,!as!well!as!to!maintain!the!normal!water!requirement.! According! to! the! extent! of! the! peritoneal! carcinomatosis! surgery,!preoperative! hydratation! up! to! 10G15! ml/kg/h! is! required! [97].! Furthermore,! most!anaesthetics! cause! peripheral! vasodilatation.! Either! vasoconstrictors! or! fluid!replacement!is!needed.!In!the!case!of!the!kidney,!under!control!of!angiotensin,!adequate!efferent! arteriolar! vasoconstriction! is! maintained,! which! is! responsible! for! the!development!of! the! glomerular! filtration!pressure.! Patient! receiving! renin! angiotensin!system! blockers! treatment! who! undergoes! anaesthesia! may! develop! a! significant!decrease!in!the!perfusion!pressure!with!decreased!urine!production.!As!suggested!in!our!study,!treatment!by!renin!angiotensin!system!blockers!may!be!replace!before!a!surgery!when!a!cisplatin!based!HIPEC!is!planned.!Careful!use!of!preoperative!osmotic!laxatives!is!mandatory!because!it!can!affect!renal!function!by!increasing!risk!of!dehydratation.!!
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Prospective!investigations!are!needed!to!decrease!drastically!the!risk!of!renal!failure!for!patients!treated!by!cisplatin!based!HIPEC!and!to!select!to!highGrisk!population.!!2.3.3.4:!By!using!taxane!based!HIPEC!Because!paclitaxel!and!docetaxel!have!a!high!molecular!weight!and!hepatic!metabolism,!high! intraperitoneal! to! systemic! drug! concentration! and! exposure! ratios! might! be!achievable! after! intraperitoneal! delivery.! Based! to! the! results! of! the! two! GOG!randomized! trials! for! ovarian! cancer! (GOGG114,! GOGG172)! [32G34]! comparing! IV!carboplatin!plus!taxane!to!IP!instillation,!taxanes!are!routinely!used!intraperitonealy!in!association!with!IP!cisplatin.!!The! favorable! pharmacokinetics! of! taxanes! during! intraperitoneal! instillation!chemotherapy! and!HIPEC! have! been! confirmed! in! several! animal! and! clinical! studies,!with! a! highly! ratio! AUCIP/AUCp! ratio,! more! than! 1000! [98].! After! intraperitoneal!administration!of! taxanes,! highly! cytotoxic! concentration!of! the! agents!persists!within!the! peritoneal! cavity! for! several! days.! In! vitro,! synergistic! effect! in! a! timeGdependant!manner! has! been! demonstrated! between! paclitaxel! and! hyperthermia.! Cell! death!mechanism! seems! to! be! different! under! hyperthermic! conditions! comparing! to!normothermic! conditions:! cell! necrosis! is! significantly! higher! than! apoptosis! with!hyperthermia.!But! in! vivo,! necrosis! increases! local! inflammation!and! recruits! immune!system![99].!Clinical! experiences!with! taxane!based!HIPEC!are! limited! to! few! teams,! essentially! for!ovarian!cancer![100,!101].!The!dose!used!is!very!different.!!A!phase!II!prospective!study!was!recently!published!about!a!combined!cisplatin!and!paclitaxel!based!HIPEC!with!the!same!dose!used!in!conventional!sequential!IP![102].!44!patients!were!included.!Systemic!chemotherapyGrelated! complications! as! hematological! toxicity! and! renal! insufficiency!range!from!0%!to!28%!and!0%!to!7%,!respectively.!Largest!studies!with!a!homogenous!population!are!needed.!2.3.3.5:!By!using!Carboplatin!based!HIPEC:!!Carboplatin,!which!has!largely!supplanted!cisplatin!in!intravenous!regimens!because!of!a! more! favorable! toxicity! profile,! has! undergone! limited! study! in! the! intraperitoneal!setting!especially!with!hyperthermia.!As!previously!described,!hyperthermia! increases!the! tumor! concentration! of! carboplatin! significantly,! yielding! an! increase! in! adduct!formation! within! tumor! DNA! and! potentially! further! increasing! efficacy! [103].! Two!phase! I! studies!was! conducted! regarding! HIPEC! carboplatin! doses.! Doses! up! to! 800–1000!mg/m2!were! tolerable.! Argenta! [104]! has! published! a!monocentric! prospective,!pilot! study! about! 10! patients! who! underwent! secondary! cytoreductive! surgery! for!recurrent! platinum! sensitive! ovarian! cancer! followed! by! HIPECGcarboplatin! at! 1000!mg/m2,! with! a! low! rate! of! side! effects.! In! a! retrospective! study,! Shetty! [105]! has!compared!the!outcome!of!patients! treated!with!either!mitomycin!or!carboplatin!based!HIPEC! for!malignant! peritoneal!mesothelioma.! Despite! absence! of! randomization! and!matching,!the!authors!have!concluded!that!HIPEC!with!carboplatin!in!diffuse!malignant!peritoneal! mesothelioma! is! associated! with! improved! overall! survival! and! shorter!hospital! stay! compared! with! HIPEC! with! mitomycin.! Rettenmaier! has! published! his!experience! about! advanced! stage! ovarian! cancer! patients! who! were! treated! with!consolidation!HIPEC!with!carboplatin!at!varying!doses!(AUC!6,!8!or!10)!after!a!complete!response! to! neoadjuvant! chemotherapy! and! surgery.! He! suggested! that! carboplatin!
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based!HIPEC! is!wellGtolerated,!even!at!an!AUC!of!10! [106,!107].!Dose!escalation!study!and!phase!IGII!trials!are!needed!to!evaluate!the!real!role!of!carboplatin!for!HIPEC!2.3.3.6:!By!using!Oxaliplatin!based!HIPEC:!Because! it! induces! no! renal! or! hepatic! toxicity! and! its! efficacy! in! colorectal! cancer,!oxaliplatin! is! the!widely!used! for!HIPEC! in!France.!Gustave!Roussy! team!has! reported!several!prospective! trials!of!Oxaliplatin!based!HIPEC!following!complete!cytoreductive!surgery!for!colorectal!peritoneal!carcinomatosis![90,!108,!109].!According!to!these!results!and!the!rate!of!renal! failure!after!cisplatin!based!HIPEC,!we!have!conducted!in!France!a!multiinstitutional!phase!II!prospective!study,!evaluating!the!safety!of!an!oxaliplatin!based!HIPEC!in!ovarian!cancer!after!an!incomplete!surgery!and!6!courses! of! chemotherapy.! Regarding! to! a! 29%! severe! morbidity! rate,! this! trail! was!premature!closed!at! the! first! step! (31!patients).!Complications!were!mainly! related! to!intraGabdominal! bleeding,! sometimes! with! unexplained! repeated! episodes! of!hemoperitoneum.! This! specific! complication!was! not! related! to! the! importance! of! the!surgery.! Indeed,! limited! cytoreduction! without! bowel! resections! was! required! for!inclusion.!!In!our!PKGPD!study,!concerning!75!patients!treated!by!oxaliplatin!based!HIPEC!either!for!colorectal! PC! (n=25),! or! rare! peritoneal! disease! (n=29),! or! ovarian! cancer! (n=18)! or!other! (n=3),! hemoperitoneum! occurred! in! 27%!of! patient.! Neuropathy! and! grade! 3G4!thrombocytopenia! were! observed! in! approximately! 19! and! 14%! of! patients,!respectively.! No! statistically! significant! associations!were! found! between! toxicity! and!surgery! (duration! of! surgery,! extend! of! peritonectomy)! or! previous! treatment! with!oxaliplatin.! An! interGindividual! variability! was! reported! regarding! the! bioavaibility! of!oxaliplatin! (percentage! of! dose! absorbed! during! the! HIPEC)! with! a! statistically!significant! correlation! with! hemoperitoneum.! The! systemic! exposure! of! oxaliplatin!(AUCUF)!was!found!to!be!correlate!to!the!severity!of!the!observed!thrombocytopenia!and!the! occurrence! of! abdominal! bleeding! (Fig.! 6).!With! an! increase! of! 20%! of! the!mean!AUCUF,! we! expect! to! observe! an! increase! of! 66%! in! the! odds! to! developing!hemoperitoneum.! A! statistically! significant! correlation! was! found! between! the! total!perioperative!fluid!losses!and!thrombopenia.!
!
Fig.!6!PKLPD!analysis!This! specific! complication! has! been! noted! at! a! rate! of! 5! to! 18%! after! surgery! for!pseudomyxoma! peritonei! [110],! colorectal! cancer! [111],! and! ovarian! cancer! [112].!!Incidence! of! bleeding! varies! with! the! origin! of! cancer.! Highest! rate! of! bleeding! was!
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observed! in!patients! treated! for! appendical/pseudomyxoma!peritonei! and! for! ovarian!cancer.! One! way! to! explain! the! increasing! risk! of! hemoperitoneum! depending! to! the!pathology! is! the! pathology! itself.! Indeed,! a! ten! time!higher! level! of! fibrin! degradation!products!was!reported!in!ovarian!cancer!ascitis!than!in!colorectal!PC!and!cirrhosis.!This!finding! suggests! a! catabolism! of! fibrinogen! in! ascitis! fluid! via! coagulation! and!fibrinolysis.! It’s!the!reason!of!high!rate!of!hemorrhagic!ascitis,!and!probably!a!cause!of!high!risk!of!abdominal!bleeding!after!oxaliplatin!HIPEC.!Hypotonic! solutions! may! lead! to! diffuse! bleeding.! Because! intraperitoneal! hypotonic!solutions!increase!platinum!accumulation!in!tumors!cells!and!enhance!its!cytotoxicity!in!vitro! [113],! a!phase! I! clinical! study!of!oxaliplatin!based!HIPEC!with!dose!escalation!of!hypotonic! solution!was! carried! out! [114].! A! high! incidence! of! unexplained! abdominal!bleeding!and!thrombopenia!was!reported!using!hypotonic!solutions.!Moreover,!contrary!to! the! experimental! studies! finding,! oxaliplatin’s! penetration! in! tumor! was! not!increased.!Careful! using! of! oxaliplatin! for! HIPEC! is!mandatory! especially! for! ovarian! cancer! and!pseudomyxoma! peritonei.! According! to! our! results,! postGoperative! monitoring! of!kinetics! of! thrombopenia! especially! for! patient! with! an! important! perioperative! fluid!losses! could! be! helpful.! Indeed,! a! simple!measure! of! the! initial! concentration! into! the!peritoneum! could! dictate! a! potential! prophylactic! administration! of! platelet!concentrates.!In!the!future,!the!PKGPD!relationship!between!oxaliplatin!exposure!and!the!platelet!count!over!time!could!be!investigated!in!order!to!optimize!the!IP!administration!of!oxaliplatin!during!HIPEC!procedure.!
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3.)CONCLUSION)
! 46!
)After! more! than! 20! years! of! research,! knowledge! has! changed! regarding! PC!management,!and!the!importance!of!complete!cytoreductive!surgery!and!intraperitoneal!chemotherapy.! At! the! beginning! of! the! experience,! PKGPD! data!were! rare! and! clinical!practices!strongly!heterogeneous.!!We!contributed,!thanks!to!our!research’s!results,!to!develop!a!PK!model,!which!is!able!to!simultaneously! describe! peritoneal! and! plasma! exposure! and! proteinGbound!concentration!versus! time.!This!model!allowed!to!confirm!the!PK!advantage!to!deliver!HIPEC! laparoscopically! which! represents! probably! the! best! approach! for! patients!previously! treated! by!minimal! invasive! surgery! for! high! risk! cancer.! ! This!model! also!allowed!to!investigate!the!PKGPD!relationship!between!drug!exposure!and!toxicity.!It’s! crucial! that! each! new! step! of! development! will! be! early! evaluated! using! PKGPD!models.!Today,!new!and!major!developments!of!intraperitoneal!treatment!are!expected!using!differents!ways:!
First,! by! intraperitoneal! using! of! targeted! therapy.! Indeed,! key! biologic! targets! of! IP!therapy! in! terms! of! direct! tumor! cytotoxicity,! alterations! in! the! peritoneal! stomal!microenvironment! (such! as! a! reduction! in! angiogenesis! or! growth! factors),! or!enhancement!of!the!host!immune!response!have!not!already!been!completely!described.!Furthermore,! it! is! obvious! that! each! of! these! pathways! could! drive! targeted!interventions! that! might! further! improve! clinical! outcomes.! Intraperitoneal!administration!of!combined!targeted!therapy!and!cytotoxic!agents!have!to!be!evaluating!using!PK!model.!!!
Then,! different! methods! have! been! recently! developed! to! modifie! the! PK! of!intraperitoneal! drug! delivery,! in! order! to! enhance! the!AUC! ratio!with! a! decreasing! of!related! complication! rate.! Most! research! regarding! antiGcancer! drugs!with! liposomes,!polymeric!micelles,!and!microspheres!(Fig.!7)!have!designed!the!drug!delivery!based!on!the! enhanced! permeability! retention! effect! using! intravenous! or! intraperitoneal!administration! to! target! the! cancer! [115].! Experimentally,! nanoparticles! included! in! a!biodegradable! hydrogel! (gelatine! like)! are! frequently! used! for! intraperitoneal!administration! [116].! Some! preliminary! studies! regarding! intraperitoneal!administration!of! linked!cisplatin!microspheres! reported! favorable!AUC!ratio!between!the! peritoneal! and! the! serum! [117].! Moreover,! the! microspheres! were! seen!macroscopically! along! the! greater! omentum,! subphrenic! area,! pouch! of! Douglas,! and!hepatic! portal! region! where! tumor! metastases! are! commonly! observed,! suggesting! a!high! concentration! of! cisplatin! near! the! peritoneal! lesions.! Similar! results! have! been!reported!using!Camptotecine![118],!Paclitaxel![119G122].!Intraperitoneal!administration!of!Cisplatin!crossGlinked!with!hyaluronic!acid!based!hydrogel!was!described!by!Emoto!in!2013![121].!Because!of!hyaluronic!acid!implication!in!ovarian!tumor!progression![123],!we! have! demonstrated! the! oncologic! safety! for! using! ! hyaluronic! acid! barriers! in!peritoneal!carcinomatosis![124].!These!results!will!give!us!the!opportunity!to! join!two!important! research! programs! in! our! team:!microenvironment! and! PKGPD! analysis! for!intraperitoneal!treatment.!
Finally,! different! modalities! have! been! published! to! deliver! hyperthermia! into! the!peritoneal!cavity:!external!RadioGFrequency!devices;!hyperthermic!perfusion;! injection!of! magnetic! and! ferroelectric! particles;! injection! of! magnetic! nanoparticles! that! may!
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carry!a!pharmacological!active!drug![125].!Although!the!description!of!specific!renal!and!liver!adverse!effects!related!to!intraperitoneal!injection!of!silver!nanoparticles![126],!the!use!of!magnetic!nanoparticles! is!a!very!promising! treatment!approach!since! it!may!be!used! for! diagnostic! and! treatment.! An! ideal! magnetic! nanoparticle! would! be! able! to!detect!and!diagnose! the! tumor,! carry!a!pharmacological!active!drug! to!be!delivered! in!the! tumor! site,! apply! hyperthermia! through! an! external! magnetic! field! and! allow!treatment!monitoring!by!magnetic!resonance!imaging.!!An!important!field!of!research!is!still!open!regarding!PKGPD!studies!using!our!model!to!investigate!IP!chemotherapy!linked!to!different!particles,!with!the!possibility!to!deliver!hyperthermia!during!each!sequential!IP!injection.!!!
!
Fig.!7!An!illustrative!representation!of!differents!classes!of!third!generation!nanodrugs!(Markman!JL.!Adv!
Drug!Deliv!Rev.!2013)![127].!
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Author:!ThierryGGwénaël!FERRON!Title:! Therapeutic! methods! for! peritoneal! carcinomatosis.! Standardization! of!hyperthermic!intraperitoneal!chemotherapy!–!Pharmacokinetics!and!Pharmacodynamic!Studies!Summary!Peritoneal! carcinomatosis! (PC)! is! usually! caused! by! widespread! cancer! metastatic! cells! within! the!peritoneal! cavity! and! occurred! in! 85%! of! ovarian! cancer! patients! and! 5–20%! of! colorectal! carcinoma!patients.!Because!of!the!poverty!of!symptoms,!patients!are!diagnosed!with!an!advanced!stage.!PC!will!be!the!leading!death!cause!of!these!patients.!Recently,! the! treatment!was! limited! to! standard!palliative! surgery! and! intravenous! chemotherapy!with!very! poor! results! in! term! of! survival.! The! development! of! new! surgical! techniques! combined! with!intraperitoneal!chemotherapy!associated!or!not!with!hyperthermia!provided!new!hope!of!a!potential!cure!for!patients!with!PC.! Indeed,! complete! cytoreductive! surgery! represents! the!most! important!prognostic!factor! for!patients!with!PC!whatever! the!primary!cancer! locations.!Combined! treatment!using!complete!cytoreductive! surgery! and! intraperitoneal! chemotherapy!has!been!developed! leading! to!unprecedented!survival.! Hyperthermia! induces! a! selective! destruction! of! tumor! cells! in! hypoxic! and! acidic! parts! of!tumors,!but!leaves!normal!tissues!intact.!In!addition!heat!is!acting!for!synergy!with!the!cytotoxic!agent.!A!new! technique! to! deliver! intraoperative! intraperitoneal! chemotherapy! associated! with! hyperthermia,!called!HIPEC,!was!developed!for!patient!with!PC.! It!significantly! increases!survival! in!patients!with!colic!cancer! PC,! peritoneal! mesothelioma! and! pseudomyxoma! peritonei.! Several! ongoing! trails! have! been!designed!to!establish!the!real!role!of!HIPEC!for!different!pathology.!!
First,!because!of!the!major!development!and!the!widespread!use!of!minimal!invasive!surgery,!recruitment!of! patients! has! been! profoundly! changed!with! localized! PC.!We! have! demonstrated! in! an! experimental!study! the! feasibility! and! reliability! of! laparoscopic! peritonectomy! followed! by! oxaliplatin! based!intraperitoneal! chemotherapy! and! its! pharmacokinetics! consequences! regarding! the! peritoneal! drug!absorption,!the!increased!tissue!diffusion,!and!the!role!of! intraperitoneal!pressure.!Several!articles!were!published! in!Gynecologic* Oncology! and! in!Annals* of* Surgical* Oncology) and! in! an! international!book*
chapter*(Humana*Press)!concerning!pharmacology!and!pharmacokinetics!of!platinum!salts.!
Then,) to! establish! a! new!population! pharmacokinetic!model! and! to! compare! two!procedures! of! drug’s!delivery! during!HIPEC,! data! from! 24! patients! treated!with! oxaliplatin! based!HIPEC!were! collected! and!analyzed.!This!work!was!published!in)Cancer*Chemotherapy*and*Pharmacology.!
Finally,! different! clinical! and! pharmacodynamic! studies! were! performed! to! evaluate! the! toxicity! for!patients! who! underwent! complete! cytoreductive! surgery! associated! to! Cisplatin! or! Oxaliplatin! based!HIPEC.!)Three! different! works! were! performed! to! evaluate! the! renal! toxicity! of! cisplatin! based! HIPEC.! An!unpublished! PK! study! regarding! acute! renal! failure! in! a! doseGdeescalation! study! was! presented! at! a!PharmacoGoncologists!Meeting.!The!results!were!confirmed!in!a!bicentric!retrospective!study!highlighting!some! risk! factors! (Submitted! to! the!European* Journal* of* Surgical* Oncology).! Finally,! a! phase! I! study!dose! escalation! of! hyperthermic! intraperitoneal! cisplatin!was! conducted!with! the! establishment! of! the!recommended!dose!of!cisplatin!for!HIPEC!(Submitted!to!the!Journal*of*Clinical*Oncology).!Because!of!renal!toxicity!related!to!cisplatin!based!HIPEC,!a!phase!II!prospective!study!was!conducted!to!evaluate! the! morbidity! of! oxaliplatin! based! HIPEC.! As! a! result! of! this! high! morbidity! rate!(hemoperitoneum),!this!trial!was!prematurely!closed!and!published!in!the*European*Journal*of*Surgical*
Oncology.! Finally,! to! evaluate! the! relationship! between! oxaliplatin! exposure! and! observed! toxicity,! a!population!pharmacokinetics!was!conducted!in!75!patients!treated!with!CRS!and!oxaliplatin!based!HIPEC.!A!PK!contribution,!relative!to!the!absorption!phenomenon,!on!the!severity!of!the!thrombocytopenia!and!hemoperitoneum!was!shown.!This!work!was!published!in!Cancer*Chemotherapy*and*Pharmacology.!
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Auteur:!ThierryGGwénaël!FERRON!Titre:! Modalités! thérapeutiques! de! la! carcinose! peritoneale.! Role! de! la!chimiohyperthermie! intraperitoneale! –! Etudes! pharmacocinétiques! et!pharmacodynamiques!Mots! clefs:! ! Intraperitoneal,! chimiotherapie,! carcinose,! pharmacocinetique,!hyperthermie,!Résumé:!!La! carcinose! péritonéale! (CP)! correspond! le! plus! souvent! à! l’envahissement! métastatique! de! la! cavité!péritonéale!survenant!dans!85!à!90%!des!cas!de!l’ovaire!et!5!à!20%!des!cancers!colorectaux.!La!pauvreté!de!des!signes!cliniques!explique!que!le!diagnostic!se!fasse!à!un!stade!souvent!avancé.!!Jusque! récemment,! le! traitement! d’une! CP! était! exclusivement! palliatif! avec! une! chirurgie! de!nécessité! incomplète! et! une! chimiothérapie! systémique,! et! une! survie!médiocre.! La! cause! du! décès! est!dans! la! majorité! des! cas! la! carcinose! elleGmême.! Les! avancées! en! matière! de! chirurgie! péritonéale!extensive!et!de!chimiothérapie! intrapéritonéale!combinée!ou!non!à!une!hyperthermie!ont! fait!naître!de!nombreux!espoirs!de! curabilité.! La! chirurgie!de! cytoreduction! complète! représente! le! facteur!pronostic!essentiel,!quelque!soit!l’origine!tumorale!primitive.!L’association!d’une!chirurgie!et!d’une!chimiothérapie!intraperitonéale! a! été! développée! dans! le! cancer! de! l’ovaire! avec! des! taux! de! survie! impressionnants.!L’hyperthermie! induit! une! destruction! sélective! des! cellules! en! hypoxie,! dans! des! zones! tumorales! en!acidose,! tout! en! préservant! le! tissu! sain! environnant.! Pour! les! patients! atteints! de! CP,! une! technique!nommée!CHIP!a!été!developpée!permettant!de!délivrer!une!chimiothérapie!intrapéritonéale!en!condition!d’hyperthermie.! Une! augmentation! importante! de! la! survie! de! patients! atteints! de! CP! colorectal! ou! de!maladie! rare! du! péritoine! a! été!mise! en! évidence.!Des! essais! cliniques! sont! en! cours! afin! de! vérifier! le!bénéfice!attendu!de!l’HIPEC!dans!différentes!pathologies.!
Premièrement,!compte!tenu!de!large!développement!de!la!laparoscopie,!l’adressage!de!patients!avec! une! carcinose! localisée! est! fréquent.! Nous! avons! développé,! sur!modèle! animal,! une! technique! de!péritonectomie! laparoscopique! avec! CHIP! à! l’oxaliplatine.! Les! paramètres! pharmacocinétiques! (PK)! en!terme!d’absorption!de!la!drogue!et!de!pénétration!intraGtissulaire!ont!été!analysés!avec!mise!en!évidence!du! rôle! favorable! de! l’hyperpression! intraabdominale.! Ces! travaux! ont! été! publié! dans! Gynecologic*
Oncology,!dans!Annals*of*Surgical*Oncology!(2!articles)!et!inclus!dans!un!chapitre*de*livre*international*
(Humana*Press)*concernant!la!pharmacologie!et!la!PK!des!sels!de!platine.!
Ensuite,!nous!avons!établi!un!nouveau!modèle!de!pharmacocinétique!des!populations!que!nous!avons! appliqué! à! la! comparaison!de!deux!modes!d’administration!de! la! chimiothérapie! lors!des!CHIP!à!l’oxaliplatine,!sur!24!patients.!Ce!travail!a!été!publié!dans!Cancer*Chemotherapy*and*Pharmacology.!!
Enfin,!différentes!études!cliniques!et!pharmacodynamiques!(PD)!ont!été!réalisée!afin!d’évaluer!et!de!prédire!la!toxicité!spécifique!des!CHIP!réalisées!au!Cisplatine!et!à!l’Oxaliplatine.!Trois!travaux!successifs!ont!été!réalisés!pour!évaluer!la!toxicité!rénale!liée!au!Cisplatine.!Dans!une!étude!pilote!de!PK,!non!publiée,!de!désescalade!de!dose,!nous!avons!montré!que!le!risque!d’insuffisance!rénale! n’est! pas! expliqué! par! la! PK! (présentation! au! Congrès! de! PharmacoGOncologistes).! Cela! a! été!confirmé!dans!une!étude!rétrospective!bicentrique!avec!mise!en!évidence!de!facteurs!de!risque.!Ce!travail!est! soumis! à! publication! dans! European* Journal* of* Surgical* Oncology.! Enfin! une! étude! de! phase! I!d’escalade!de!dose!a!été!réalisée!permettant!de!déterminer!la!dose!optimale!de!Cisplatine!en!CHIP!et!est!soumise!à!publication!dans!Journal*of*Clinical*Oncology.!!Compte! tenu! de! la! toxicité! rénale! du! cisplatine,! une! étude! prospective! de! phase! II! a! évalué! la!morbidité! de! l’oxaliplatine! en! CHIP! dans! le! cancer! de! l’ovaire.! Cet! essai! a! été! clos! de! façon! anticipée!compte! tenu! du! taux! d’hémopéritoine! et! publié! dans! European* Journal* of* Surgical* Oncology.! Afin!d’analyser! et! prédire! ce! risque,! une! étude! PKGPD! a! été! conduite! sur! 75! patients! traités! par! CHIP! à!l’oxaliplatine! avec! une! corrélation! PK! entre! ! l’absorption! et! la! survenue! de! thrombopénie! et!d’hémoperitoine.!Ce!travail!est!publié!dans!Cancer*Chemotherapy*and*Pharmacology.!
